Last updated: Apr 30, 2020 - 02:00 BST
| MERMAIDS 2: European Study of Major Infectious Disease Syndromes Related to COVID-19 |
Coronavirus disease 19 infection, Respiratory disease, Respiratory tract infection |
biological sampling alone |
|
|
Universitair Medisch Centrum Utrecht |
|
Netherlands |
2020-05-01 |
2022-04-30 |
MERMAIDS 2, NCT04364711, RECOVER - MERMAIDS 2.0 |
Phase Not Applicable |
Not yet recruiting |
0 |
24 Months |
2000 |
MJM Bonten |
2020-04-29 |
| Intravascular Access of COVID-19 Patient Under Personal Protective Equipment |
Coronavirus disease 19 infection |
NIO alone, Standard intravenous cannula alone, intraosseous access alone, intravenous access alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University |
Poland |
2020-01-12 |
2020-02-25 |
IO_PPE_MS_1, NCT04366297 |
Phase Not Applicable |
Completed |
0 |
1 Month |
41 |
Jacek Smereka, PhD, Łukasz Szarpak, Assoc Prof PhD |
2020-04-29 |
| The University of the Philippines Hydroxychloroquine PEP Against COVID-19 Trial |
Coronavirus disease 19 infection |
hydroxychloroquine alone, standard preventive measures alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
University of the Philippines |
|
Philippines |
2020-04-30 |
2021-05-31 |
NCT04364815, RGAO-2020-0339 |
Phase 3 Clinical |
Not yet recruiting |
0 |
13 Months |
960 |
Belen L Dofitas, MD |
2020-04-29 |
| COVID-T: COVID-19 Search in Conjunctival Cells |
Coronavirus disease 19 infection, Lung disease |
computed tomography alone, conjunctival swab alone, nasopharyngeal swab alone, real time-PCR alone, x-ray alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Policlinico Universitario Agostino Gemelli |
|
Italy |
2020-03-26 |
2020-05-30 |
0013008/20, COVID-T, NCT04364594 |
Phase Not Applicable |
No longer recruiting |
0 |
2 Months |
50 |
|
2020-04-29 |
| SCOPe: To Study the Clinical characteristics and treatment Outcome of COVID-19 Patients admitted in hospitals of Max Healthcare |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Super Speciality Hospital |
|
India |
2020-04-25 |
|
CTRI/2020/04/024859, SCOPe |
Phase Not Applicable |
Not yet recruiting |
0 |
|
1000 |
Dr Ram Shankar Mishra, Dr Sandeep Budhiraja, Rajesh Saxena |
2020-04-29 |
| To study the effectiveness of Ivermectin with standard of care treatment versus standard of care treatment for COVID-19 cases. A Pilot Study |
Coronavirus disease 19 infection |
ivermectin alone |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Max Super Speciality Hospital |
|
India |
2020-04-25 |
|
CTRI/2020/04/024858 |
Phase 2 Clinical |
Not yet recruiting |
0 |
|
50 |
Dr Ram Shankar Mishra, Dr Sandeep Budhiraja, Rajesh Saxena |
2020-04-29 |
| Bid data analytic COVID-19 |
Coronavirus disease 19 infection |
predictive visual analytic method alone |
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-30 |
2020-08-31 |
54648, NMRR-20-790-54648 |
Phase Not Applicable |
Not yet recruiting |
0 |
4 Months |
|
Dr Mohd Azahadi Omar, Encik MOHAMAD FUAD BIN MOHAMAD ANUAR |
2020-04-29 |
| RNA-based vaccine for COVID-19 |
Coronavirus disease 19 infection |
RNA-based vaccine alone |
|
|
Institute for Medical Research (IMR) - Setia Alam |
|
Malaysia |
2020-06-01 |
2022-12-31 |
54569, NMRR-20-764-54569 |
Phase Not Applicable |
Status not specified |
0 |
31 Months |
|
Dr MASITA BINTI ARIP, Ms Ching Yee Ming |
2020-04-29 |
| COVID-19 NGS: NGS Diagnostic in COVID-19 Hosts: Genetic Cause Relating to the Course of Disease Progression |
Coronavirus disease 19 infection |
DNA methylation analysis alone, T-cell receptor repertoire sequencing alone, methylation beadchip (EPIC) array alone, next generation sequencing alone, whole genome sequencing alone, whole transcriptome sequencing alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Tubingen |
|
Germany |
2020-04-30 |
2021-08-31 |
COVID-19 NGS, COVID-19 NGS, NCT04364828 |
Phase Not Applicable |
Not yet recruiting |
0 |
16 Months |
1000 |
Michael Bitzer, Prof. Dr., Olaf Rieß, Prof. Dr. |
2020-04-29 |
| COVID-19: investigation into biochemical and hematological parameters in clinical laboratory |
Coronavirus disease 19 infection |
|
|
|
UNIVERSITI INDUSTRI SELANGOR (UNISEL) - SHAH ALAM CAMPUS |
|
Malaysia |
2020-04-29 |
2020-05-29 |
54641, NMRR-20-760-54641 |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
CHIA ZHEN ZHAN |
2020-04-29 |
| Lung Recruitment Device for COVID-19 |
Coronavirus disease 19 infection |
Chest physiotherapy alone |
|
|
|
Dymedso Inc, Fonds de la Recherche en Sante du Quebec |
|
2020-05-01 |
2020-12-31 |
MP-21-2020-2871, NCT04361435 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
50 |
Atsushi Kawaguchi, MD PhD, Philippe Jouvet, MD PhD MBA, Saly Salti, MSc |
2020-04-29 |
| LAPTRANSCOV: Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients |
Coronavirus disease 19 infection |
RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier René-Dubos |
|
France |
2020-04-23 |
2020-10-31 |
CHRD 0420, LAPTRANSCOV, NCT04361396 |
Phase Not Applicable |
Not yet recruiting |
2 |
6 Months |
40 |
Christophe Poncelet, Maryline Delattre, Nelson Trelles, Veronique Da Costa |
2020-04-29 |
| AIC: Azithromycin in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-20 |
2020-05-05 |
AIC, AZITHROMYCIN IN COVID-19, NCT04359316 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
40 |
Mehran Lack, MD, Mohammad Fathi, MD, Nader Markazi, MD, Nasser Malekpour Alamdari, MD, Sanaz Zargar Balaye Jam, MD, Sasan Tavana, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA |
2020-04-29 |
| An International, multicenter clinical study to evaluate the efficacy and safety of Polyoxidonium in hospitalized COVID-19 patients |
Coronavirus disease 19 infection |
Polyoxidonium alone |
|
|
NPO Petrovax Pharm LLC |
|
Russian Federation |
|
|
|
Phase Not Applicable |
Not yet recruiting |
1 |
|
|
|
2020-04-29 |
| CYNK001COVID: Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 |
Coronavirus disease 19 infection, Lower respiratory tract infection |
CYNK-001 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Celularity Inc, Sorrento Therapeutics Inc |
Infectious Disease Research Institute, Lung Biotechnology Inc |
US |
2020-04-30 |
2021-11-30 |
CYNK-001-COVID-19, CYNK001COVID, NCT04365101 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
19 Months |
86 |
Corey Casper, MD MPH, Erica Rave, MS, IDRI |
2020-04-29 |
| OzonoCOVID19: Indirect Endovenous Systemic Ozone for New Coronavirus Disease (COVID 19) in Non-intubated Patients |
Coronavirus disease 19 infection |
Base WHO recommended treatment. alone, Systemic indirect endovenous ozone therapy alone, ozone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Católica San Antonio de Murcia |
Sociedad Española de Ozonoterapia |
Spain |
2020-04-30 |
2020-06-30 |
NCT04359303, OzonoCOVID19, P.INV. OZONO-COVID19 VER.1.2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
2 Months |
50 |
Francisco J Hidalgo Tallón, MD, PhD, Jose Baeza Noci, MD, PhD |
2020-04-29 |
| COVIDHIV: Clinical Characterization Protocol for COVID-19 in People Living With HIV |
Coronavirus disease 19 infection, HIV infection |
auto-questionnaires alone, biological collection alone, qualitative interviews alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-10-31 |
2020-A00984-35, COVIDHIV, NCT04361604 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
270 |
Antoine Chéret, Dr |
2020-04-29 |
| Metabolon Study to Provide Better Understanding of COVID-19 |
Coronavirus disease 19 infection |
|
|
|
Institute For Systems Biology, Metabolon Inc |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
James R. Heath, Ph.D, Jason Goldman, M.D |
2020-04-29 |
| HASCOPT: Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial |
Coronavirus disease 19 infection, Respiratory failure |
azithromycin plus hydroxychloroquine |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital St. Joseph, Marseille, France |
|
France |
2020-04-30 |
2021-01-31 |
HASCOPT, HASCOPT2020, NCT04365231 |
Phase 3 Clinical |
Not yet recruiting |
0 |
9 Months |
50 |
Laurence CUREL, Maria mg Gackiere, Raoul RD Desbriere, MD, Xavier-Côme xcd Donato |
2020-04-29 |
| Effect of RBT-9 on Preventing Progression of COVID-19 in High-Risk Individuals |
Coronavirus disease 19 infection |
RBT-9 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Renibus Therapeutics Inc |
|
|
2020-06-01 |
2021-12-31 |
NCT04364763, REN-005 |
Phase 2 Clinical |
Not yet recruiting |
0 |
19 Months |
252 |
|
2020-04-29 |
| A study to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease19 (COVID-19) |
Coronavirus disease 19 infection |
routine therapy alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
|
2nd People's Hospital of Fuyang City, Anhui Provincial Hospital |
China National Center For Biotechnology Development, Department of Science and Technology of Anhui Province |
China |
|
|
|
Phase Not Applicable |
Status not specified |
2 |
|
21 |
|
2020-04-29 |
| COVID-RPC: Observational, Cohort of COVID-19 Patients at Raymond-Poincare |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-05-31 |
20SBS-COVID-RPC, COVID-RPC, NCT04364698 |
Phase Not Applicable |
Not yet recruiting |
0 |
1 Month |
500 |
Aurelien Dinh, MD, Simon Bessis, MD |
2020-04-29 |
| Convalescent Plasma for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Ente Ospedaliero Cantonale, |
|
Switzerland |
2020-04-27 |
2020-06-30 |
2020-00895, NCT04365439 |
Phase 2 Clinical |
Not yet recruiting |
0 |
2 Months |
10 |
Beatrice Bernasconi, Enos Bernasconi, Enos Bernasconi, M.D., Stefano Fontana, M.D. |
2020-04-29 |
| Covid-19 Associated Coagulopathy |
Blood clotting disorder, Coronavirus disease 19 infection |
enoxaparin sodium alone |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Iowa |
|
US |
2020-04-16 |
2021-04-16 |
202004235, NCT04360824 |
Phase 4 Clinical |
Not yet recruiting |
0 |
12 Months |
170 |
Usha Perepu |
2020-04-29 |
| Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Andalusian Network for Design and Translation of Advanced Therapies |
|
Spain |
2020-04-30 |
2021-12-31 |
NCT04366245, PC/COVID-19 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
20 Months |
72 |
Ana Cardesa Gil |
2020-04-29 |
| Proving the efficacy of Homeopathic treatment in prevention and cure of COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Ars Alb , Bryonia Alba , Camphora , Helleborus niger , Justicia Adhatoda |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Welling Healthcare Private Limited |
|
India |
2020-05-04 |
|
CTRI/2020/04/024857 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Angelo Smith, Dr Sourabh R Welling |
2020-04-29 |
| HIGH-PRONE-COVID-19: Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
prone decubitus alone, usual care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
|
France |
2020-04-30 |
2020-11-30 |
2020-A01121-38, DR200125, HIGH-PRONE-COVID-19, HIGH-PRONE-COVID-19, NCT04358939 |
Phase Not Applicable |
Not yet recruiting |
13 |
7 Months |
248 |
Agathe DELBOVE, MD, Anne-Charlotte TELLIER, MD, Arnaud THILLE, MD-PhD, Christophe GUITTON, MD, Damien ROUX, MD-PhD, Erwan L'HER, MD-PhD, Gaetan PLANTEFEVE, MD, Guillaume VOIRIOT, MD, Jean DELLAMONICA, MD-PhD, Jean REIGNIER, MD-PhD, Mai-Anh NAY, MD, Saadalla NSEIR, MD, Stephan EHRMANN, MD-PhD, Yoanatan PEREZ, MD, Yonatan PEREZ, MD |
2020-04-29 |
| COVID-19 CAir: SARS-CoV-2 Associated Respiratory Failure Recovery |
Coronavirus disease 19 infection, Respiratory failure |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Zurich |
|
Switzerland |
2020-05-31 |
2020-12-31 |
2020-00745, COVID-19 CAir, NCT04365595 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
200 |
Christian F Clarenbach, MD, Dario Kohlbrenner, MSc |
2020-04-29 |
| COP-COVID-19: Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone, supportive management alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario Dr. Jose E. Gonzalez |
|
Mexico |
2020-04-27 |
2021-05-30 |
COP-COVID-19, IF20-00002, NCT04358783 |
Phase 2 Clinical |
Not yet recruiting |
1 |
13 Months |
30 |
Adrian Camacho-Ortiz, MD, Eduardo Pérez Alba, MD, Laura Marina Nuzzolo Shihadeh, MD |
2020-04-29 |
| COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box, Randomized, Controlled Trial |
Coronavirus disease 19 infection |
COVID-19 barrier box alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of British Columbia |
|
Canada |
2020-05-31 |
2021-04-30 |
H20-01270, NCT04366141 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
120 |
Anton Chau, MD, Tim Jen, MD |
2020-04-29 |
| A Proof of Concept study of Nu.Q COVID-19 Triage Test in COVID-19 patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
Volition’s Nu.QTM nucleosome assays alone |
|
|
VolitionRX Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-29 |
| JAKINKOV: Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation |
Coronavirus disease 19 infection, Inflammatory disease, Respiratory distress syndrome, Viral pneumonia |
anakinra alone, Jakavi plus Kineret |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
Assistance Publique Hopitaux De Marseille |
France |
2020-05-01 |
2020-08-31 |
2020-001963-10, 2020-CHITS-003, JAKINKOV, NCT04366232 |
Phase 2 Clinical |
Not yet recruiting |
3 |
4 Months |
50 |
David DELARBRE, MD, Gilles HITTINGER, MD, Gilles KAPLANSKI, MD, Jean-Philippe Suppini, PhD |
2020-04-29 |
| A study to track coronavirus (COVID-19) in the general population |
Coronavirus disease 19 infection |
|
|
|
University of Oxford |
|
UK |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
300000 |
Department for Health and Social Care, Office for National Statistics |
2020-04-29 |
| ESCAPE: Study to evaluate the efficacy and tolerability of treatment with vafidemstat in combination with standard of care treatment to prevent Acute Respiratory Distress Syndrome in adult severely ill patients with COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
standard of care treatment alone, vafidemstat alone |
Lysine specific histone demethylase 1 inhibitor, MAO B inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oryzon Genomics SA |
|
Spain |
2020-04-24 |
|
2020-001618-39, CL08-ORY-2001_COVID-19, ESCAPE |
Phase 2 Clinical |
No longer recruiting |
1 |
|
40 |
Sonia Gutiérrez |
2020-04-29 |
| AUTONOMIC: Stress Biomarkers Leading to Professional Burnout Among People Involved in a Mobile Intensive Care Unit During the COVID-19 Pandemic |
Anxiety disorder, Coronavirus disease 19 infection, Post traumatic stress disorder |
electrocardiography alone, electrodermal test alone, emotional stimulation test alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Direction Centrale du Service de Sante des Armees |
Institut de Recherche Biomedicale des Armees |
France |
2020-04-30 |
2020-06-30 |
2020-COVID19-11, AUTONOMIC, NCT04365335 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
60 |
Damien CLAVERIE, MD, PhD |
2020-04-29 |
| SINK COVID-19: Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19 |
Coronavirus disease 19 infection |
Ketalar alone, naltrexone (once-monthly controlled-release, Medisorb), Alkermes alone, Ketalar plus naltrexone (once-monthly controlled-release, Medisorb), Alkermes |
Opioid receptor antagonist, Opioid receptor mu antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
William Beaumont Hospitals |
|
US |
2020-04-30 |
2020-08-31 |
2020-097, NCT04365985, SINK COVID-19 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
500 |
Matthew Sims, MD, Matthew Sims, MD PhD, Maureen Cooney, RN, BSN |
2020-04-29 |
| Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients |
Coronavirus disease 19 infection, Respiratory disease |
anti-SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Albert Einstein College of Medicine |
New York University |
US |
2020-04-17 |
2023-04-30 |
2020-11467, NCT04364737 |
Phase 2 Clinical |
Recruiting |
0 |
36 Months |
300 |
Hyunah Yoon, MD, Liise-anne Pirofski, MD, Mila Ortigoza, MD |
2020-04-29 |
| REMDECO-19: Multicenter, Retrospective Study of the Effects of Remdesivir in the Treatment of Severe Covid-19 Infections |
Coronavirus disease 19 infection |
remdesivir alone |
RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-05-31 |
APHP200522, NCT04365725, REMDECO-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
200 |
Jeremie ZERBIT, PharmaD, Jérémie ZERBIT, PharmaD |
2020-04-29 |
| Progesterone for the Treatment of COVID-19 in Hospitalized Men |
Coronavirus disease 19 infection |
progesterone (sc, in vitro fertlilization), Institut Biochimique alone, standard of care alone |
Progesterone receptor agonist |
Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cedars-Sinai Medical Center |
Institut Biochimique SA |
US |
2020-04-27 |
2021-04-17 |
NCT04365127, STUDY00000611 |
Phase 1 Clinical |
Recruiting |
0 |
11 Months |
40 |
Sara Ghandehari, MD, Vanessa Vasco |
2020-04-29 |
| COVIDMES: Efficacy and safety evaluation of umbilical cord mesenchymal stem cells for the treatment of patients with respiratory failure due to coronavirus (COVID-19) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
umbilical cord mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Banc De Sang I Teixits |
|
Spain |
2020-04-23 |
|
2020-001505-22, BST-COVID-01, COVIDMES |
Phase 1/Phase 2 Clinical |
No longer recruiting |
1 |
|
30 |
Banc de Sang i Teixits |
2020-04-29 |
| BIRCOV: ARB, ACEi, DRi in COVID-19 |
Coronavirus disease 19 infection, Hypertension |
angiotensin converting enzyme inhibitor (ACEi) therapy alone, angiotensin receptor blocker (ARB) therapy alone, dopamine reuptake inhibitor (DRI) therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical Practice Prof D. Ivanov |
|
Ukraine |
2020-04-01 |
2021-08-01 |
BIRCOV, COVID20, NCT04364984 |
Phase Not Applicable |
Recruiting |
1 |
16 Months |
10 |
Dmytro Ivanov, MD, Prof, Mariia Ivanova, MD, PhD |
2020-04-29 |
| DURO-SIN: COVID-19 in an academic teaching hospital in Konstanz/Germany - evaluation of the 'double rule out - single rule in' concept |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum Konstanz, II. Medizin |
|
Germany |
2020-04-27 |
|
81/2020, DRKS00021605, DURO-SIN, U1111-1251-0310 |
Phase Not Applicable |
Recruiting |
1 |
|
200 |
Stephan Walterspacher |
2020-04-29 |
| Factors Associated With Clinical Outcomes in Patients Hospitalized for COVID-19 in GHT-93 Est |
Coronavirus disease 19 infection, Viral pneumonia |
corticosteroid therapy alone, systematic antibiotic therapy alone, Variable regimens including azithromycin , baricitinib , hydroxychloroquine , lopinavir + ritonavir , sarilumab , tocilizumab |
HIV protease inhibitor, IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Centre Hospitalier Intercommunal Robert Ballanger |
Groupe Hospitalier Pitie-Salpetriere |
France |
2020-03-14 |
2020-07-31 |
GHTRB-2020-01, NCT04366206 |
Phase Not Applicable |
Recruiting |
2 |
4 Months |
143 |
Benjamin Rossi, MD, Dr. Hélène GROS, Hélène Gros, MD, Lee S Nguyen, MD, PhDc |
2020-04-29 |
| Evaluating AVM-0703 for Treatment of COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
AVM-0703 plus hydrocortisone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AVM Biotechnology LLC |
Medpace Inc |
|
2020-06-30 |
2023-06-30 |
AVM0703-101, NCT04366115 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
36 Months |
126 |
Brandon Franklin |
2020-04-29 |
| Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter, Cohort Study |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin alone, baricitinib alone, hydroxychloroquine alone, lopinavir + ritonavir alone, oseltamivir alone, remdesivir alone, sarilumab alone, tocilizumab alone |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, IL-6 receptor antagonist, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, RNA polymerase modulator |
|
Groupe Hospitalier Pitie-Salpetriere |
CMC Ambroise Paré, Centre Hospitalier Intercommunal Montfermeil-Le Raincy, Centre Hospitalier Intercommunal Robert Ballanger |
France |
2020-03-14 |
2020-12-31 |
CIC1421-20-06, NCT04365764 |
Phase Not Applicable |
Recruiting |
2 |
9 Months |
400 |
Anis Saib, MD, Hélène Gros, MD, Joe-Elie Salem, MD, PhD, Lee S Nguyen |
2020-04-29 |
| COV-CREM: Study of Specific Viral Immune Responses Induced by SARS-CoV-2 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital of Besancon |
|
France |
2020-04-20 |
2025-04-20 |
2020/502, COV-CREM, NCT04365322 |
Phase Not Applicable |
Recruiting |
1 |
60 Months |
60 |
Kevin BOUILLER, MD, Marie KROEMER, PharmD PhD |
2020-04-29 |
| CBP-COVID: Impact of SARS-COV2 Infection and Confinement on Diagnostic and Therapeutic Management of Lung Cancer: Ambispective Study Extended Over Two Time Periods |
Coronavirus disease 19 infection, Lung tumor |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier le Mans |
ONCOPL (FR) |
|
2020-06-30 |
2022-08-28 |
CBP-COVID, CHM-2020/S15/03, NCT04366219 |
Phase Not Applicable |
Not yet recruiting |
0 |
25 Months |
2000 |
CHRISTELLE JADEAU, OLIVIER MOLINIER, MD |
2020-04-29 |
| A larger phase IIb/III trial of recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals for the potential prevention of coronavirus infection COVID-19 caused by SARS-CoV-2 (2019-nCoV) |
Coronavirus disease 19 infection |
recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals alone |
Angiotensin converting enzyme 2 modulator |
|
Linear Clinical Research Limited |
|
Australia |
|
|
|
Phase 2/Phase 3 Clinical |
Planned |
1 |
|
|
|
2020-04-29 |
| The Psychological Impact of COVID-19 Outbreak on COVID-19 Survivors and Their Families |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
Queen Mary Hospital |
Hong Kong |
2020-04-27 |
2021-06-30 |
NCT04365348, UW20-300 |
Phase Not Applicable |
Not yet recruiting |
1 |
14 Months |
300 |
Agnes YK Lai, PhD, Mary SM Ip, MD |
2020-04-29 |
| A phase I clinical trial of recombinant subunit-trimer vaccine (COVID-19) in healthy adult and healthy elderly trial participants |
Coronavirus disease 19 infection |
recombinant subunit-trimer vaccine (COVID-19), Clover Biopharmaceuticals alone |
Angiotensin converting enzyme 2 modulator |
Healthy volunteers accepted |
Clover Biopharmaceuticals AUS Pty Ltd, Coalition for Epidemic Preparedness Innovations, Linear Clinical Research Limited |
|
Australia |
|
|
|
Phase 1 Clinical |
Planned |
1 |
|
|
|
2020-04-29 |
| COVIPACT: Impact of the COVID-19 Infectious Epidemic on the Management of Oncology and Onco-hematology Patients and on the Psychological Consequences for Patients and Caregivers |
Acute stress disorder, Cognitive disorder, Coronavirus disease 19 infection, Hematological neoplasm, Post traumatic stress disorder, Sleep disorder, Solid tumor |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Francois Baclesse |
|
France |
2020-04-15 |
2020-12-31 |
2020-A00879-30, COVIPACT, NCT04366154 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
385 |
Audrey FAVEYRIAL, MD, Florence JOLY, PhD |
2020-04-29 |
| OUTCOV: Outpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome |
Bordetella pertussis infection, Coronavirus disease 19 infection, Dyspnea |
azithromycin alone, hydroxychlororquine alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Groupe Hospitalier Paris Saint-Joseph |
|
France |
2020-04-28 |
2021-01-28 |
NCT04365582, OUTCOV, OUTCOV |
Phase 3 Clinical |
Not yet recruiting |
5 |
9 Months |
640 |
Christos CHOUAID, MD, Helene Beaussier, MD PhD, Hilario Nunes, MD, Jean Marc NACCACHE, MD, Jean-Marc Naccache, MD, Pierre CHARLES, MD |
2020-04-29 |
| Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers |
Coronavirus disease 19 infection |
Lactobacillus coryniformis K8 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Puleva Biotech SA |
|
Spain |
2020-04-24 |
2020-10-31 |
NCT04366180, P054 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
314 |
Raquel Rodriguez Blanque |
2020-04-29 |
| COVIDGHPSJCite: Become of Patients Infected or Suspected of Being Infected by Covid-19 and Supported by the GHPSJ and the Establishments of the Paris Plaisance Hospital City |
Coronavirus disease 19 infection |
|
|
|
Groupe Hospitalier Paris Saint-Joseph |
|
France |
2020-04-01 |
2022-12-31 |
COHORTE COVID GHPSJ CITEH, COVIDGHPSJCite, NCT04365530 |
Phase Not Applicable |
Recruiting |
5 |
33 Months |
2000 |
Benoit PILMIS, MD, Bernard DURAND GASSELIN, MD, Bernard Durand Gasselin, MD, Florence Bonte, MD, Helene BEAUSSIER, PharmD, pHD, Maxime TOUZOT, MD |
2020-04-29 |
| Canakinumab to Reduce Deterioration of Cardiac and Respiratory Function Due to COVID-19 |
Coronavirus disease 19 infection, Heart injury, Inflammatory disease, Respiratory failure |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cleveland Clinic Foundation |
|
US |
2020-04-24 |
2020-12-31 |
IND 149328, NCT04365153 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
45 |
Calvin Sheng, M. D., Ossama Abou Hassan, M. D., Paul C Cremer, M. D., Sidhharth Dugar, M. D., Tom Wang, M. D., Venu Menon, M. D., Yuki Kuramochci, RN BSN, Yuki Kuramochi, RN BSN |
2020-04-29 |
| CardiacCovid: Patient Recovery From Heart Surgery During the Covid-19 Pandemic |
Cardiac surgical procedure, Coronavirus disease 19 infection, Depression |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barts and The London NHS Trust |
Queen Mary University of London |
UK |
2020-04-18 |
2021-12-31 |
132127, CardiacCovid, NCT04366167 |
Phase Not Applicable |
Recruiting |
1 |
20 Months |
100 |
Aung Ye Oo, MD, Julie Sanders, PhD, Teofila Bueser, MSc |
2020-04-29 |
| A Novel Nomogram to Predict Severity of COVID-19 |
Coronavirus disease 19 infection |
RT-PCR test alone, computed tomography imaging alone, novel nomogram model prediction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xinqiao Hospital of Chongqing |
|
China |
2020-01-17 |
2021-12-31 |
NCT04366024, XQONC-016 |
Phase Not Applicable |
Recruiting |
1 |
23 Months |
1000 |
Jianguo Sun, Sun Jianguo |
2020-04-29 |
| A phase II, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of OT-101 in adult patients hospitalized with COVID-19 and pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
OT-101 alone |
Factor IX agonist |
|
Mateon Therapeutics Inc |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-29 |
| PRE-VENT: A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of pacritinib plus standard of care versus placebo plus standard of care in hospitalized patients with severe COVID-19, including patients with and without cancer |
Coronavirus disease 19 infection |
pacritinib alone, standard of care alone |
CSF-1 antagonist, Cytochrome P450 reductase inhibitor, Flt3 tyrosine kinase inhibitor, IRAK-1 protein kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
CTI BioPharma Corp |
|
US |
2020-04-27 |
|
PRE-VENT |
Phase 3 Clinical |
Not yet recruiting |
0 |
|
358 |
John Mascarenhas |
2020-04-29 |
| REACOVIM: Study of Clinical and Immune Severity Profiles of Patients Infected With SARS-Cov2 (COVID-19) |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Direction Centrale du Service de Sante des Armees |
|
France |
2020-04-20 |
2022-04-20 |
2020-COVID19-05, NCT04365166, REACOVIM |
Phase Not Applicable |
Not yet recruiting |
2 |
24 Months |
100 |
Clément DUBOST, MD, PhD, Nicolas LIBERT, MD, PhD |
2020-04-29 |
| Cardiovascular Effects of COVID-19 |
Cardiovascular disease, Coronavirus disease 19 infection |
fluoxetine (Zydis, tablet, autism), Autism Therapeutics alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-04-08 |
2020-12-31 |
20-00416, NCT04365699 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
500 |
Stuart Katz, MD |
2020-04-29 |
| PIIPPI: COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients |
Coronavirus disease 19 infection |
Standard PPE alone, Standard care alone, povidone-iodine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Kentucky |
|
US |
2020-05-31 |
2021-05-31 |
58748, NCT04364802, PIIPPI |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
250 |
Alexandra E Kejner, MD, James Porterfield, MD, PhD, Melissa Thompson-Bastin, PharmD, Nikita Gupta, MD, Nikta Gupta, MD |
2020-04-29 |
| PEAC: Protective Effect of Aspirin on COVID-19 Patients |
Coronavirus disease 19 infection, Viral pneumonia |
aspirin alone, combined standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Xijing Hospital |
|
China |
2020-02-10 |
2020-06-30 |
NCT04365309, PEAC, XI JINGH |
Phase 2/Phase 3 Clinical |
Recruiting |
1 |
4 Months |
128 |
Cai Yue |
2020-04-29 |
| The Psychological Impact of the COVID-19 on Students |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-26 |
2021-03-31 |
NCT04365361, UW20-298 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
300 |
Agnes YK Lai, PhD, Kelvin MP Wang, PhD, LAI YK Agnes, PhD |
2020-04-29 |
| A phase III trial to evaluate NT-300 for the early treatment of COVID-19 and other viral respiratory illnesses |
Coronavirus disease 19 infection, Viral respiratory tract infection |
nitazoxanide (controlled-release, viral infections), Romark alone |
|
|
Romark Laboratories LC |
|
|
|
|
|
Phase 3 Clinical |
Planned |
0 |
|
|
|
2020-04-29 |
| A clinical study of POL-6014 in the treatment of patients with COVID-related acute respiratory distress syndrome |
Coronavirus disease 19 infection, Respiratory distress syndrome |
lonodelestat alone |
Leukocyte elastase inhibitor |
|
Santhera Pharmaceuticals AG |
Cold Spring Harbor Laboratory |
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-29 |
| PREVENT-COVID Trial: Prazosin to Prevent COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory tract infection |
once daily prazosin (OROS), ALZA alone |
Alpha 1A adrenoceptor antagonist, Cyclic nucleotide phosphodiesterase inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
Fast Grants |
US |
2020-04-30 |
2020-12-31 |
COV2001, IRB00246659, NCT04365257, PREVENT-COVID Trial |
Phase 2 Clinical |
Not yet recruiting |
0 |
8 Months |
220 |
Chetan Bettegowda, MD/PhD |
2020-04-29 |
| Mon-Covid: Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino) |
Coronavirus disease 19 infection |
home care monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mario Negri Gynecologic Oncology group |
|
Italy |
2020-04-21 |
2020-12-31 |
MON-COVID, Mon-Covid, NCT04361916 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
425 |
Chiara Gerardi, PhD, Guido Bertolini, MD, Rita Banzi, PhD, Roberto Stura |
2020-04-29 |
| Use of Contemporary Live Tele-Video Conferencing for Continuing Surgical Training at the time of COVID-19 pandemic |
Coronavirus disease 19 infection |
|
|
|
Sultanah Aminah Hospital |
|
Malaysia |
2020-05-01 |
2020-05-31 |
NMRR-20-814-54742 |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
dr henry tan chor lip |
2020-04-29 |
| Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
allogeneic and expanded adipose tissue-derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Andalusian Network for Design and Translation of Advanced Therapies |
Junta De Andalucia |
Spain |
2020-04-30 |
2021-10-31 |
2020-001364-29, ADIQURE/COVID-19, NCT04366323 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
18 Months |
26 |
Ana Cardesa Gil, Clinical Trial Unit |
2020-04-29 |
| Stress Level Among Healthcare Workers in Handling COVID-19 Patients in Sarawak General Hospital |
Coronavirus disease 19 infection |
|
|
|
Universiti Malaysia Sarawak |
|
Malaysia |
2020-05-04 |
2020-10-30 |
54744, NMRR-20-819-54744 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
|
Dr. Sim Sze Kiat |
2020-04-29 |
| CancerMCO: CancerMCO |
Coronavirus disease 19 infection |
|
|
|
Universiti Putra Malaysia |
|
Malaysia |
2020-05-01 |
2020-11-01 |
54786, CancerMCO, NMRR-20-825-54786 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr Sri Ganesh Muthiah |
2020-04-29 |
| CT-COVID-AI: CT-COVID-AI |
Coronavirus disease 19 infection |
Chest CT Diagnosis alone |
|
|
Hospital Sungai Buloh |
|
Malaysia |
2020-05-01 |
2020-11-02 |
54784, CT-COVID-AI, NMRR-20-826-54784 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
|
Dr Mohan Dass Pathmanathan |
2020-04-29 |
| Needle Stick Injuries in Emergency Medical Service Practice |
Coronavirus disease 19 infection |
Cardiopulmonary resuscitation alone, double gloves alone |
|
|
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences |
Poland |
2020-02-28 |
2020-04-24 |
NCT04363788, OH_PPE_1 |
Phase Not Applicable |
Completed |
1 |
1 Month |
300 |
|
2020-04-29 |
| DISTANSE COVID: Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized, Controlled Trial |
Coronavirus disease 19 infection |
Cash transfer alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Michaels Hospital |
|
Canada |
2020-04-20 |
2021-06-30 |
20-081, DISTANSE COVID, NCT04359264 |
Phase Not Applicable |
Not yet recruiting |
2 |
14 Months |
392 |
Mike Bedard, Mike Bedard, MD, Nav Persaud, Nav Persaud, MD, MSc |
2020-04-29 |
| Adapting the Decathlon Group Easybreathe snorkelling face mask for the safer administration of oxygen and/or continuous positive airway pressure and in the intra/interhospital transportation of patients with proven or suspected COVID 19 infection |
Coronavirus disease 19 infection |
Easybreathe snorkelling face mask alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Monash Health |
|
Australia |
2020-04-27 |
2020-10-27 |
ACTRN12620000472976p |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
100 |
Dr Simon Joosten |
2020-04-29 |
| COVID-19 Recovered Volunteer Research Participant Pool Registry |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California Los Angeles |
|
US |
2020-04-08 |
2042-04-20 |
20-000625, NCT04359602 |
Phase Not Applicable |
Recruiting |
0 |
264 Months |
10000 |
Antonia Petruse, MBA, Arash Naeim, MD, PhD |
2020-04-29 |
| Different PEEP Settings of COVID-19 Induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ARDSnet table PEEP setting alone, Optimizing compliance alone, Optimizing oxygenation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Southeast University |
|
China |
2020-03-05 |
2020-03-25 |
COVID-19 PEEP TITRATION, NCT04359251 |
Phase Not Applicable |
Completed |
1 |
|
20 |
Chun C Pan, Chun Pan |
2020-04-29 |
| STRIPE-3: Study for Testing and Reviewing Improvised PPE Effectiveness 3 |
Coronavirus disease 19 infection |
Anesthetic facemask based improvised personal protective equipment alone, Snorkel-based improvised personal protective equipment alone, light exercise alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guy's & St Thomas' Hospital NHS Trust |
|
UK |
2020-04-28 |
2020-10-28 |
NCT04362163, STRIPE-3, TAP_PRG_21_04_2020_2 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
10 |
Paul R Greig, MBChB |
2020-04-29 |
| REST: Online Cognitive Behavioral Therapy (CBT) for Stress Disorders in Health Workers Involved in the Care of Patients During the Covid-19 Epidemic |
Acute stress disorder, Coronavirus disease 19 infection |
Online cognitive behavioral therapy (CBT) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital of Strasbourg |
|
|
2020-05-01 |
2021-10-01 |
7799, NCT04362358, REST |
Phase Not Applicable |
Not yet recruiting |
0 |
17 Months |
120 |
Luisa Weiner, MD |
2020-04-29 |
| TVP-COVID-RIV: Influence of COVID-19 Infection in Thromboembolic Venous Disease: National Cohort Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sociedad Espanola de Angiologia y Cirugia Vascular |
|
Spain |
2020-04-30 |
2020-12-31 |
NCT04361981, RIV-R3, TVP-COVID-RIV |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
50 |
Joaquin De Haro, MD |
2020-04-29 |
| Liver Injury in Patients With COVID-19 |
Coronavirus disease 19 infection, Liver injury |
|
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad Austral De Argentina |
|
Argentina |
2020-04-15 |
2020-12-31 |
CIE N° P 20-011, NCT04358380 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
34 |
Marcelo O Silva, MD |
2020-04-28 |
| DAWN AZITHRO: COVID-19: A randomized, open-label, adaptive, proof-of-concept clinical trial of new antiviral drug candidates against SARS-CoV-2 |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
UZ Leuven-University Hospitals |
|
Belgium |
2020-04-22 |
|
2020-001614-38, DAWN AZITHRO, S63935 |
Phase 2 Clinical |
Recruiting |
1 |
|
240 |
Clinical trial center UZ Leuven, clinical trial center UZ Leuven |
2020-04-28 |
| COVID19 HTAA: COVID19 HTAA |
Coronavirus disease 19 infection |
|
|
|
Hospital Tengku Ampuan Afzan |
|
Malaysia |
2020-04-25 |
2020-07-31 |
54513, COVID19 HTAA, NMRR-20-811-54513 |
Phase Not Applicable |
Status not specified |
1 |
3 Months |
90 |
Dr SOH TZE VEE |
2020-04-28 |
| The epidemiology of COVID-19 cases and disease surveillance system in Hulu Langat district, Selangor |
Coronavirus disease 19 infection |
|
|
|
Pejabat Kesihatan Daerah Hulu Langat |
|
Malaysia |
2020-04-24 |
2021-04-23 |
54757, NMRR-20-809-54757 |
Phase Not Applicable |
Status not specified |
1 |
12 Months |
|
Dr WAN MING KEONG |
2020-04-28 |
| MLCOVID: MLCOVID |
Coronavirus disease 19 infection |
Machine Learning alone |
|
|
Institute For Medical Research (Inc In Malaysia) |
|
Malaysia |
2020-04-24 |
2021-04-23 |
54483, COVID19-HSB/2, MLCOVID, NMRR-20-807-54483 |
Phase Not Applicable |
Status not specified |
1 |
12 Months |
|
Dr Suresh Kumar, Dr WONG XIN CI |
2020-04-28 |
| QTc COVID: QTc COVID |
Coronavirus disease 19 infection |
|
|
|
Hospital Sungai Buloh |
|
Malaysia |
2020-04-30 |
2020-05-30 |
54728, NMRR-20-798-54728, QTc COVID |
Phase Not Applicable |
Status not specified |
1 |
1 Month |
|
Ms KOH HUI MOON |
2020-04-28 |
| IP COVID-19: IP COVID-19 |
Coronavirus disease 19 infection |
|
|
|
National Institutes of Health Malaysia |
|
Malaysia |
2020-04-30 |
2020-09-30 |
54770, IP COVID-19, NMRR-20-793-54770 |
Phase Not Applicable |
Status not specified |
1 |
5 Months |
|
Dr. Ainul Nadziha bt. Mohd. Hanafiah, Roslinda binti Abu Sapian |
2020-04-28 |
| Study of FT-516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia |
Coronavirus disease 19 infection, Hypoxia |
FT-516 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Masonic Cancer Center |
|
US |
2020-05-04 |
2022-01-31 |
IDIM-2020-28708, NCT04363346 |
Phase 1 Clinical |
Not yet recruiting |
0 |
20 Months |
12 |
Dr.Joshua Rhein, MD, Mahsa Abassi, DO,MPH, Meghan Rothenberger, MD, Timothy Schacker, MD |
2020-04-29 |
| COVID AMBU 60: Multicenter, Observational Study on Management COVID-19 Positive Outpatients in a French Cluster |
Coronavirus disease 19 infection |
observational management alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Maison de Sante Pluridisciplinaire de Creil |
|
France |
2020-03-01 |
2020-12-31 |
2020-A01059-30, COVID AMBU 60, NCT04363099 |
Phase Not Applicable |
Recruiting |
1 |
10 Months |
1000 |
DIMI Svetlane, Svetlane DIMI, Svetlane DIMI, M.D |
2020-04-28 |
| COVID-EC Study: Clinical Characteristics of Patients With COVID-19 in Guayaquil, Ecuador |
Coronavirus disease 19 infection, Respiratory tract infection |
azithromycin alone, chloroquine alone, corticosteroids alone, enoxaparin alone, heparin alone, hydroxychloroquine alone, ivermectin alone, lopinavir + ritonavir alone, nitazoxanide alone, oseltamivir alone, tocilizumab alone |
Chloride channel modulator, Exo-alpha sialidase inhibitor, HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinico San Carlos |
Universidad Catolica Santiago de Guayaquil |
Spain |
2020-04-30 |
2020-05-31 |
001, COVID-EC Study, NCT04362969 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
300 |
Jorge Carriel M. |
2020-04-29 |
| Collection of Biological Samples With Clinical Characterization of Covid-19 Patients |
Coronavirus disease 19 infection |
blood sampling alone |
|
|
Centre Hospitalier Intercommunal Creteil |
|
France |
2020-05-01 |
2020-12-01 |
COVIGENET, NCT04363385 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
500 |
Bernard MAITRE, Ph D, Bernard Maitre, Ph D, Isabelle HAU, MD |
2020-04-29 |
| Rhu-pGSN for Severe Covid-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
gelsolin, BioAegis Therapeutics alone |
Actin antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
BioAegis Therapeutics Inc |
|
|
2020-06-30 |
2020-09-30 |
BTI-202, NCT04358406 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
60 |
Mark J DiNubile, MD, Susan L Levinson, PhD |
2020-04-29 |
| CEDiD: COVID-19 Early Diagnosis in Doctors |
Coronavirus disease 19 infection |
Empatica E4 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King's College London |
Empatica Srl |
UK |
2020-04-27 |
2020-05-27 |
CEDID STUDY STH, CEDiD, NCT04363489 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
30 |
Alexander Zargaran, Anne Greenough, Dina Radenkovic, Dina Radenkovic, MBBS, BSc, Dr Alexander Zargaran |
2020-04-29 |
| Levamisole and Isoprinosine in Immune-prophylaxis of Egyptian Healthcare Workers Facing COVID-19 |
Coronavirus disease 19 infection |
isoprinosine alone, levamisole alone, isoprinosine plus levamisole |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-01 |
FMASU P20A/ 2020, NCT04360122 |
Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Fatma Soliman E Ebeid |
2020-04-29 |
| The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
pulmonary physiotherapy techniques alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-20 |
2020-08-01 |
99-1-103-47429, NCT04357340 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
40 |
Behrouz Attarbashi Moghaddam, Ph.D., Mohammad Javaherian, Ph.D. cand., Seyyed Reza Raees Karami, MD., Zahra Ahmadinejad, MD. |
2020-04-29 |
| CovImmune: Study of Immune Response During SARS-CoV-2 Infection - (COVID-19) |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-22 |
2020-10-22 |
20-PP-05, CovImmune, NCT04355351 |
Phase Not Applicable |
Not yet recruiting |
3 |
6 Months |
400 |
Barbara SEITZ-POLSKI, MCUPH, Jean DELLAMONICA, PUPH, Matteo VASSALLO, PH, elisa DEMONCHY, PH, johanna PLANCHARD, PH, sonia BOYER-SUAVET, PH |
2020-04-29 |
| Convalescent Plasma Trial in COVID-19 Patients |
Coronavirus disease 19 infection, Hypoxia, Viral pneumonia |
convalescent plasma alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Royal College of Surgeons in Ireland - Medical University of Bahrain |
Bahrain Defence Force Royal Medical Services, Military Hospital, Mohammed Bin Khalifa Bin Sulman Al Khalifa Cardiac Centre, Awali, Salmaniya Medical Complex |
Bahrain |
2020-04-19 |
2020-06-30 |
BDF/R&REC/2020-423, NCT04356534 |
Phase 2 Clinical |
Not yet recruiting |
1 |
2 Months |
40 |
Abdulkarim Abdulrahman, Dr., Abdulrahman Almadani, Dr., Amal Hejab, Dr., Manaf Al Qahtani, Dr., Manal Al Sayed, Dr., Pearl Wasif, MSc., Salman Yousif Alali, Dr., Sameer Otoom, Prof., Stephen Atkin, Prof. |
2020-04-29 |
| Nancy-CovH-AKI: Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe COVID-19 Infection |
Coronavirus disease 19 infection, Heart injury, Renal injury |
biological samples specific to research alone, clinical examination alone, telephone follow-up alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Central Hospital, Nancy, France |
|
France |
2020-04-15 |
2020-10-18 |
2020PI072, NCT04354610, Nancy-CovH-AKI |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
57 |
Antoine KIMMOUN, MD, PhD, Patrick ROSSIGNOL, MD, PhD |
2020-04-29 |
| FatCovid-19: Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability |
Chronic fatigue syndrome, Coronavirus disease 19 infection |
actigraphy alone, blood test alone, electromyography alone, ergometer alone, magnetic resonance imaging alone, maximal effort test alone, neuromuscular evaluation alone, peripheral nerve stimulation alone, transcranial magnetic stimulation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Centre Hospitalier Universitaire de Saint Etienne |
Universite Jean Monnet |
France |
2020-04-30 |
2021-12-31 |
2020-A00982-37, 20CH085, FatCovid-19, NCT04363606 |
Phase Not Applicable |
Not yet recruiting |
3 |
20 Months |
52 |
Guillaume THIERY, MD PhD, Jérome MOREL, MD PhD, Jérôme MOREL, MD PhD, Laurent GERGELE, MD, Lydia OUJAMAA, MD, Léonard FEASSON, MD PhD, Pascal GIRAUX, MD, Pierre CROISILLE, MD PhD |
2020-04-28 |
| MARIPOSA: A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
standard of care alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Roche Holding AG |
|
|
2020-05-04 |
2020-08-03 |
CA42481, MARIPOSA, NCT04363736 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
100 |
Clinical Trials |
2020-04-28 |
| COVIDeF: Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being |
Coronavirus disease 19 infection |
Variable regimens including blood sampling |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-03-31 |
2022-03-31 |
2020-A00754-35, APHP200382, COVIDeF, NCT04352348 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
2000 |
Linda Gimeno, Pierre HAUSFATER, MD, Pierre Hausfater, MD |
2020-04-29 |
| COMBAT-COVID19: The COMBAT-COVID-19 Pilot Study |
Coronavirus disease 19 infection, Respiratory distress syndrome |
colchicine alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Maimonides Medical Center |
|
US |
2020-04-23 |
2021-06-30 |
2020-04-12, COMBAT-COVID19, NCT04363437 |
Phase 2 Clinical |
Recruiting |
0 |
14 Months |
70 |
Antonios Likourezos, MA, MPH, Antonios Likourezos, MPH, Felix Yang, MD |
2020-04-29 |
| Early Identification and Treatment of Cytokine Storm Syndrome in Covid-19 |
Coronavirus disease 19 infection, Respiratory failure |
anakinra alone |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Alabama at Birmingham |
|
US |
2020-05-31 |
2020-12-31 |
CHATHAM-CYTOKINE COVID-19, NCT04362111 |
Phase 3 Clinical |
Not yet recruiting |
0 |
7 Months |
20 |
Angela Kendrach, Walter W Chatham, MD |
2020-04-29 |
| GETAFE: Low-dose Lenalidomide for Non-severe COVID-19 Treatment Trial |
Coronavirus disease 19 infection |
lenalidomide plus low molecular weight heparin (LMWH) |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Universitario de Getafe |
|
Spain |
2020-04-27 |
2020-12-31 |
COVID19-EC01, GETAFE, NCT04361643 |
Phase 4 Clinical |
Not yet recruiting |
1 |
8 Months |
120 |
Joaquin De Haro, MD, Joaquin De Haro, MD,PhD |
2020-04-29 |
| Tocilizumab Treatment in Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto Nacional de Cancerologia de Mexico |
Roche Pharma (Schweiz) AG |
Mexico |
2020-04-01 |
2020-08-01 |
INF-3343-20-22-1, NCT04363853 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
200 |
Diana Flores Estrada, Oscar G Arrieta, MD M Sc., Oscar G Arrieta, Oncologist, Oscar Gerardo Arrieta Rodríguez |
2020-04-28 |
| The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , ceftriaxone , colchicine , lopinavir + ritonavir , omega-3 , selenium , tiamine , vitamin A , vitamin C , vitamin D |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-03-20 |
2020-05-30 |
NCT04360980, SBMU.IR.REC.165423 |
Phase 2 Clinical |
Recruiting |
2 |
2 Months |
80 |
CKDRC,SBMU, MD, Nooshin Dalili, Dr, Nooshin Dalili, MD, SBMU, nooshin dalili |
2020-04-28 |
| COVID 19 Biomarkers |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
|
University of British Columbia |
|
Canada |
2020-03-30 |
2021-09-30 |
H20-00971, NCT04363008 |
Phase Not Applicable |
Recruiting |
4 |
18 Months |
150 |
Cheryl Wellington, PhD, Mypinder Sekhon, Mypinder Sekhon, MD |
2020-04-28 |
| The Impact of COVID-19 Pandemic on the Smoking Behavior of Young Smokers and the Youth Quitline Service in Hong Kong |
Coronavirus disease 19 infection, Nicotine dependence |
Telephone survey alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
The University of Hong Kong |
|
Hong Kong |
2020-04-24 |
2020-06-30 |
NCT02758028_1, NCT04360863 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
150 |
Ho Cheung William Li, PhD, Long Kwan Ho, MPhil |
2020-04-28 |
| Psychological Impact of Corona Virus Among Doctors in Assiut University Hospitals |
Acute stress disorder, Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assiut University |
|
Egypt |
2020-05-31 |
2021-06-30 |
NCT04363229, PSHYCOLOGICAL IMPACT OF CORONA |
Phase Not Applicable |
Not yet recruiting |
1 |
13 Months |
250 |
Mariam Roshdy Elkhayat, mariam elkhayat, MD, shimaa abdelsameaa, MD |
2020-04-29 |
| Clinical Impact of Bactek-R in Subject With Mild Pneumonia Due to COVID-19 Infection |
Coronavirus disease 19 infection, Viral pneumonia |
MV-130 alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Inmunotek SL |
BioClever 2005 SL |
|
2020-05-10 |
2020-07-31 |
MV130-SLG-35, NCT04363814 |
Phase 3 Clinical |
Not yet recruiting |
0 |
2 Months |
100 |
Guillermo Ángeles, Guillermo Ángeles, MD, M. Polanco, Martín Martín, MD, Miguel Casanovas, PhD, MD, Natalia García, Nicolas Batlle, MD, Raymundo Hernández |
2020-04-28 |
| ANACONDA: Anakinra for COVID-19 Respiratory Symptoms |
Coronavirus disease 19 infection, Respiratory disease |
anakinra alone, optimized standard of care alone |
Type I IL-1 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
INSERM CIC-P 1415, Swedish Orphan Biovitrum AB |
|
2020-04-27 |
2020-09-24 |
2020-001734-36, ANACONDA, ANACONDA-COVID-19, DR200111, NCT04364009 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
240 |
Alexandra AUDEMARD-VERGER, MD-PhD, Elodie MOUSSET |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled, proof-of-concept, phase II trial of Metablok for lung and kidney inflammation in patients with COVID-19 |
Coronavirus disease 19 infection, Lung inflammation, Nephritis |
Metablok alone |
Dehydropeptidase-1 modulator |
|
Arch Biopartners Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-28 |
| LEAD COVID-19: The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations |
Blood clotting disorder, Coronavirus disease 19 infection, Vitamin D deficiency |
aspirin alone, aspirin plus vitamin D |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Louisiana State University Health Sciences Center New Orleans |
|
US |
2020-05-31 |
2020-12-31 |
20-063, LEAD COVID-19, NCT04363840 |
Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
1080 |
Frank H Lau, MD |
2020-04-29 |
| Alterations in inflammatory and coagulation variables in COVID-19 patients |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Munich |
|
Germany |
2020-04-27 |
|
20-296, DRKS00021581 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Tobias Nitschke |
2020-04-29 |
| AziA: Azithromycin + Amoxicillin/clavulanate versus Amoxicillin/clavulanate in COVID-19 Patients With Pneumonia in Non-intensive Unit |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including amoxicillin + clavulanate , azithromycin , cephalosporin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-04-30 |
2020-07-30 |
AziA, NCT04363060, RC20_0168 |
Phase 3 Clinical |
Not yet recruiting |
3 |
3 Months |
104 |
Blandine RAMMAERT, MD, PhD, Emmanuel MONTASSIER, Romain DECOURS, MD, PhD, Vincent DUBEE, MD, PhD |
2020-04-28 |
| Sarilumab for Patients With Moderate COVID-19 Disease: A Randomized Controlled Trial With a Play-The-Winner Design |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , remdesivir , sarilumab |
IL-6 receptor antagonist, RNA polymerase modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
VA Boston Healthcare System |
|
US |
2020-04-10 |
2023-04-10 |
IRB 3305, NCT04359901 |
Phase 2 Clinical |
Recruiting |
0 |
36 Months |
120 |
Colleen Shannon, MPH, Patricia Woods, RN, MSN, Paul Monach, MD, Sara Schiller, MPH, Westyn Branch-Elliman, MD |
2020-04-29 |
| Identification of predictive biomarkers for severe progression of COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bundeswehrkrankenhaus Berlin |
|
Germany |
2020-05-03 |
|
DRKS00021591, Eth-10/20 |
Phase Not Applicable |
Not yet recruiting |
4 |
|
100 |
Christian Zobel, Maximilian Schreiner |
2020-04-28 |
| CytoResc: CytoSorb Rescue for COVID-19 Cytokine Storm |
Coronavirus disease 19 infection |
CytoSorb therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Charité Campus Virchow-Klinikum |
|
Germany |
2020-05-01 |
|
CytoResc, DRKS00021447, EA1/069/20, U1111-1250-8875 |
Phase 2b Clinical |
Not yet recruiting |
4 |
|
100 |
Philipp Enghardt, Torsten Slowinski |
2020-04-28 |
| Local Thermotherapy for Patients With Moderate Symptoms of COVID-19 |
Coronavirus disease 19 infection |
electric chest pad alone, electric cushion therapy alone, thermotherapy alone |
|
|
National Institute of Perinatology |
Directorate for Quality and Health Education, Juarez de Mexico Hospital, Laboratorios Silanes SA De CV |
Mexico |
2020-04-30 |
2020-11-30 |
CONACYTF0005-2020-01S311971, NCT04363541, U1111-1250-7416 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
298 |
Gabriela Ibañez Cervantes, PhD, Norma del Carmen Galindo Sevilla, PhD, Norma del Carmen Galindo-Sevilla |
2020-04-29 |
| ESCAPE: Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma therapy |
Coronavirus disease 19 infection |
High-Titer COVID-19 Convalescent Plasma (HT-CCP) alone |
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Brigham & Women's Hospital |
|
US |
2020-04-30 |
2021-12-31 |
2020P001215, ESCAPE, NCT04361253 |
Phase 3 Clinical |
Not yet recruiting |
0 |
20 Months |
220 |
Karina Oganezova, Richard Kaufman, MD |
2020-04-29 |
| COVID.PPI: The influence of proton pump inhibitor therapy on the clinical course of COVID-19 |
Coronavirus disease 19 infection |
proton pump inhibitors therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-05-01 |
|
254/20, COVID.PPI, DRKS00021523 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
200 |
Dominik Bettinger |
2020-04-28 |
| Impact of WeChat-based parenting education for children with autism spectrum disorder and their mothers during the epidemic of Coronavirus disease 2019 (COVID-19) |
Autism, Coronavirus disease 19 infection |
WeChat-based parenting education alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs) |
Fujian Maternity and Child Health Care Hospital |
|
China |
2020-02-01 |
2020-10-31 |
ChiCTR2000031772 |
Phase 0 Clinical |
Recruiting |
1 |
9 Months |
105 |
Guihua Liu |
2020-04-29 |
| COVID-AGE: Clinical-epidemiological Characterization of COVID-19 Disease in Hospitalized Older Adults |
Coronavirus disease 19 infection |
glucocorticoids alone, Variable regimens including anakinra , azithromycin , baricitinib , ceftriaxone , emtricitabine + tenofovir , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor, Type I IL-1 receptor antagonist |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Complejo Hospitalario Universitario de Albacete |
|
Spain |
2020-04-20 |
2020-07-31 |
COVID-AGE, NCT04362943, PAS-BAR-2020-04 |
Phase 4 Clinical |
Recruiting |
2 |
3 Months |
576 |
Almudena Avendaño Céspedes, RN, PhD, Pedro Abizanda Soler, MD,PhD |
2020-04-28 |
| Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
clazakizumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-30 |
2020-07-31 |
IRB00247932, NCT04363502 |
Phase 2 Clinical |
Not yet recruiting |
0 |
3 Months |
30 |
Nada Alachkar, MD, Russell Wesson, MD |
2020-04-28 |
| PROTECT: A Randomized Study With Hydroxychloroquine Versus Observational Support for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (IRST) SRL |
Universita di Bologna |
Italy |
2020-05-31 |
2021-03-31 |
IRST100.47, NCT04363827, PROTECT |
Phase 2 Clinical |
Not yet recruiting |
1 |
10 Months |
2300 |
Giovanni Martinelli, Prof., Oriana Nanni, Pierluigi Viale, Prof. |
2020-04-29 |
| Study for Healthy Behavior, Psychological Analysis and Psychological Reconstruction Strategies of Students Population Keeping in Home Under the Pandemic of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Psychiatric disorder |
Face-to-face consultation alone, Phone consultation alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Sun Yat-Sen University |
National Natural Science Foundation of China |
China |
2020-03-18 |
2021-03-18 |
ChiCTR2000032095 |
Phase 0 Clinical |
Recruiting |
1 |
12 Months |
130 |
Peijia Liu |
2020-04-28 |
| The Danish Pre-HCQ COVID19 Dialysis Study: Hydroxychloroquine for prevention of COVID-19 in patients on chronic dialysis |
Coronavirus disease 19 infection |
Plaquenil alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rigshospitalet, Denmark |
|
Denmark |
2020-04-15 |
|
2020-001257-51, The Danish Pre-HCQ COVID19 Dialysis Study |
Phase 3 Clinical |
Recruiting |
1 |
|
568 |
Department of Nephrology 2132 |
2020-04-29 |
| A pilot study in patients with SARS-CoV-2 infection |
Coronavirus disease 19 infection |
|
|
|
Hemogenyx Pharmaceuticals Ltd |
|
|
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-29 |
| A Study for Efficacy and Safety of Live Biotherapeutic MRx-4DP0004 to Treat COVID-19 |
Coronavirus disease 19 infection |
MRx-0004 alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
4D pharma plc |
|
UK |
2020-05-31 |
2020-09-30 |
MRX-4DP0004-II-001, NCT04363372 |
Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
90 |
Clinical Operations, Dinesh Saralaya, MBBS, MD, MRCP, FRCP |
2020-04-29 |
| Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill |
Coronavirus disease 19 infection |
Mycobacterium w alone, standard care therapy alone |
Interferon gamma receptor agonist, MAPK gene modulator, TLR-2 agonist, TLR-4 agonist, TLR-9 agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cadila Pharmaceuticals Ltd |
Council of Scientific and Industrial Research (India) |
|
2020-04-30 |
2021-04-30 |
CRSC20006, NCT04358809 |
Phase 3 Clinical |
Not yet recruiting |
0 |
12 Months |
480 |
Anil Avhad, MBBS, Sanjay Patel, MBBS |
2020-04-29 |
| Pharmacological Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment |
Coronavirus disease 19 infection |
Ascor (McGuff Pharmaceuticals, Ltd) plus magnesium chloride |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Thomas Jefferson University |
|
US |
2020-04-30 |
2021-04-30 |
JT#15681, NCT04363216 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
66 |
Dagan Coppock, M.D., Melissa McCarey, Michael W Foster, M.D. |
2020-04-28 |
| COroFet: Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic |
Coronavirus disease 19 infection |
RT-PCR alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Toulouse |
|
France |
2020-04-17 |
2022-04-30 |
COroFet, NCT04360811, RC31/20/0123 |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
3600 |
Charlotte Dubucs, MD, Marion Groussolles, MD |
2020-04-28 |
| HCQPreP: Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Louisiana State University Health Sciences Center New Orleans |
Lafayette General Medical Center, University Of Louisiana At Lafayette |
US |
2020-05-04 |
2020-08-03 |
HCQPreP, LSU NO HSC IRB 20-050, NCT04363450 |
Phase 3 Clinical |
Not yet recruiting |
0 |
3 Months |
1700 |
Ann Chauffe, Ann D. Chauffe, DO, MPH, Rebecca B. Lee, DO, MS |
2020-04-28 |
| Comparison of VieScope versus Macintosh Laryngoscope for Intubation in Level Cpersonal Protective Equipment Conditions |
Coronavirus disease 19 infection, Edema |
Vie Scope laryngoscope alone, intubation alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Lazarski University |
Medical University of Bialystok, Poznan University of Medical Sciences, Wroclaw Medical University |
Poland |
2020-01-20 |
2020-02-25 |
INT_PPE_2020_1, NCT04363775 |
Phase Not Applicable |
Completed |
1 |
1 Month |
35 |
Łukasz Szarpak |
2020-04-29 |
| ACCESS: ACCESS A Master Digital Surveillance Protocol for COVID-19 |
Coronavirus disease 19 infection |
mobile app (Medable Inc) alone, wearable sensor alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medable Inc |
American Heart Association, Biointellisense Inc, Datavant, PWNHealth LLC |
US |
2020-04-20 |
2031-10-01 |
ACCESS, NCT04363268, PRO00041635 |
Phase Not Applicable |
Recruiting |
0 |
137 Months |
1000000 |
Ingrid Oakley-Girvan, Ph.D., Ingrid Oakley-Girvan, PhD, Jena Daniels, B.S., Jena Daniels, BS, Michelle Longmire, M.D., Reem Yunis, Ph.D., Reem Yunis, PhD |
2020-04-29 |
| Effect of plasma of patients recovered from Covid-19 versus control group on treatment of Covid-19 |
Coronavirus disease 19 infection |
Variable regimens including chloroquine , lopinavir , plasma , ritonavir |
Cytochrome P450 3A4 inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hamadan University of Medical Sciences |
|
Iran |
2020-05-14 |
|
IR.UMSHA.REC.1399.037, IRCT20120215009014N353 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
100 |
Dr. Ebrahim Jalili, Dr. Jalal Poorolajal, Dr. Saeid Bashirian, Samereh Ghelichkhani |
2020-04-29 |
| CAN-COVID: Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
canakinumab alone, standard of care alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG, Novartis Farmaceutica SA |
|
Spain |
2020-04-30 |
2020-10-05 |
2020-001370-30, CACZ885D2310, CAN-COVID, NCT04362813 |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
450 |
Novartis Pharmaceuticals, Trial Monitoring Organization (TMo) |
2020-04-29 |
| Dose-Finding Study of Ivermectin in the Treatment of COVID-19 |
Coronavirus disease 19 infection |
ivermectin alone, standard regimen therapy alone |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Chistasazan notash fartak |
|
Iran |
2020-05-04 |
|
IR.QUMS.REC.1399.017, IRCT20200408046987N1 |
Phase 3 Clinical |
Not yet recruiting |
2 |
|
100 |
Dr Abbas Allami, Dr. Aliakbar Karami, Nematollah Gheibi, dr. morteza shakhs niaee |
2020-04-29 |
| VA-REACH: VA Remote and Equitable Access to COVID-19 Healthcare Delivery |
Coronavirus disease 19 infection |
azithromycin alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
San Francisco VA Health Care System |
|
US |
2020-04-30 |
2021-08-31 |
20-30517, NCT04363203, VA-REACH |
Phase 4 Clinical |
Not yet recruiting |
0 |
16 Months |
600 |
Salomeh Keyhani, MD MPH, Staff Physician |
2020-04-28 |
| COVIDAM: An open-label, single-center, randomized, controlled trial to evaluate the effect of hydroxychloroquine on viral shedding in mild COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Institute of Tropical Medicine |
|
Belgium |
2020-04-12 |
|
2020-001417-21, COVIDAM, ITM202004 |
Phase 2 Clinical |
Recruiting |
1 |
|
206 |
Yven Van Herrewege |
2020-04-29 |
| A first-in-human trial of recombinant adenoviral vector vaccine targeting SARS-CoV-2 spike protein for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
recombinant adenoviral vector vaccine targeting SARS-CoV-2 spike protein (liquid formulation, COVID-19), ReiThera alone |
COVID19 Spike glycoprotein modulator |
|
ReiThera Srl |
|
Italy |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-29 |
| ONCOVID-19: Prospective Analysis of Morbi-mortality of Patients With Cancers in Active Phase of Treatment Suspected or Diagnosed of a SARS-CoV-2 Infection |
Coronavirus disease 19 infection, Hematological neoplasm, Solid tumor |
medical treatment alone |
|
|
Centre Leon Berard |
|
France |
2020-04-02 |
2020-06-30 |
ET20-069, NCT04363632, ONCOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
150 |
Julien GAUTIER, Souad ASSAAD, Dr |
2020-04-29 |
| PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients |
Coronavirus disease 19 infection |
Electric Impedance Tomography (EIT) alone, positive end-expiratory pressure (PEEP) decremental alveolar recruitment alone, positive end-expiratory pressure (PEEP) incremental alveolar recruitment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Szeged |
Budapesti Müszaki És Gazdaságtudományi Egyetem, Hochschule Furtwangen, Germany |
Hungary |
2020-05-01 |
2021-04-19 |
COVID-19EIT, NCT04360837 |
Phase Not Applicable |
Not yet recruiting |
1 |
11 Months |
10 |
András Lovas, MD PhD |
2020-04-28 |
| ROCOCO: Serology COVID-19 From the Cornwall Hospital Union |
Coronavirus disease 19 infection |
immunoglobulin (IgG) Dia-Pro serological test alone, serum test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de Cornouaille |
Centre Hospitalier Regional Universitaire de Brest |
France |
2020-05-04 |
2020-11-04 |
29BRC20.0122, NCT04363593, ROCOCO |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
3200 |
Marie-Sarah FANGOUS, PH |
2020-04-29 |
| RESPIRE: Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
ruxolitinib alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
L'Azienda USL Nord Ovest |
Azienda Ospedaliera Universitaria Senese, Azienda Ospedaliero, Universitaria Pisana, Fondazione Toscana Gabriele Monasterio |
Italy |
2020-04-25 |
2020-05-31 |
2020.COVID-19.RUXO106, NCT04361903, RESPIRE |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
13 |
Barbara Dr Meini, Pharmacist, Enrico Dr Capochiani, hematologist |
2020-04-29 |
| SJTRC: St. Jude Tracking of Viral and Host Factors Associated With COVID-19 |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Jude Children's Research Hospital |
|
US |
2020-04-23 |
2025-03-20 |
NCT04362995, SJTRC, SJTRC |
Phase Not Applicable |
Recruiting |
0 |
58 Months |
1517 |
Aditya H. Gaur, MD, Jeremie H. Estepp, MD, Joshua Wolf, MBBS, PhD, FRACP, Paul G. Thomas, PhD |
2020-04-29 |
| COPEP: Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland |
Coronavirus disease 19 infection |
Plaquenil alone, lopinavir + ritonavir alone |
HIV protease inhibitor |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires De Geneve |
|
Switzerland |
2020-04-30 |
2020-10-31 |
CCER 2020-00864, COPEP, NCT04364022 |
Phase 3 Clinical |
Recruiting |
2 |
6 Months |
420 |
Alexandra Calmy, Prof, Niklaus Labhardt, Prof |
2020-04-29 |
| OSACOVID-19: Obstructive Sleep Apnea and Covid-19 Outcomes |
Coronavirus disease 19 infection, Obstructive sleep apnea, Viral pneumonia |
polysomnography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Koc University |
|
Turkey |
2020-04-20 |
2020-12-31 |
2020.140.IRB1.030, NCT04363333, OSACOVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
275 |
The OSACOVID-19 Study Group, Yeliz Celik, MSc, Yuksel Peker, MD, PhD |
2020-04-29 |
| Arkansas Expanded Access COVID-19 Convalescent Plasma Treatment Program |
Coronavirus disease 19 infection |
convalescent plasma alone, acetaminophen plus diphenhydramine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Arkansas |
|
|
|
|
260944, NCT04363034 |
Phase Not Applicable |
Suspended |
0 |
|
|
|
2020-04-29 |
| A Pilot Study to Assess Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Oregon Health Sciences University |
OHSU Knight Cancer Institute |
US |
2020-05-31 |
2021-06-30 |
NCT04363866, STUDY00021303 |
Phase 4 Clinical |
Not yet recruiting |
0 |
13 Months |
40 |
Brett Rodgers, Marcel Curlin, MD |
2020-04-29 |
| Immune Cells in Inflammatory Arthritis With Coronaviruses, Including COVID-19 |
Coronavirus disease 19 infection, Rheumatoid arthritis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Manchester |
|
UK |
2020-05-01 |
2021-05-01 |
282566, NCT04363047 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
125 |
Anne C Barton, Dr. Sebastien Viatte, Lynne Macrae |
2020-04-29 |
| AdoPro-Cov19: Adolescents and Health Professionals Faced With the Necessity for Changing to Remote Care During the COVID-19 Outbreak Quarantine |
Coronavirus disease 19 infection |
|
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Hôpital Cochin |
INSERM |
France |
2020-05-31 |
2020-12-31 |
AdoPro-Cov19, NCT04363671, P20-670 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
30 |
Carretier Emilie, Emilie Carretier, MD, Jonathan Lachal, PhD |
2020-04-28 |
| Clinical and Immunologic Impact of Perinatal SARS-CoV-2 (COVID-19) Infection |
Coronavirus disease 19 infection, Cough, Fever, Viral pneumonia |
|
|
Female |
Fundacion Infant |
|
Argentina |
2020-05-01 |
2020-09-30 |
NCT04362956, PERINATAL COVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
200 |
Gaston Ofman, Head of Perinatal Research, Gaston Ofman, MD |
2020-04-29 |
| RuXoCoil: Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Philipps-Universitat Marburg |
|
Germany |
2020-05-31 |
2020-11-30 |
KKS-278, NCT04359290, RuXoCoil |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
15 |
Andreas Burchert, Prof Dr., Andreas Neubauer, Prof Dr. |
2020-04-29 |
| A medical records based study for epidemiological characteristics of 88 patients with new coronavirus pneumonia (COVID-19) and its impact on severe disease |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First People's Hospital of Jiangxia District, Wuhan (Union Jiangnan Hospital) |
|
China |
2020-01-29 |
2020-03-16 |
ChiCTR2000032239 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
88 |
Gu Xue |
2020-04-29 |
| COVIDITY: A Phase I Study of Vaccine SCIB-1 For the Treatment of COVID-19 |
Coronavirus disease 19 infection |
SCIB-1 alone |
Immunoglobulin Fc receptor modulator |
|
Scancell Ltd |
Nottingham Trent University, University of Nottingham |
UK |
2021-03-31 |
|
COVIDITY |
Phase 1 Clinical |
Planned |
1 |
|
|
Christopher Coleman, Dr. Sally Adams, Graham Pockley, James Dixon, Janet Daly, Jonathan Ball, Lindy Durrant |
2020-04-29 |
| CoCo-Neuro: Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders |
Coronavirus disease 19 infection, Neurological disease, Psychiatric disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-24 |
2022-04-24 |
APHP200525, CoCo-Neuro, NCT04362930 |
Phase Not Applicable |
Not yet recruiting |
0 |
24 Months |
2000 |
CECILE DELORME, MD, Jean-Christophe CORVOL, MD,PHD |
2020-04-29 |
| Investigation of the B- and T-cell Repertoire and Immune Response in Patients With Acute and Resolved COVID-19 Infection |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Cancer Institute |
National Institutes of Health Clinical Center |
US |
2020-05-01 |
2024-12-01 |
20-C-0103, 200103, NCT04362865 |
Phase Not Applicable |
Recruiting |
0 |
55 Months |
150 |
Leah E Hoffman, R.N., Robert J Kreitman, M.D. |
2020-04-29 |
| A trial to evaluate plasma therapy for the treatment of COVID-19 patients |
Coronavirus disease 19 infection |
plasma therapy alone |
|
|
Korea Center for Disease Control & Prevention |
|
South Korea |
|
|
|
Phase 2 Clinical |
Recruiting |
1 |
|
2 |
|
2020-04-28 |
| A clinical trial of a plasma therapy for the treatment of patients with Covid-19 |
Coronavirus disease 19 infection |
plasma therapy alone |
|
|
Korea Center for Disease Control & Prevention |
|
South Korea |
2020-07-31 |
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-28 |
| Hydroxychloroquine and Nitazoxanide Combination Therapy for COVID-19 |
Coronavirus disease 19 infection |
Hydroxychloroquine plus nitazoxanide |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tanta University |
|
Egypt |
2020-05-31 |
2020-12-31 |
HCQ/NTZ, NCT04361318 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Kamal Okasha, MD, PhD |
2020-04-29 |
| Comparison of suspected or negative cases with confirmed cases of COVID-19 at Max Hospital |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Max Healthcare Institute Ltd, India |
|
India |
2020-04-28 |
|
CTRI/2020/04/024772 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
90 |
Samreen Siddiqui, Sujeet Jha |
2020-04-29 |
| A trial to remotely monitor the cardiac safety of patients with COVID-19 via data gathered from Withings Move ECG Watch |
Cardiotoxicity drug-induced, Coronavirus disease 19 infection |
Withings Move ECG Watch alone |
|
|
Cardiologs Technologies |
|
France |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
Jean-Claude Deharo |
2020-04-28 |
| Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects |
Coronavirus disease 19 infection |
VPM-1002 alone |
Listeriolysin stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Serum Institute of India Privated Ltd |
|
India |
2020-04-21 |
|
CTRI/2020/04/024749, SII-rBCG/COVID-19/IN-01 |
Phase 3 Clinical |
Not yet recruiting |
5 |
|
5946 |
Dr Hitt Sharma, Dr Pradeep Dcosta, Dr Sanjay Lalwani, Dr Savita Verma, Dr Umesh Shaligram, Dr Vasudev Rajapantula, Dr Venkat Rao |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Xiang-Sha-Liu-Jun Pill in the treatment of novel coronavirus pneumonia (COVID-19) decline in digestive function during convalescence |
Coronavirus disease 19 infection, Dyspepsia, Viral pneumonia |
Xiang-Sha-Liu-Jun pill alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Ezhou Hospital of traditional Chinese Medicine in Hubei Province |
State Administration of Traditional Chinese Medicine People's Republic of China |
China |
2020-04-01 |
2020-06-30 |
ChiCTR2000032237, ChiMCTR2000003234 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
200 |
Hong Ying, Shao Xianzhi |
2020-04-29 |
| Clinical study for the potential impact of novel coronavirus pneumonia (COVID-19) on endocrine system |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Jiao Tong University |
|
China |
2020-04-23 |
2020-05-06 |
ChiCTR2000032233 |
Phase Not Applicable |
No longer recruiting |
2 |
|
28 |
Jiang Lai, Mao Yanfei |
2020-04-29 |
| COVID-19 Patient Positioning Pragmatic Trial |
Coronavirus disease 19 infection |
Prone position alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-04-30 |
2021-06-30 |
200727, NCT04359797 |
Phase Not Applicable |
Not yet recruiting |
0 |
14 Months |
300 |
Cheryl L Gatto, PhD, Todd W Rice, MD, MSc |
2020-04-28 |
| COVAPID: Impact of SARS-CoV-2 Infection on the Incidence of Ventilator-acquired Infections |
Coronavirus disease 19 infection, Influenza virus infection, Lower respiratory tract infection, Viral pneumonia |
mechanical ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-07-31 |
2020-A00995-34, 2020_27, COVAPID, NCT04359693 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
1071 |
Saad Nseir, MD,PhD |
2020-04-29 |
| Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- or Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers |
Coronavirus disease 19 infection, Viral respiratory tract infection |
nitazoxanide (controlled-release, viral infections), Romark alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Romark Laboratories LC |
|
|
2020-04-27 |
2020-08-31 |
NCT04359680, RM08-3007 |
Phase 3 Clinical |
Recruiting |
0 |
4 Months |
800 |
Matthew Bardin, PharmD, BCPS |
2020-04-29 |
| COVASE: Nebulized Dornase Alfa for Treatment of COVID-19 |
Coronavirus disease 19 infection, Inflammatory disease |
dornase alfa alone, standard of care alone |
Deoxyribonuclease I stimulator, Deoxyribonuclease stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of London |
|
UK |
2020-05-01 |
2020-11-01 |
132333, COVASE, NCT04359654 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
50 |
Donna Basire, Joanna Porter, MD PhD, Misha Ladva, Novin Fard |
2020-04-29 |
| BCG-Denmark versus no-BCG for COVID 19 prevention |
Coronavirus disease 19 infection |
BCG-Denmark alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Jawaharlal Institute of Postgraduate Medical Education Research |
|
India |
2020-05-01 |
|
CTRI/2020/04/024833 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
1826 |
Narayanan Parameswaran |
2020-04-29 |
| Imatinib in COVID-19 infection |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
All India Institute of Medical Sciences |
|
India |
2020-04-26 |
|
CTRI/2020/04/024806 |
Phase 2 Clinical |
Recruiting |
1 |
|
100 |
Akash Kumar |
2020-04-29 |
| Impact of Covid-19 pandemic on practice pattern of Indian urologists |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over), Asian Ancestry |
Sanjay Gandhi Postgraduate Institute of Medical Sciences |
|
India |
2020-04-24 |
|
CTRI/2020/04/024805 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
160 |
Sanjoy Kumar Sureka |
2020-04-28 |
| Screening of proprietary Chinese medicines in convalescent rehabilitation of novel coronavirus pneumonia (COVID-19) convalescent patients |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia, Viral pneumonia |
shumian capsule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-01 |
2020-07-10 |
ChiCTR2000032214, ChiMCTR2000003233 |
Phase Not Applicable |
Not yet recruiting |
3 |
3 Months |
200 |
Ba Yuanming, Li Li |
2020-04-29 |
| Evaluation of safety and efficacy of convalescent plasma in COVID-19 patients |
Coronavirus disease 19 infection |
convalesecent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
International Stemcell Services Limited |
|
India |
2020-04-30 |
|
CTRI/2020/04/024804, F. No. X. 11026/71/2020-BD, IMD/CoV/003/2020 |
Phase 2 Clinical |
Recruiting |
1 |
|
|
Dr Jyothnsa Rao, Dr Vishal Rao, Meena Dalal |
2020-04-29 |
| A medical records based study for the impact of wearing medical masks on oxygen saturation in adult surgical patients after general anesthesia during novel coronavirus pneumonia (COVID-19) pandemic |
Coronavirus disease 19 infection |
medical masks alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
First Affiliated Hospital of Chongqing Medical University |
|
China |
2020-04-23 |
2020-05-23 |
ChiCTR2000032213 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
151 |
Feng Lv, Su Min |
2020-04-28 |
| Effectiveness to Manage Covid 19 Pandemic by Teaching Ventilatory Management to Non-anesthesiology Residents |
Coronavirus disease 19 infection |
ventilatory management teaching alone |
|
Young Adults (18-44 yrs) |
GSL Medical College |
|
India |
2020-01-01 |
|
CTRI/2020/04/024747 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
26 |
TATIKONDA CHANDRA MOULI |
2020-04-29 |
| A medical records based retrospective study for the effectiveness and safety of Xi-Yan-Ping injection combined with conventional protocol in the treatment of common type novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
Xiyanping alone, conventional treatment alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shanghai Public Health Clinical Center |
|
China |
2020-05-15 |
2020-08-22 |
ChiCTR2000032412 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
426 |
Hongzhou Lu, Lin Wenjun |
2020-04-29 |
| The efficacy and safety of high dose intravenous vitamin C in the treatment of novel coronavirus pneumonia (COVID-19): a prospective, randomized, controlled trial |
Coronavirus disease 19 infection, Viral pneumonia |
Vitamin C alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Rui Jin Hospital |
Science and Technology Commission of Shanghai Municipality |
China |
2020-01-01 |
2020-06-01 |
ChiCTR2000032400 |
Phase 2 Clinical |
Recruiting |
1 |
5 Months |
120 |
Bing Zhao, Enqiang Mao |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Xiaoyao capsule in the improvement of sleep mood disorder of convalescence patients of novel coronavirus pneumonia (COVID-19) |
Anxiety disorder, Coronavirus disease 19 infection, Viral pneumonia |
xiaoyao capsule alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Xiaogan Traditional Chinese Medicine Hospital |
Ministry of Science and Technology of the People´s Republic of China |
China |
2020-04-01 |
2020-07-01 |
ChiCTR2000032399, ChiMCTR2000003249 |
Phase not specified |
Recruiting |
3 |
3 Months |
200 |
Yang Guiping, Zhou Jing |
2020-04-29 |
| TRONCHER: Assessment of Efficacy and Safety of Tocilizumab Compared to Deferoxamine, Associated With Standards Treatments in COVID-19 (+) Patients Hospitalized In Intensive Care in Tunisia |
Coronavirus disease 19 infection |
usual standard treatment alone, enoxaparin sodium plus tocilizumab |
Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Abderrahmane Mami Hospital |
Datametrix AG, Eshmoun Clinical Research Centre |
Tunisia |
2020-05-04 |
2020-10-04 |
ECC2020-06, NCT04361032, TRONCHER |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
260 |
Chokri Jeribi, Dr, Dr Jalila Ben Khelil, Eshmoun Clinical Research Centre |
2020-04-29 |
| Physical Activity in University Students Around COVID-19 Confinement |
Coronavirus disease 19 infection, Pain |
online survey alone |
|
Healthy volunteers accepted |
Universidad del Pais Vasco |
Universidad De Cantabria, Universidad De Castilla-La Mancha, Universidad De Las Palmas De Gran Canaria, Universidad Miguel Hernandez de Elche, Universidad Politecnica de Madrid, Universidad Publica De Navarra, Universidad de Extremadura, Universidad de Sevilla, Universidad de Zaragoza, Universitat Jaume I de Castelló, Universitat de les Illes Balears, University of Cadiz, University of Granada, University of León, University of Valencia |
Spain |
2020-04-16 |
2020-10-20 |
COVID_PA2020, NCT04361019 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
25000 |
Ana Rodriguez, PhD, Ander Espin, MSc, Ander Espin, Ph D, Diego Jimenez, PhD, Diego Moliner, PhD, Domingo Gonzalez, PhD, Francisco B Ortega, PhD, Francisco J Vera, PhD, Idoia Labayen, PhD, Ignacio Ara, PhD, Jon Irazusta, PhD, Jonatan Ruiz, PhD, Jose Antonio Casajus, PhD, Jose Antonio Serrano, PhD, Jose Castro, PhD, Josep Tur, PhD, Luis Carrasco, PhD, Marcela Gonzalez, PhD, Mari Carmen Gomez, PhD, Maria Jose Cuevas, PhD, Maria Jose Noriega, PhD, Narcis Gusi, PhD, Pedro J Benito, PhD, Susana Aznar, PhD |
2020-04-28 |
| PSY-CO-CHU: Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: an Online Survey |
Anxiety disorder, Coronavirus disease 19 infection, Insomnia, Pain |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-09 |
2020-04-22 |
LOCAL COVID 2019/JYL-01), NCT04358640, PSY-CO-CHU |
Phase Not Applicable |
Recruiting |
1 |
|
2000 |
Jean-Yves LEFRANT, Jean-Yves LEFRANT, MD,PhD, Jean-Yves Lefrant, MD,PhD |
2020-04-29 |
| COVID-19 Mortality Prediction Model |
Coronavirus disease 19 infection, Viral pneumonia |
COViage alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dascena |
|
US |
2020-04-01 |
2020-04-17 |
04202001, NCT04358510 |
Phase Not Applicable |
Completed |
0 |
|
114 |
|
2020-04-29 |
| COSA: Registry of COVID-19 Patients Treated With the Seraph 100 Microbind Affinity Blood Filter |
Coronavirus disease 19 infection, Respiratory failure |
Seraph 100 Microbind affinity blood filter alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hannover Medical School |
|
Germany |
2020-04-15 |
2021-10-01 |
COSA, COSA-8998, NCT04361500 |
Phase Not Applicable |
Recruiting |
2 |
17 Months |
100 |
Bernhard MW Schmidt, Jan T Kielstein, Prof, Julius J Schmidt, Julius J Schmidt, Dr |
2020-04-28 |
| KICC-COVID19: Keto-diet for Intubated Critical Care COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
Ketogenic diet alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johns Hopkins University |
|
US |
2020-04-20 |
2020-08-01 |
IRB00247383, KICC-COVID19, NCT04358835 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
15 |
Mackenzie Cervenka, MD, Tanya McDonald, MD PhD |
2020-04-29 |
| Clinical Features and Risk Factors Associated With Worse Outcome in Patients Hospitalized for COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-09 |
2020-04-17 |
7773, NCT04362345 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Antonin HUGEROT, MD, Charlotte KAEUFFER, MD, Coralie LE HYARIC, MD, François DANION, MD, Joy MOOTIEN, MD, Nicolas LEFEBVRE, MD, Nicolas MEYER, MD, PhD, Olivier HINSCHBERGER, MD, Saïd CHAYER, PhD, HDR, Yves HANSMANN, MD, PhD, Yvon RUCH, MD |
2020-04-28 |
| MARNEVO-Covid: Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection |
Coronavirus disease 19 infection, Epilepsy, Viral encephalitis |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier de PAU |
|
|
2020-05-05 |
2021-01-05 |
CHPAU2020/02, MARNEVO-Covid, NCT04361344 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
30 |
|
2020-04-28 |
| START: START (Siddha Treatment Accelerating Recovery from SARS-CoV-2 Test) trial of Siddha treatment for patients with novel coronavirus infectious disease (COVID-19) |
Coronavirus disease 19 infection |
standard care alone, Brammanandha bairavam plus Kabasura kudineer |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Eminentlabs GmbH |
|
India |
2020-04-17 |
2020-06-26 |
ISRCTN13311119, NV-05-943-2020, START |
Phase 2 Clinical |
Recruiting |
1 |
2 Months |
116 |
Mr Thanicakachalam |
2020-04-29 |
| RAPID COVID COAG: Coagulopathy of COVID-19: A Pragmatic, Randomized, Controlled Trial of Therapeutic Anticoagulation Versus Standard Care |
Blood clotting disorder, Coronavirus disease 19 infection |
dalteparin sodium alone, enoxaparin sodium alone, tinzaparin sodium alone, unfractionated heparin alone |
Antithrombin III, Factor IIa antagonist, Factor Xa antagonist, Low molecular weight heparin |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Michaels Hospital |
University of Vermont Medical Center |
Canada, US |
2020-04-30 |
2020-12-31 |
NCT04362085, RAPID COVID COAG, RAPID COVID-COAG |
Phase 3 Clinical |
Not yet recruiting |
1 |
8 Months |
462 |
Mary Cushman, MD, Michelle Sholzberg, MD, FRCPC, Peter Jüni, MD, FESC |
2020-04-28 |
| A phase IIb/III, multinational, adaptive pilot to pivotal trial design of NP-120 in COVID-19 infected patients from progressing to mechanical ventilation with intubation and death |
Coronavirus disease 19 infection |
ifenprodil (injectable/intravenous, COVID-19/acute lung injury), Nash Pharmaceuticals alone, standard of care alone |
NMDA receptor epsilon 2 subunit inhibitor |
|
Algernon Pharmaceuticals |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
100 |
|
2020-04-27 |
| COVSurf: A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19 |
Coronavirus disease 19 infection |
COVSurf drug delivery system alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Southampton NHS Foundation Trust |
Bill & Melinda Gates Foundation, University College London |
UK |
2020-04-27 |
2020-11-02 |
COVSurf, NCT04362059, RHM CRI0399 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
24 |
Danny B Pratt, Michael P Grocott, MD |
2020-04-29 |
| Expanded Access to Convalescent Plasma to Treat and Prevent Pulmonary Complications Associated With COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
anti-SARS-CoV-2 convalescent plasma cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tulane University School of Medicine |
|
US |
|
|
2020-595, NCT04358211 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Nakhle Saba, MD |
2020-04-28 |
| Evaluation of Antibody Tests for COVID-19 |
Coronavirus disease 19 infection |
rapid-format, point-of-care antibody test kit alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
|
US |
2020-04-27 |
2020-10-27 |
202004088, NCT04360954 |
Phase Not Applicable |
Recruiting |
0 |
6 Months |
1000 |
Gary Weil, MD, Peter Fischer, PhD, Teresa Tufte, MPH |
2020-04-29 |
| STOP COVID 19: Sequencing and Tracking of Phylogeny in COVID-19 Study |
Coronavirus disease 19 infection |
Nanopore-based whole genome sequencing alone, phylogenetic analysis alone |
|
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Portsmouth Hospitals |
University of Portsmouth |
UK |
2020-05-31 |
2022-09-30 |
NCT04359849, PHT/2020/34, STOP COVID 19 |
Phase Not Applicable |
Recruiting |
1 |
28 Months |
500 |
Alice Mortlock, Samuel Robson |
2020-04-28 |
| A clinical study of atexakin alfa for the treatment in patients with COVID-19-induced ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome |
atexakin alfa alone |
IL-6 receptor agonist |
|
Real Relief Holding ApS |
NeuroRx Inc |
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-27 |
| Plasma Therapy of COVID-19 in Critically Ill Patients |
Coronavirus disease 19 infection |
anti-SARS-CoV-2 convalescent plasma cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Columbia University |
New York Blood Center |
US |
2020-04-30 |
2021-04-30 |
AAAS9924, NCT04359810 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
105 |
Andrew Eisenberger, MD, Max O'Donnell, MD, Walter I. Lipkin, MD |
2020-04-29 |
| CHEER: Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Shaheed Zulfiqar Ali Bhutto Medical University Islamabad |
|
Pakistan |
2020-04-25 |
2020-09-25 |
CHEER, F.1-1/2015/ERB/SZABMU/549, NCT04359537 |
Phase 2 Clinical |
Not yet recruiting |
1 |
5 Months |
200 |
Fibhaa Syed, FRCP, Mohammed Ali Arif, FRCP, Rauf Niazi, FRCP |
2020-04-29 |
| Treatment Of Coronavirus Disease 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP) |
Coronavirus disease 19 infection |
Anti-Sars-CoV-2 convalescent plasma alone |
|
|
US Army Medical Research and Development Command |
|
|
|
|
NCT04360486, S-20-02 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Andrew P Cap, MS, MD, PhD, FACP |
2020-04-29 |
| Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection) |
Coronavirus disease 19 infection, Systemic inflammatory response syndrome |
standard of care alone, tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Emory University |
National Cancer Institute |
US |
2020-05-30 |
2022-05-30 |
NCI-2020-02314, NCT04361552, P30CA138292, STUDY00000419, WINSHIP4998-20 |
Phase 3 Clinical |
Recruiting |
0 |
24 Months |
180 |
Ajay K Nooka, Ajay K. Nooka, Shondolyn D. Richburg |
2020-04-29 |
| COVID19 LTFU: Long-Term Outcomes of Patients With COVID-19 |
Coronavirus disease 19 infection |
physical disability assessment tool alone, psychological Sequelae assessment tool alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-08 |
2021-12-30 |
20-0538, COVID19 LTFU, NCT04360538 |
Phase Not Applicable |
Recruiting |
0 |
20 Months |
500 |
Anne Pohlman, MSN, Bhakti Patel, MD, John Kress, MD, Krysta Wolfe, MD |
2020-04-29 |
| Pulsed Inhaled Nitric Oxide for the Treatment of Patients With Mild or Moderate COVID-19 |
Coronavirus disease 19 infection |
nitric oxide (inhaled, INOpulse), Bellerophon alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Bellerophon Therapeutics LLC |
|
|
|
|
NCT04358588, PULSE-EAP-001 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Hunter Gilles, MD, Michelle Alamo, Valerie Parker |
2020-04-29 |
| THROMBOVID: Study of Hemostasis in Case of Severe COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
|
2020-04-17 |
2021-05-01 |
7774, NCT04359992, THROMBOVID |
Phase Not Applicable |
Not yet recruiting |
0 |
12 Months |
50 |
Charles TACQUARD |
2020-04-29 |
| LIINC: Long-term Impact of Infection With Novel Coronavirus (COVID-19) |
Coronavirus disease 19 infection |
biological sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California San Francisco |
|
US |
2020-04-17 |
2024-12-21 |
20-30479, LIINC, NCT04362150 |
Phase Not Applicable |
Not yet recruiting |
0 |
56 Months |
800 |
Michael J Peluso, MD, Rebecca Hoh, Rebecca Hoh, MS, RD, Steven Deeks, MD, Steven G Deeks, MD |
2020-04-27 |
| Efficacy of tenofovir in covid-19 |
Coronavirus disease 19 infection |
hydroxychloroquine plus tenofovir disoproxil fumarate |
DNA polymerase inhibitor, HIV-1 reverse transcriptase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ardabil University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.AUMS.REC.1399.051, IRCT20200421047155N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
86 |
Shahab Bohlooli, Shahram Habibzadeh, Sina Parsay |
2020-04-28 |
| A 24-patient clinical trial to test the safety and exploratory efficacy of umbilical cord-derived mesenchymal stem cells for the treatment of COVID-19 associated with lung inflammation |
Coronavirus disease 19 infection, Lung inflammation |
umbilical cord-derived mesenchymal stem cells (intravenous, COVID-19/lung inflammation/acute lung injury/acute respiratory distress syndrome), University of Miami alone |
|
|
KCNQ2 Cure Alliance Foundation, University of Miami Miller School of Medicine |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
24 |
Camillo Ricordi, M.D |
2020-04-29 |
| CV-COVID-19: Long-term Effects of Coronavirus Disease 2019 on the Cardiovascular System |
Cardiac failure, Coronavirus disease 19 infection, Heart arrhythmia, Myocardial infarction, Stroke, Sudden cardiac death |
real-time reverse transcriptase-polymerase chain reaction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-20 |
2025-08-31 |
CV-COVID-19, HCB/2020/0457, NCT04359927 |
Phase Not Applicable |
Recruiting |
1 |
64 Months |
10000 |
Luis Ortega Paz, MD, PhD, Luis Ortega, MD, PhD, Manel Sabaté, MD, PhD, Salvatore Brugaletta, MD, PhD |
2020-04-28 |
| FIC: Favipiravir in Hospitalized COVID-19 Patients |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-04-20 |
2020-05-05 |
FAVIPIRAVIR IN COVID-19, FIC, NCT04359615 |
Phase 4 Clinical |
Not yet recruiting |
1 |
|
40 |
Mehran Lack, MD, Mohammad Fathi, MD, Nader Markazi, MD, Nasser Malekpour Alamdari, MD, Sanaz Zargar Balaye Jam, MD, Sasan Tavana, MD, Seyed Sina Naghibi Irvani, MD, MPH, MBA |
2020-04-29 |
| Plasma Collection From Convalescent and/or Immunized Donors for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
convalescent immune plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institutes of Health Clinical Center |
|
US |
2020-05-01 |
2030-04-14 |
20-CC-0092, 200092, NCT04360278 |
Phase Not Applicable |
Recruiting |
0 |
119 Months |
1500 |
Kamille A West, M.D. |
2020-04-29 |
| Ivermectin and Nitazoxanide Combination Therapy for COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure |
ivermectin plus nitazoxanide |
Chloride channel modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tanta University |
|
Egypt |
2020-05-31 |
2020-12-31 |
IVR/NTZ, NCT04360356 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
7 Months |
100 |
Kamal Okasha, Md, PhD, Nahla Elashmawy, Md, PhD |
2020-04-27 |
| VTE COVID: Increased Risk of VTE and Higher Hypercoagulability in Patients Recovered in ICU and in Medical Ward for COVID-19 |
Coronavirus disease 19 infection, Thromboembolism |
fondaparinux sodium alone, low-molecular-weight heparin alone |
Factor Xa antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Quovadis Associazione |
Azienda Ospedaliera di Padova |
Italy |
2020-05-31 |
2020-06-30 |
NCT04359212, VTE COVID, VTE COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
80 |
Giuseppe Camporese, MD, Paolo Simioni, MD |
2020-04-29 |
| Evaluation efficacy of a herbal combination (contains Glycyrrhiza glabra, Mentha pulegium and Urtica) in controlling symptoms in patients with COVID-19 |
Coronavirus disease 19 infection |
herbal extract (Glycyrrhiza glabra, Mentha pulegium and Urtica) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baqiyatallah University of Medical Sciences |
|
Iran |
2020-03-30 |
2020-05-31 |
IR.BMSU.REC.1399.054, IRCT20080901001165N49 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
80 |
Ali Ghazivini, Dr. Rezaeiyan, Hossein Biganeh, Parisa Kianpour, Siamak Mohammadi, Yunes Panahi |
2020-04-27 |
| The effect of Naproxen in recovery and reducing mortality in patients with COVID-19 |
Coronavirus disease 19 infection |
naproxen alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Iran University of Medical Sciences |
|
Iran |
2020-04-13 |
|
IR.IUMS.REC.1399.001, IRCT20200410047009N1 |
Phase 4 Clinical |
Recruiting |
1 |
|
101 |
Maryam Esghaei |
2020-04-29 |
| effects of the 2-drug diet (hydroxychloroquine + umifenovir(Arbidol)) compared with Hydroxy chlorquine on the of mortality rate in patients with moderate symptoms of COVID-19 infections |
Coronavirus disease 19 infection |
Arbidol plus hydroxychloroquine, Amin Pharmaceutical Company |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-22 |
|
IR.MUMS.REC.1399.103, IRCT20200325046859N2 |
Phase 2/Phase 3 Clinical |
No longer recruiting |
1 |
|
40 |
Rozita Khodashahi |
2020-04-28 |
| Evaluation of the colchicine tablet efficacy as an adjuvant therapy for patients with mild to moderate COVID-19 |
Coronavirus disease 19 infection |
colchicine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mashhad University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.MUMS.REC.1399.096, IRCT20200408046990N2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
40 |
Sepideh Elyasi |
2020-04-27 |
| Atrium COVID-19 Syndromic and Serological Surveillance |
Coronavirus disease 19 infection |
daily syndromic surveillance alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Atrium Health |
|
US |
2020-04-30 |
2021-12-31 |
04-20-11A, NCT04361123 |
Phase Not Applicable |
Not yet recruiting |
0 |
20 Months |
450000 |
Melanie Hogg, MS, Michael Runyon, MD, MPH |
2020-04-27 |
| Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19) |
Coronavirus disease 19 infection, Lung disease, Sepsis, Viral pneumonia |
Reuquinol alone, Reuquinol plus azithromycin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Apsen Farmaceutica SA |
Universidade Federal de Sao Paulo - UNIFESP |
Brazil |
2020-05-04 |
2020-11-04 |
APS001/2020, NCT04361461 |
Phase 3 Clinical |
Not yet recruiting |
1 |
6 Months |
500 |
Dr. Eduardo Alexandrino Servolo de Medeiros, M.D, Fernanda Martinez, B.Sc. |
2020-04-28 |
| Precision Immunology to Determine the Immune Response in Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Bonn |
|
Germany |
2020-04-20 |
2022-09-30 |
BOST-03, NCT04360733 |
Phase Not Applicable |
Recruiting |
1 |
29 Months |
200 |
Chrisitan Bode, MD, Christian Bode, MD, Dr. Christian Bode, Folkert Steinhagen, MD |
2020-04-29 |
| Effect of lithium carbonate on COVID-19 |
Coronavirus disease 19 infection |
lithium carbonate alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-05-02 |
|
IR.MUMS.REC.1399.145, IRCT20081019001369N5 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
40 |
Hossein Hosseinzadeh, Javad Dehghan Nayyeri |
2020-04-27 |
| Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients |
Coronavirus disease 19 infection |
telmisartan alone |
Angiotensin II receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Hawaii |
|
US |
2020-07-01 |
2021-06-30 |
H051, NCT04360551 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
40 |
Cecilia M Shikuma, MD, Debra Ogata-Arakaki, RN |
2020-04-27 |
| COVIDORL: Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity |
Coronavirus disease 19 infection, Olfaction disorder |
budesonide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fondation Ophtalmologique Adolf De Rothschild |
Assistance Publique Hopitaux de Paris |
France |
2020-04-25 |
2021-05-25 |
COVIDORL, MDL_2020_10, NCT04361474 |
Phase 3 Clinical |
Not yet recruiting |
1 |
13 Months |
120 |
Amélie Yavchitz, Mary DAVAL, Mary Daval |
2020-04-29 |
| NCoV: Neurocognitive Impairment in Patients With COVID-19 |
Cognitive disorder, Coronavirus disease 19 infection, Delirium |
|
|
|
University of Rostock |
Ludwig-Maximilians University of Munich, University College London |
Germany |
2020-04-15 |
2021-04-01 |
COVID-BRAIN, NCT04359914, NCoV |
Phase Not Applicable |
Recruiting |
1 |
11 Months |
80 |
Gerd Klinkmann, MD, Johannes Ehler, MD |
2020-04-29 |
| STOP-COVID19: A multicenter, investigator-initiated, prospective, randomized, double-blind, placebo-controlled trial of brensocatib in patients with severe COVID-19 |
Coronavirus disease 19 infection |
brensocatib alone |
Dipeptidyl peptidase I inhibitor |
|
University of Dundee |
Insmed Inc |
UK |
|
|
STOP-COVID19 |
Phase 2 Clinical |
Status not specified |
1 |
|
300 |
Professor James Chalmers |
2020-04-27 |
| AVINALI: Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19 |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome |
aviptadil alone, standard of care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
NeuroRx Inc |
|
|
2020-06-01 |
2020-10-01 |
AVINALI, NCT04360096, RLF-100-002 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
144 |
Jonathan C Javitt, MD, MPH, Robert E Besthof, MIM |
2020-04-28 |
| Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Zealand University Hospital |
|
Denmark |
2020-04-22 |
|
2020-001459-42, 26223678Hans |
Phase 2 Clinical |
No longer recruiting |
1 |
|
40 |
Hans Hasselbalch |
2020-04-29 |
| Isotretinoin in Treatment of COVID-19 (Randomized) |
Coronavirus disease 19 infection |
isotretinoin alone, Variable regimens including ascorbic acid , azithromycin , clarithromycin , cyanocobalamin , hydroxychloroquine , isotretinoin , lopinavir + ritonavir , oseltamivir , paracetamol |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, Retinoic acid receptor agonist |
Young Adults (18-44 yrs) |
Tanta University |
|
Egypt |
2020-04-21 |
2020-09-30 |
9469305C, NCT04361422 |
Phase 3 Clinical |
Not yet recruiting |
1 |
5 Months |
300 |
Lamia Elgarhy |
2020-04-29 |
| UHID-COVID19: Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab |
Coronavirus disease 19 infection, Viral pneumonia |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital for Infectious Diseases |
|
Croatia |
2020-04-16 |
2021-04-15 |
NCT04359667, UHID-04, UHID-COVID19 |
Phase 2 Clinical |
Recruiting |
1 |
12 Months |
30 |
Arijana Pavelic, BA, Marko Kutlesa, MD, PhD, Miroslav Mayer, MD, PhD, Rok Civljak, MD, PhD |
2020-04-29 |
| COVID-19 PREVENTION: Medication for prevention of Corona-virus for Danish nursing home residents |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , vitamin D , zinc |
|
Healthy volunteers accepted, Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Odense University Hospital |
|
Denmark |
2020-04-23 |
|
2020-001363-85, 60152610, COVID-19 PREVENTION |
Phase 3 Clinical |
No longer recruiting |
1 |
|
206 |
Clinical Trial Information |
2020-04-29 |
| CQOTE: Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 |
Coronavirus disease 19 infection, HIV infection |
chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Cape Town |
|
South Africa |
2020-05-01 |
2021-07-31 |
CQOTE, HIV-COVID-19 CQOTE, NCT04360759 |
Phase 3 Clinical |
Not yet recruiting |
2 |
15 Months |
560 |
Amy Ward, MBBCh, Bianca Sossen, MBChB, Bianca Sossen, MBChB, MSc, Bianca Sossen, MBChB, MSc), Graeme Meintjes, PhD, Jacob Standler, MBChB, Mpumi Maxebengula, BCom, Nompumelelo Maxebengula, Sean Wasserman, MBChB, Trevor Ayanda Mnguni, MBChB, FCP(SA) |
2020-04-29 |
| A Study to Explore the Role of Gut Flora in COVID-19 Infection |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
ProgenaBiome |
|
US |
2020-04-16 |
2021-07-31 |
NCT04359836, PRG-041 |
Phase Not Applicable |
Recruiting |
0 |
15 Months |
250 |
Jordan Daniels, MS, Sabine Hazan, MD |
2020-04-28 |
| Leflunomide in Mild COVID-19 Patients |
Coronavirus disease 19 infection |
leflunomide alone |
Dihydroorotate dehydrogenase inhibitor, Protein tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chicago |
|
US |
2020-04-30 |
2020-07-31 |
IRB20-0622, NCT04361214 |
Phase 1 Clinical |
Not yet recruiting |
0 |
3 Months |
20 |
Laurencia Perea, Michael Millis, Michael Millis, MD |
2020-04-29 |
| Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone, standard of care alone |
RNA polymerase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Fujifilm Pharmaceuticals USA, Inc |
|
US |
2020-04-17 |
2020-12-31 |
FAVI-COV-US201, NCT04358549 |
Phase 2 Clinical |
Recruiting |
0 |
8 Months |
50 |
FPHU Study Coordinator |
2020-04-29 |
| PassItOn II: Passive Immunity Trial of Nashville II |
Coronavirus disease 19 infection, Respiratory tract infection |
pathogen reduced SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt University Medical Center, US |
|
US |
2020-04-24 |
2021-04-30 |
200738, NCT04362176, PassItOn II |
Phase 3 Clinical |
Not yet recruiting |
0 |
12 Months |
500 |
Amanda J Bistran-Hall, Todd Rice, MD |
2020-04-29 |
| A phase I trial to evaluate AlloRx Stem Cells for the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
AlloRx Stem Cells alone |
|
|
Vitro Diagnostics Inc |
|
US |
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-27 |
| Frequency and Clinical Evolution of Olfactory and Taste Disorders in COVID-19 Patients |
Coronavirus disease 19 infection, Dysgeusia, Dysomia |
|
|
|
Centre Hospitalier Universitaire De Nice |
|
France |
2020-03-20 |
2020-05-31 |
20ODONTOCOVID.06, NCT04361565 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
50 |
|
2020-04-29 |
| Acral Cutaneous Thrombotic Vasculopathy and COVID-19 Infection |
Acrocyanosis, Coronavirus disease 19 infection, Necrosis, Purpura, Raynauds disease, Vascular disease |
|
|
|
University Hospital, Montpellier |
Assistance Publique Hopitaux De Marseille, Lyon-Sud Hospital Center, Marseille University Hospital |
France |
2020-04-01 |
2020-10-30 |
NCT04361786, RECHMPL20_0211 |
Phase Not Applicable |
Recruiting |
1 |
6 Months |
10 |
Didier BESSIS, PhD, Léo-Paul Secco, Student |
2020-04-29 |
| PRECOVIA: Longitudinal Study of Covid-19 Infection Among HCW in a French University Hospital |
Coronavirus disease 19 infection |
SARS-Cov2 testing alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
Roquette Freres |
France |
2020-04-30 |
2020-09-30 |
2020-A00950-39, 2020_34, NCT04362267, PRECOVIA |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
150 |
Annie SOBASZEK, MD, Annie SOBASZEK, MD,PhD |
2020-04-29 |
| CytokCOVID19: Pilot Study on Cytokine Filtration in COVID-19 ARDS |
Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
cytokine adsorption alone, sodium heparin alone, standard intensive care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-17 |
2020-07-31 |
CytokCOVID19, HCB/2020/0464, NCT04361526 |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
40 |
Manuel Castellà, MD PhD |
2020-04-29 |
| A multicenter, randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
shengmai decoction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Wuhan 7th Hospital, Wuhan Hospital of Traditional Chinese Medicine, Xiaogan Traditional Chinese Medicine Hospital |
|
China |
2020-04-15 |
2020-07-15 |
ChiCTR2000032205, ChiMCTR2000003235 |
Phase Not Applicable |
Not yet recruiting |
3 |
3 Months |
200 |
Mao Lina, Xia Ping |
2020-04-29 |
| A multicenter, randomized, double-blind, parallel-controlled trial for Qi-Mai-Fei-Luo-Ping Mixture in the improvement of lung function of novel coronavirus pneumonia (COVID-19) in the convalescent period |
Coronavirus disease 19 infection, Viral pneumonia |
Qi-Mai-Fei-Luo-Ping mixture alone, rehabilitation education guidance alone, respiratory training alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hubei province hospital of Traditional Chinese Medicine |
|
China |
2020-04-01 |
2021-03-31 |
ChiCTR2000032165, ChiMCTR2000003230 |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
60 |
Xiao Mingzhong |
2020-04-29 |
| MICROVID: Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With SARS-CoV2 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-09-30 |
2020-A01042-37, 2020_28, MICROVID, NCT04359706 |
Phase Not Applicable |
Not yet recruiting |
1 |
5 Months |
30 |
Saad Nseir, MD,PhD |
2020-04-29 |
| COVID19-SETH: COVID-19 in Liver Transplant Recipients |
Coronavirus disease 19 infection |
|
|
|
Hospital Clinic of Barcelona |
Sociedad Española de Trasplante Hepático |
Spain |
2020-03-01 |
2021-03-31 |
COVID19-SETH, HCB/2020/0384, NCT04361591 |
Phase Not Applicable |
Recruiting |
1 |
13 Months |
200 |
Jordi Colmenero, Jordi Colmenero, MD PhD, SETH Scientific Committee |
2020-04-29 |
| Estrogen Patch for COVID-19 Symptoms |
Coronavirus disease 19 infection, Viral pneumonia |
estradiol (transdermal patch, vasomotor symptoms/ osteoporosis), Bayer Schering alone |
Estradiol agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stony Brook University Hospital |
|
US |
2020-04-20 |
2020-11-15 |
NCT04359329, SBU-ESTROGENPATCH-COVID19 |
Phase 2 Clinical |
Recruiting |
0 |
6 Months |
110 |
Alison Stopeck, MD, Andrew Handel, MD, Antonio Gasparis, MD, Christina Preece, Christina Preece, MD, Jie Yang, PhD, Patricia Thompson, Patricia Thompson, PhD, Sharon Nachman, MD |
2020-04-29 |
| A medical records based study for ECMO in the rescue therapy of extremely critical novel coronavirus pneumonia (COVID-19) patients |
Coronavirus disease 19 infection, Viral pneumonia |
ECMO alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
BaYi Brain Hospital, Children's Hospital of Chongqing Medical University |
|
China |
2020-04-22 |
2020-05-21 |
ChiCTR2000032162 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
80 |
Cao Huiling, Feng Zhichun |
2020-04-29 |
| Study for evolution and clinical outcomes study of novel coronavirus pneumonia (COVID-19) patients: a retrospective, cohort study |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tongji Hospital, Tongji Medical College |
National Natural Science Foundation of China |
China |
2020-02-01 |
2020-06-30 |
ChiCTR2000032161 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
2000 |
Gao Qinglei, Wang Ya |
2020-04-29 |
| CORTICOVIDHUGO: Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Standard of care alone, hydrocortisone hemisuccinate alone, prednisone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Tours |
|
France |
2020-05-31 |
2020-11-30 |
CORTI-COVID-19-HUGO, CORTICOVIDHUGO, DR200136, NCT04359511 |
Phase 3 Clinical |
Not yet recruiting |
12 |
6 Months |
210 |
BAZIN YANN, MD, GOUPIL FRANCOIS, MD, GUY TIPHAINE, MD, JOUNEAU STEPHANE, MD, PhD, LEMMENS BRUNO, MD, LIOGER BERTRAND, MD, LOUIS BERNARD, MD, PhD, MAILLOT FRANCOIS, MD, MARCHAND ADAM Sylvain, MD, PhD, MOREL HUGUES, MD, PECQUERIAUX OLIVIER, MD, POPA Mihai, MD, RABUT Thi- Tuyet Hong, MD, ROY XAVIER, MD, pascal magro, MD, sylvain marchand-adam, MD, PhD |
2020-04-29 |
| Efficacy and safety of ulinastatin in the Treatment of novel coronavirus pneumonia (COVID-19) |
Coronavirus disease 19 infection, Viral pneumonia |
ulinastatin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shanghai Public Health Clinical Center |
|
China |
2020-04-22 |
2020-12-31 |
ChiCTR2000032135 |
Phase 4 Clinical |
Not yet recruiting |
1 |
8 Months |
50 |
Hongzhou Lu, Yun Ling |
2020-04-29 |
| HBOTCOVID19: Hyperbaric Oxygen Therapy Effect in COVID-19 RCT |
Coronavirus disease 19 infection, Respiratory insufficiency |
hyperbaric oxygen therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assaf-Harofeh Medical Center |
|
|
2020-04-26 |
2020-07-30 |
120-20-ASF, HBOTCOVID19, NCT04358926 |
Phase Not Applicable |
Not yet recruiting |
0 |
3 Months |
30 |
Amir Hadanny, MD, Shai Efrati, MD |
2020-04-29 |
| The effect of pomegranate tea on symptom relief of COVID-19 patients: a double-blind, randomized clinical trial study |
Coronavirus disease 19 infection, Viral pneumonia |
pomegranate tea alone, standard treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shahrekord University of Medical Sciences and Health Services |
|
Iran |
2020-04-20 |
|
IR.SKUMS.REC.1399.017, IRCT20200416047104N1 |
Phase Not Applicable |
Recruiting |
1 |
|
66 |
Dr. Fereidoun Rahmani, Dr. Mehraban Sadeghi, Dr. Zahra Lorigooini, Dr. Zohreh Abolhassanzadeh, Vahid Reisi-Vanani |
2020-04-29 |
| TX-COVID: Solid Organ Transplant Recipients With Covid-19 French Registry |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-08 |
2021-04-08 |
7766, NCT04360707, TX-COVID |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
300 |
Gabriela GAUTIER, MD, Samira FAFI-KREMER, MD, PhD, Saïd CHAYER, PhD, HDR, Sophie CAILLARD, MD, PhD |
2020-04-29 |
| COVID-DEX: Dexmedetomidine to Improve Outcomes of ARDS in Critical Care COVID-19 Patients |
Coronavirus disease 19 infection, Pulmonary edema, Respiratory distress syndrome, Respiratory insufficiency |
Variable regimens including dexmedetomidine , propofol, AstraZeneca/Fresenius , remifentanil |
Alpha 2 adrenoceptor agonist, Opioid receptor mu agonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Clinic of Barcelona |
|
Spain |
2020-04-15 |
2020-06-30 |
COVID-DEX, NCT04358627, SPEC-M, SPEC-M COVID-19 |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
80 |
Pedro L Gambus, PhD MD, Xavier Borrat, PhD MD |
2020-04-29 |
| CIPOLLINI: Nasal Epithelial Genetic and Single Cell RNA COVID-19 Study |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Medical Center Groningen |
|
Netherlands |
2020-06-30 |
2022-06-30 |
CIPOLLINI, CIPOLLINI, NCT04359459 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
150 |
Daan Pouwels, PhD, Dirk-Jan Slebos, MD PhD, Janesh Pillay, MD PhD, Maarten van den Berge, Maarten van den Berge, MD PhD |
2020-04-29 |
| Examination of test accuracy of COVID-19 rapid antibody kit |
Coronavirus disease 19 infection |
rapid antibody kit alone |
|
Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ja Akita Koseiren Omagari Kosei Medical Care Center |
|
Japan |
2020-04-23 |
|
UMIN000040235 |
Phase Not Applicable |
Recruiting |
1 |
|
20 |
Toshiki Horii |
2020-04-29 |
| COCARDE: Myocardial Involvement of Severe Acute Respiratory Syndrome-Cov-2 (Covid19) Infected Patients |
Coronavirus disease 19 infection, Myocardial disease |
transthoracic echocardiography alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Toulouse |
|
France |
2020-04-04 |
2020-11-04 |
2020-A00852-37, COCARDE, NCT04358952, RC31/20/0117 |
Phase Not Applicable |
Recruiting |
1 |
7 Months |
50 |
Olivier LAIREZ, PU-PH, Vincent MINVILLE, PU PH, Vincent MINVILLE, PU-PH |
2020-04-27 |
| Targeted Steroids for ARDS Due to COVID-19 Pneumonia: A Pilot, Randomized Clinical Trial |
Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia |
dexamethasone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Colorado at Denver and Health Sciences Center |
|
|
2020-05-01 |
2020-12-31 |
20-0811, NCT04360876 |
Phase 2a Clinical |
Not yet recruiting |
0 |
8 Months |
90 |
|
2020-04-29 |
| Database for diagnosis and therapy of COVID-19 infected patients |
Coronavirus disease 19 infection |
data collection alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The Institute for Research in Operative Medicine |
|
Germany |
2020-04-26 |
|
75/2020, DRKS00021514 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
150 |
Sarah Schwarz, Tim Mathes |
2020-04-29 |
| Quercetin in COVID-19 |
Coronavirus disease 19 infection |
quercetin alone, routine drug therapy alone |
|
|
Ahvaz University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.AJUMS.REC.1399.087, IRCT20200419047128N2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
60 |
Ali khodadadi, Mohamad Badavi, َAli Khodadadi |
2020-04-29 |
| Evaluation of the effects of Sitagliptin administration in patients with COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including hydroxychloroquine , lopinavir + ritonavir , sitagliptin (Dr. Abidi Pharmaceuticals) |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Shaheed Beheshti Medical University |
|
Iran |
2020-05-04 |
|
IR.SBMU.NRITLD.REC.1399.029, IRCT20200420047147N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
84 |
Afshin Zarghi, Ahad Zare, Dr. Atefe Abedini, Farzaneh Dastan |
2020-04-29 |
| Effect of NK cell therapy in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
allogeneic natural killer cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Middle East Gene Therapy corporation |
|
Iran |
2020-04-27 |
|
IR.TUMS.VCR.REC.1399.069, IRCT20200417047113N1 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
70 |
Minoo Mohraz, Sahar Shojaei |
2020-04-29 |
| Performance Evaluation of BCG Vaccination in Healthcare Personnel to Reduce the Severity of SARS-COV-2 Infection |
Coronavirus disease 19 infection |
vaccine BCG alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Antioquia |
|
Colombia |
2020-04-30 |
2021-11-30 |
NCT04362124, PEC03_2020 |
Phase 3 Clinical |
Not yet recruiting |
1 |
19 Months |
1000 |
Juan C Cataño, MD.MI.ID, Juan C cataño, MD.MI.ID, Liliana Lopez, BSc.MSc |
2020-04-29 |
| Classification of COVID-19 Infection in Posteroanterior Chest X-rays |
Coronavirus disease 19 infection |
DenseNet121 alone, PCX images (chest X-rays) alone, VGG16 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Dascena |
|
US |
2020-04-01 |
2020-04-17 |
04202002, NCT04358536 |
Phase Not Applicable |
Completed |
0 |
|
230 |
|
2020-04-29 |
| Baricitinib Therapy in COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
baricitinib plus lopinavir + ritonavir |
HIV protease inhibitor, Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale Misericordia e Dolce |
|
Italy |
2020-03-16 |
2020-04-07 |
HPRATO-4, NCT04358614 |
Phase 2/Phase 3 Clinical |
Completed |
1 |
|
12 |
Fabrizio Cantini |
2020-04-29 |
| A clinical study of CLBS-119 for repair of COVID-19 induced lung damage in patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure |
Coronavirus disease 19 infection, Lung injury, Respiratory failure |
CLBS-119 alone |
|
|
Caladrius Biosciences Inc |
|
US |
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
|
|
2020-04-28 |
| Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 |
Coronavirus disease 19 infection |
autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences alone, Variable regimens including autologous adipose-derived mesenchymal stem cells (iv infusion, rheumatoid arthritis), Hope Biosciences , azithromycin , hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hope Biosciences Inc |
Advanced Diagnostics Healthcare, Hope Biosciences Stem Cell Research Foundation |
US |
2020-05-15 |
2020-10-31 |
ALLOGENEIC TREATMENT COVID-19, NCT04362189 |
Phase 2 Clinical |
Not yet recruiting |
0 |
5 Months |
110 |
Joseph Gathe, MD, FACP, Katherine Ruppert, PhD, Mariann England, Rajiv Thakur, MD, Sherry Diers, RN, Thinh Vo, MD |
2020-04-29 |
| A clinical trial of Mitotech-19 for the treatment of acute respiratory distress syndrome in patients with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Mitotech-19 alone |
|
|
Mitotech SA |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-28 |
| RUXCOVID: Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm |
Coronavirus disease 19 infection, Viral pneumonia |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone, standard-of-care alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
Incyte Corp |
Germany |
2020-04-30 |
2020-06-29 |
2020-001662-11, CINC424J12301, INCB 18424-368, NCT04362137, RUXCOVID |
Phase 3 Clinical |
Recruiting |
1 |
2 Months |
402 |
Medizinischer Infoservice (MCC), Novartis Pharmaceuticals |
2020-04-28 |
| Adaptive, multicenter, randomized, open, comparative clinical trial of the efficacy and safety of the drug favipiravir in patients hospitalized with COVID-19 |
Coronavirus disease 19 infection |
favipiravir alone |
RNA polymerase inhibitor |
|
Kromis LLC |
|
Russian Federation |
2020-04-23 |
2020-12-31 |
COVID-FPR-01 |
Phase 3 Clinical |
Status not specified |
17 |
8 Months |
390 |
|
2020-04-25 |
| CORONA: A multicenter, randomized, double-blind, placebo-controlled, adaptively designed clinical trial of the efficacy and safety of levilimab (BCD-089) in patients with severe COVID-19 |
Coronavirus disease 19 infection |
BCD-089 alone |
IL-6 receptor antagonist |
|
Biocad Ltd |
|
Russian Federation |
2020-04-22 |
2022-12-30 |
BCD-089-4, CORONA |
Phase 3 Clinical |
Status not specified |
4 |
32 Months |
250 |
|
2020-04-25 |
| A clinical trial of convalescent plasma for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
onvalescent plasma alone |
|
Healthy volunteers accepted |
Viravaxx AG |
|
|
|
|
|
Phase Not Applicable |
Not yet recruiting |
0 |
|
600 |
|
2020-04-24 |
| Study of Shreepad Shree Vallabh SSV Formulation to improve immunity in quarantine patients of COVID-19 |
Coronavirus disease 19 infection, Immunization |
SSV Formulation tablet alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
SSV Phytopharmaceuticals |
|
India |
2020-04-27 |
|
CTRI/2020/04/024659, Protocol No. SSV-SF-04/2020 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
30 |
Dr Samadhan Patil, Dr Yogesh Dound |
2020-04-28 |
| RTLS Technology Study |
Coronavirus disease 19 infection |
Real Time Location System alone |
|
|
The Royal Wolverhampton Hospitals Nhs Trust |
Cornell University, La Trobe University |
UK |
2020-01-06 |
2020-12-31 |
2019SUR107, NCT04114110 |
Phase Not Applicable |
No longer recruiting |
1 |
11 Months |
2000 |
|
2020-04-27 |
| CONCOR-1: Convalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness |
Coronavirus disease 19 infection |
Convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hamilton Health Sciences Corp, Hema-Quebec |
Canadian Blood Services, Universite De Montreal, University of Toronto |
Canada |
2020-04-27 |
2020-12-31 |
CONCOR-1, CONCOR-1, NCT04348656 |
Phase 3 Clinical |
Not yet recruiting |
27 |
8 Months |
1200 |
Andrew Shih, Anne-Sophie Lemay, Arjuna Ponnampalam, Benjamin Rioux-Masse, Brian Berry, Christine Cserti, Danielle Talbot, David Welbourne, Donald M Arnold, MD, Erin B Jamula, MSc., Jacob Pendergrast, Julie Rousseau, Katerina Pavenski, Luigina Mollica, Menaka Pai, Michelle Zeller, Nadine Shehata, Patrice Beauregard, Patricia Pelletier, Shuoyan Ning, Stephen Caplan, Susan Nahirniak, Tony Giulivi, Valerie Arsenault, Vincent Laroche, Yulia Lin, Ziad Solh |
2020-04-27 |
| PRA-001: Plasma Rich Antibodies From Recovered Patients From COVID19 |
Coronavirus disease 19 infection |
Variable regimens including Antibody-Rich Plasma , azithromycin , hydroxychroquine , oseltamivir |
Exo-alpha sialidase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ain Shams University |
|
Egypt |
2020-04-20 |
2020-12-31 |
FMASU P15/ 2020, NCT04348877, PRA-001 |
Phase 2 Clinical |
Not yet recruiting |
1 |
8 Months |
20 |
Hossam Fahmy, Professor of Faculty of Medicine |
2020-04-27 |
| WAVES: Airway Pressure Release Ventilation for mechanically ventilated patients with COVID-19 in Western Australian Intensive Care Units: an observational study |
Coronavirus disease 19 infection |
Airway pressure release ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sir Charles Gairdner Hospital |
|
Australia |
2020-04-27 |
|
ACTRN12620000474954p, WAVES |
Phase Not Applicable |
Not yet recruiting |
8 |
|
100 |
A/Prof Matthew Anstey |
2020-04-27 |
| COVID RASP: Reducing acute severe respiratory events in health care workers during the Covid-19 pandemic with OM-85 |
Coronavirus disease 19 infection, Respiratory disease |
OM-85 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Queensland |
Australian Government |
Australia |
2020-06-01 |
2020-07-31 |
ACTRN12620000473965p, BV-2020/19, COVID RASP, U1111-1250-2920 |
Phase 3 Clinical |
Not yet recruiting |
3 |
2 Months |
1000 |
Mrs Sharon Brabon, Prof Peter Sly |
2020-04-28 |
| An investigator initiated study to test COVID-19 pneumonia patients with Unyvero HPN panel for bacterial co-infections |
Bacterial infection, Coronavirus disease 19 infection, Viral pneumonia |
Unyvero system alone |
|
|
Karolinska Institutet |
OpGen Inc |
Sweden |
2020-04-21 |
|
|
Phase Not Applicable |
Recruiting |
1 |
|
|
|
2020-04-24 |
| Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial) |
Coronavirus disease 19 infection |
Measles Mumps and Rubella vaccine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Misr University for Science and Technology |
Kasr Alainy School of Medicine |
Egypt |
2020-04-15 |
|
PACTR202004693933092 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
200 |
Ahmed Mukhtar, Mahmoud Nassar, Mostafa Alfishawy |
2020-04-27 |
| COVIPOC: Senicapoc in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial |
Coronavirus disease 19 infection, Respiratory insufficiency |
senicapoc alone |
KCNN potassium channel-4 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarhus University |
|
Denmark |
2020-04-14 |
|
0001, 2020-001420-34, COVIPOC |
Phase 2 Clinical |
Recruiting |
1 |
|
|
www.Clinicaltrials.gov |
2020-04-27 |
| A phase I clinical study to assess ABL novel prophylactic COVID-19 vaccine and to analyze biomarker to characterize the immune profile of subjects participating in the study |
Coronavirus disease 19 infection |
ABL novel prophylactic COVID-19 vaccine alone |
|
|
Advanced BioScience Laboratories Inc |
Institut Merieux SA |
|
|
|
|
Phase 1 Clinical |
Planned |
0 |
|
|
|
2020-04-27 |
| Efficacy and safety of IHP Detox Tea (a special blend of Andrographis paniculata, Garcinia kola and Psidium guajava) for treatment of Corona virus disease 2019 (COVID-19): a pilot placebo-controlled randomized trial |
Coronavirus disease 19 infection |
IHP Detox Tea alone, conventional therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Neimeth International Pharmaceuticals Plc |
|
Nigeria |
2020-05-01 |
|
PACTR202004761408382 |
Phase Not Applicable |
Not yet recruiting |
2 |
|
72 |
Charles Esimone, George Eleje, Jude Duru |
2020-04-29 |
| A diagnostic study IgG and/or IgM antibodies to the SARS-CoV-2 (novel 2019 coronavirus) through ZEUS's lateral flow test |
Coronavirus disease 19 infection |
ZEUS's lateral flow test alone |
|
Healthy volunteers accepted |
Zeus Scientific Inc |
|
US, China |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
|
2020-04-24 |
| A medical records based study for 'Guangdong Pneumonia NO.1' in the Treatment of Novel Coronavirus Pneumonia (COVID-19) |
Coronavirus disease 19 infection, Pneumonia |
Guangdong Pneumonia NO.1 alone, basic treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Guangzhou Hospital |
|
China |
2020-02-11 |
2020-11-30 |
ChiCTR2000031888, ChiMCTR2000003208 |
Phase Not Applicable |
Recruiting |
3 |
9 Months |
300 |
Liansheng Lin, Luping Lin |
2020-04-27 |
| A phase II clinical study of stem cells to treat hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection |
stem cells alone |
|
|
Personalized Stem Cells Inc |
|
|
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-24 |
| A study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
Guangzhou Wondfo Biotech Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-24 |
| A validation study of Wondfo SARS-CoV-2A point of care test for the diagnosis of COVID-19 |
Coronavirus disease 19 infection |
Wondfo SARS-CoV-2A point of care test alone |
|
|
National Institute of Virology |
Cellmid Ltd, World Health Organization |
India |
|
2020-04-22 |
|
Phase Not Applicable |
Completed |
1 |
|
36 |
|
2020-04-24 |
| A phase IIa, multicenter clinical trial of Cannabidiol-Steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol-steroid alone |
|
|
Stero Biotechs Ltd |
|
|
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
40 |
|
2020-04-25 |
| An IP Protected Cliniacl Trial of Cannabidiol- steroid formulation for the treatment of COVID-19 infection |
Coronavirus disease 19 infection |
cannabidiol- steroid alone |
|
|
Stero Biotechs Ltd |
Mor Research Applications Ltd |
Israel |
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
1 |
|
10 |
|
2020-04-25 |
| Prophylaxis of COVID-19 infection with hydroxychloroquine in healthcare personnel with high risk of infection |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Mútua Terrassa University Hospital |
|
Spain |
2020-04-18 |
|
2020-001536-98, PREPSARS |
Phase 3 Clinical |
Recruiting |
1 |
|
300 |
HOSPITAL UNIVERSITARI MUTUA TERRASSA, INTERNAL MEDICINE DEPARTMENT |
2020-04-27 |
| Study to investigate the safety and effects of vaccines in healthy adults |
Coronavirus disease 19 infection |
BNT-162a1 alone |
COVID19 Spike glycoprotein modulator |
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
BioNTech SE |
Pfizer Inc |
Germany |
2020-04-20 |
|
2020-001038-36, BNT162-01, U1111-1249-4220 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
|
196 |
Clinical Study Management |
2020-04-28 |
| A trial to evaluate BNT-162 for the prevention of COVID-19 infection |
Coronavirus disease 19 infection |
BNT-162a1 alone |
COVID19 Spike glycoprotein modulator |
|
BioNTech SE |
Pfizer Inc |
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-27 |
| CIGB-2020 in contacts and suspects of SARS-CoV-2 infection |
Coronavirus disease 19 infection |
CIGB-2020 alone, conventional treatment alone |
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Center for Genetic Engineering and Biotechnology |
Instituto Pedro Kouri |
Cuba |
2020-03-27 |
2020-06-30 |
CIGB 2020-01, RPCEC00000306 |
Phase 1/Phase 2 Clinical |
Recruiting |
1 |
3 Months |
80 |
Julia Cuesta Diéguez, Zurina Cinza Estévez |
2020-04-27 |
| PrevenCOVID-19: Study for the prevention of COVID-19 infection in healthcare personnel |
Coronavirus disease 19 infection |
hydroxychloroquine (Dolquine) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla |
|
Spain |
2020-04-19 |
|
2020-001440-26, PrevenCOVID-19, PrevenCOVID-19 |
Phase 3 Clinical |
Recruiting |
1 |
|
184 |
CTU-HUVR, Clinical trial information |
2020-04-27 |
| TAC-COVID19: Outpatient Treatment Of Covid-19 With Early Pulmonary Corticosteroids As An Opportunity To Modify The Course Of The Disease |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , paracetamol , prednisone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Hospital San Juan de Dios Burgos |
Hospital Universitario de Burgos |
Spain |
2020-04-19 |
|
2020-001622-64, TAC-COVID19, TAC-COVID19 |
Phase 4 Clinical |
Recruiting |
1 |
|
200 |
María Jesús Coma |
2020-04-28 |
| COVID-Aging: Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , telmisartan |
Angiotensin II receptor antagonist |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hopitaux Universitaires de Strasbourg |
|
France |
2020-04-24 |
2021-06-01 |
2020-001303-16, 7747, COVID-Aging, NCT04359953 |
Phase 3 Clinical |
Recruiting |
2 |
13 Months |
1600 |
Frédéric BLANC, Frédéric BLANC, MD |
2020-04-29 |
| CAPACoV19: Long Term Physical Functional Limitations in Daily Living in SARS-CoV2 Infected Patients Hospitalized in the Acute Phase Then Requiring Rehabilitation |
Coronavirus disease 19 infection |
data record alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Reims |
|
France |
2020-05-01 |
2022-02-01 |
CAPACoV19, NCT04356378, PO20055 |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
300 |
Francois BOYER, François BOYER |
2020-04-27 |
| Efficacy of Tocilizumab on Patients With COVID-19 |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure |
tocilizumab (intravenous), Roche/Chugai alone |
IL-6 receptor antagonist, IL-6 receptor modulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
Genentech Inc |
US |
2020-04-27 |
2020-08-30 |
2020P001159, NCT04356937 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
300 |
Ana D Fernandes, MA, John H Stone, MD, John H Stone, MD,MPH |
2020-04-27 |
| CORONA-SHIELD: Assessing the System for High-Intensity Evaluation During Radiotherapy During Changes in Response to COVID-19 |
Coronavirus disease 19 infection |
radiation therapy alone, telehealth alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Duke University |
|
US |
2020-04-14 |
2021-04-30 |
CORONA-SHIELD, NCT04357574, PRO00105266 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
1000 |
Manisha Palta, MD |
2020-04-24 |
| COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1 |
Coronavirus disease 19 infection, Respiratory failure |
best supportive care alone, nivolumab alone |
Programmed cell death protein 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Queen Mary Hospital |
The University of Hong Kong |
Hong Kong |
2020-04-14 |
2021-08-31 |
NCT04356508, UW20213 |
Phase 2 Clinical |
Not yet recruiting |
1 |
16 Months |
15 |
Gerry Gin Wai Kwok, MBBS |
2020-04-23 |
| A phase II, randomized, double-blind, placebo-controlled clinical study to evaluate the safety and preliminary efficacy of ATYR-1923 in confirmed COVID-19 positive patients with severe respiratory complications |
Coronavirus disease 19 infection |
ATYR-1923 alone |
Neuropilin 2 inhibitor |
|
aTyr Pharma Inc |
|
US |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
30 |
|
2020-04-23 |
| A single-blinded, randomized, placebo-controlled phase II trial of prophylactic treatment with oral azithromycin versus placebo in cancer patients undergoing antineoplastic treatment during the covid-19 pandemic |
Coronavirus disease 19 infection |
azithromycin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
|
Austria |
2020-04-14 |
|
2020-001327-13, OnCoVID19Trial |
Phase 2 Clinical |
Recruiting |
1 |
|
200 |
Matthias Preusser |
2020-04-23 |
| A clinical study evaluate the safety and efficacy of combination of chloroquine with azithromycin and interferon beta-1b, to prevent admission to intensive care, mechanical ventilation and/or death to combat COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , chloroquine , interferon beta-1b, Bayer |
Interferon beta ligand |
|
Bayer Inc, Population Health Research Institute |
|
Canada |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-23 |
| MV-COVID19: Measles Vaccine in HCW |
Coronavirus disease 19 infection |
measles, mumps, rubella vaccine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Kasr El Aini Hospital |
|
Egypt |
2020-05-01 |
2020-11-01 |
MV-COVID19, N-20-2020, NCT04357028 |
Phase 3 Clinical |
Not yet recruiting |
2 |
6 Months |
200 |
Abeer Ahmed, MD, Ahmed M Mukhtar, M.D, Doaa Ghaith, MD, Marwa Rashad, MD, Mostafa Alfishawy, MD |
2020-04-24 |
| A pilot study to assess the effect of beta-nicotinamide mononucleotide (NMN) in the prevention/treatment of patients with Covid-19 |
Coronavirus disease 19 infection |
beta-nicotinamide mononucleotide alone |
|
|
Shinkowa Pharmaceutical Co Ltd |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-23 |
| Immune Response to Covid-19 in 300 Health Care Workers With Mild Symptoms |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Sciensano |
Jessa Hospital |
Belgium |
2020-04-30 |
2020-07-30 |
JESSA300, NCT04356586 |
Phase Not Applicable |
Recruiting |
2 |
3 Months |
300 |
Maria Goossens, MD, PhD |
2020-04-24 |
| Feasibility, early intervention, chinese herbal treatment, addition to standard of care, COVID-19 |
Coronavirus disease 19 infection |
Chinese herbal treatment alone, standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sunway TCM Centre |
|
Malaysia |
2020-05-01 |
2020-10-30 |
54625, NMRR-20-759-54625 |
Phase Not Applicable |
Status not specified |
1 |
5 Months |
100 |
Dr LIM REN JYE, Dr Lee Yee Leng |
2020-04-24 |
| PACA: Nebulized Rt-PA for ARDS Due to COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
invasive mechanical ventilation alone, nebulized recombinant tissue-plasminogen activator (rt-PA) alone, non-invasive ventilation alone, standard of care alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University College London |
|
|
2020-04-14 |
2021-01-14 |
132151, NCT04356833, PACA |
Phase 2 Clinical |
Not yet recruiting |
0 |
9 Months |
24 |
Mark Phillips |
2020-04-23 |
| SCout: Risk Stratification With Chest CT to Rule-out Suspected SARS-CoV-2 Infections |
Coronavirus disease 19 infection, Viral pneumonia |
CT-imaging alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jena University Hospital |
|
Germany |
2020-04-15 |
2020-04-30 |
IDIR-001-2020, NCT04357938, SCout |
Phase Not Applicable |
No longer recruiting |
1 |
|
145 |
Ulf Teichgräber, Prof. Dr. |
2020-04-23 |
| RISC-19-ICU: The Risk Stratification in COVID-19 Patients in the ICU Registry |
Coronavirus disease 19 infection |
standard of care alone |
|
|
University of Zurich |
|
Switzerland |
2020-03-13 |
2022-03-31 |
KEK-ZH-REQ-2020-00322, NCT04357275, RISC-19-ICU |
Phase Not Applicable |
Recruiting |
1 |
24 Months |
10000 |
Dorothea Heuberger, PhD, Jonathan Montomoli, MD, PhD, Matthias P Hilty, MD, Pedro D Wendel Garcia, MSc, Philippe Guerci, MD, Reto A Schüpbach, MD, Theirry Fumeaux, MD |
2020-04-23 |
| MODIF: Myocardial Infarction Rates Overview During COVID-19 Pandemic In France |
Coronavirus disease 19 infection, Myocardial infarction |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Société Française de Cardiologie |
INSERM |
France |
2020-04-27 |
2020-07-31 |
2020-03, MODIF, NCT04357314 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
80 |
Guillaume BONNET, MD, Guillaume CAYLA, MD, Tessa BERGOT |
2020-04-23 |
| COVIP: Impact of Long-term Protease Inhibitors in Patients Living With HIV on the Incidence of COVID-19 |
Coronavirus disease 19 infection, HIV-1 infection, HIV-2 infection |
antiretroviral therapy alone, protease inhibitor therapy alone, usual care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Intercommunal Creteil |
Centre Hospitalier Intercommunal Villeneuve Saint Georges, Service des Urgences |
France |
2020-04-30 |
2020-10-31 |
COVIP, COVIP, NCT04357639 |
Phase Not Applicable |
Not yet recruiting |
5 |
6 Months |
794 |
Alice RAFFETIN, MD, GARRAIT Valérie, MD, Gallien Sebastien, MD, Raffetin Alice, MD, SALMON Dominique, MD, Vignier Nicolas, MD |
2020-04-27 |
| Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease |
Coronavirus disease 19 infection, Viral pneumonia |
azithromycin plus hydroxychloroquine (JWT-629) |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Novartis AG |
|
|
2020-04-30 |
2020-07-21 |
CJWT629A12301, NCT04358081 |
Phase 3 Clinical |
Not yet recruiting |
0 |
2 Months |
444 |
Novartis Pharmaceuticals |
2020-04-23 |
| AVoCaDO: Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation |
Coronavirus disease 19 infection, Hypoxia, Respiratory distress syndrome, Respiratory failure |
ascorbic acid alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hunter Holmes Mcguire Veteran Affairs Medical Center |
Mcguire Research Institute Inc |
US |
2020-04-16 |
2020-08-01 |
AVoCaDO, DAVIS 001, NCT04357782 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
3 Months |
20 |
Brian C Davis, MD |
2020-04-23 |
| COVID-19 Among Egyptian Health Care Providers |
Coronavirus disease 19 infection |
online self-administered questionnaire alone |
|
|
Assiut University |
|
Egypt |
2020-04-30 |
2020-05-31 |
COVIDQ, NCT04357431 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
600 |
Ahmed Mohamed Abbas |
2020-04-23 |
| WAVE: Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories |
Coronavirus disease 19 infection |
smartwatch alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Inselspital, Berne |
ETH Zurich |
Switzerland |
2020-05-01 |
2020-07-31 |
NCT04357834, WAVE, WAVE |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
100 |
Aristomenis Extradaktylos, Prof. MD, David D Srivastava, MD, MBA, David Srivastava, MD, MBA |
2020-04-29 |
| COPLASCOV19: Convalescent Plasma For Ill Patients By COVID-19 |
Coronavirus disease 19 infection, Respiratory disease, Viral pneumonia |
convalescent plasma alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Instituto De Seguridad Y Servicios Sociales De Los Trabajadores Del Estado |
Angeles Chihuahua Hospital, GENERAL HOSPITAL OF THE STATE OF SONORA, HOSPITAL CENTRAL NACIONAL PEMEX NORTE, HOSPITAL DE ZONA No.14 IMSS, IMSS General Hospital of Zone 2A "Troncoso", SECRETARIA DE SALUD DEL ESTADO DE SONORA |
Mexico |
2020-05-31 |
2020-12-31 |
COPLASCOV19, NCT04356482, TERAPLASCOV2 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
5 |
7 Months |
90 |
CARLOS BEST, MD, Carlos Martinez-Murillo, MD, Diego Espinoza, MD, FERNANDO PEREZ-JACOBO, MD, LUIS villela, MD, Luis M Villela, MD, Luis Villela, MD,MSc, Melani Otañez, MD |
2020-04-29 |
| Sarilumab treatment in cytokine storm caused by infection with COVID-19 |
Coronavirus disease 19 infection, Respiratory failure |
sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Clinica Universidad de Navarra |
|
Spain |
2020-04-16 |
|
2020-001255-40, STRIKE-SARS-CoV2 |
Phase 2 Clinical |
No longer recruiting |
1 |
|
60 |
UCEC |
2020-04-29 |
| Covid-Thelium: Assessment of Endothelial and Hemostatic Changes During Severe SARS-CoV-2 Infection |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospital Boisguillaume |
|
France |
2020-04-09 |
2020-08-31 |
2020/097/OB, Covid-Thelium, NCT04357847 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
100 |
EBESNIER, emmanuel besnier, MD, thomas clavier, MD, PhD |
2020-04-27 |
| SARICOR: Clinical Trial of Sarilumab in Adults With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
best available treatment alone, sarilumab alone |
IL-6 receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Maimonides Biomedical Research Institute of Cordoba |
Consejeria de Salud. Junta de Andalucia |
Spain |
2020-04-18 |
2020-07-27 |
2020-001531-27, NCT04357860, SARICOR, SARICOR |
Phase 2 Clinical |
Recruiting |
1 |
3 Months |
120 |
Antonio Luque, José Carlos Garrido Gracia, Julián de la Torre Cisneros, MD, Rafael León López, MD |
2020-04-28 |
| COVID-TGT: Analysis of the Coagulopathy Developed by COVID-19 Infected Patients |
Coronavirus disease 19 infection |
fibrin generation markers assays alone, thrombin generation test assay alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-04-30 |
2021-01-31 |
COVID-TGT, NCT04356950, PHRC-I/2020/JCG-01 |
Phase Not Applicable |
Not yet recruiting |
4 |
9 Months |
175 |
Albert Sotto, Anissa Megzari, Antonia Perez Martin, Catherine Lechiche, Charles Cazenave, Claire Roger, Claudine Barbuat, Didier Laureillard, Isabelle Quere, Jean-Christophe Gris, Jean-François Faucher, Jean-Marc Mauboussin, Jean-Yves Lefrant, Kada Klouche, Laurent Muller, Paul Loubet, Saber D Barbar, Vincent Le Moing |
2020-04-24 |
| Plasma Adsorption in Patients With Confirmed COVID-19 |
Coronavirus disease 19 infection |
D2000 plasma adsorption cartridge alone, Optia secondary plasma device alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Marker Therapeutics AG |
|
|
2020-04-27 |
2020-12-01 |
MH-007/B, NCT04358003 |
Phase Not Applicable |
Not yet recruiting |
0 |
7 Months |
2000 |
Eeke Romo, MD |
2020-04-25 |
| Registry of Hospitalized Pediatric Patients with SARS-CoV-2 Infection (COVID-19) |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University Hospital Carl Gustav Carus |
|
Germany |
2020-03-18 |
|
BO-EK-110032020, DRKS00021506 |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Jakob Armann |
2020-04-24 |
| Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Institute of Allergy and Infectious Diseases |
Teva Pharmaceutical Industries Ltd |
|
2020-05-01 |
2021-03-05 |
38720, ACTG A5395, NCT04358068 |
Phase 2b Clinical |
Not yet recruiting |
0 |
10 Months |
2000 |
Davey Smith, MD |
2020-04-24 |
| ICOS: Psychological Outcome of COVID-19 Lockdown on Psychiatric Hospital Staff and Close Relatives |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Psychiatric disorder |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre hospitalier de Ville-Evrard |
|
France |
2020-04-01 |
2020-06-30 |
10477M-ICOS, ICOS, NCT04357418 |
Phase Not Applicable |
No longer recruiting |
1 |
3 Months |
1320 |
Clemence ISAAC, PhD, Dominique JANUEL, Pr |
2020-04-29 |
| Thrombomodulin-modified Thrombin Generation Assay (TGA-TM) in Patients With Critical Infections |
Coronavirus disease 19 infection |
thrombin generation assay alone, thrombomodulin-modified thrombin generation assay alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical University of Vienna |
Medizinisch-Wissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien |
Austria |
2020-04-17 |
2020-12-01 |
NCT04356144, TGA-TM-CRITICAL-2019 |
Phase Not Applicable |
Not yet recruiting |
1 |
7 Months |
60 |
Lukas Infanger, Lukas Infanger, MD, Marion Wiegele, MD |
2020-04-24 |
| Dysosmia and Dysgeusia in COVID-19 patients |
Coronavirus disease 19 infection, Dysgeusia, Dysomia |
smell and taste test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kantonsspital Aarau |
|
Switzerland |
2020-04-22 |
|
2020-00666, DRKS00021516 |
Phase Not Applicable |
Recruiting |
1 |
|
100 |
Thirza Singer-Cornelius |
2020-04-27 |
| Evaluation of the efficacy and safety of methylprednisolone pulse therapy in treatment of Covid-19 patients with Acute respiratory distress syndrome |
Coronavirus disease 19 infection |
methylprednisolone pulse therapy alone, hydroxychloroquine plus methylprednisolone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Artesh University of Medical Sciences |
|
Iran |
2020-03-30 |
|
IR.AJAUMS.REC.1399.008, IRCT20200406046963N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Ebrahim Hazrati, Ebrahim hazrati, Ramin Hamidi Farahani, Reza Mosaed |
2020-04-24 |
| A prospective, single-center, parallel-group, open-label, randomized clinical trial to assess the efficacy of CPAP in 200 COVID-19 confirmed or suspected patients within the Mount Sinai Health System with respiratory symptoms |
Coronavirus disease 19 infection, Obstructive sleep apnea |
CPAP alone, WatchPAT ONE alone |
|
|
Itamar Medical (Cm) 1997 Ltd |
|
US |
|
|
|
Phase 2 Clinical |
Status not specified |
0 |
|
200 |
Neomi Shah |
2020-04-27 |
| What’s the STORY?: A pilot, multi-site, UK immunization program to assess novel coronavirus infection (COVID-19) rates in children and teenagers across the UK |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
University of Oxford |
United Kingdom Research & Innovation |
UK |
|
|
What’s the STORY? |
Phase Not Applicable |
Recruiting |
1 |
|
1200 |
Professor Matthew Snape |
2020-04-23 |
| A compassionate use program of Ruconest in hospitalized patients with confirmed COVID-19 infections suffering from related severe pneumonia who did not improve despite standard treatment, including hydroxychloroquine and lopinavir/ritonavir |
Coronavirus disease 19 infection, Viral pneumonia |
conestat alfa alone |
Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor |
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Pharming Group NV |
|
Switzerland |
|
|
|
Phase 2 Clinical |
Status not specified |
1 |
|
5 |
|
2020-04-23 |
| Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19) |
Coronavirus disease 19 infection |
rapid salivary test alone |
|
Healthy volunteers accepted |
Università degli Studi dell'Insubria |
|
Italy |
2020-04-16 |
2020-07-31 |
68/2020, NCT04357327 |
Phase Not Applicable |
Recruiting |
1 |
3 Months |
100 |
Lorenzo Azzi, Lorenzo Azzi, DDS |
2020-04-27 |
| Comparison of New Coronavirus (Covid-19) Awareness in Individuals of Different Age Groups: Analysis of Turkey |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Istanbul University-Cerrahpasa |
|
Turkey |
2020-05-31 |
2020-06-30 |
60350273-605.99-, NCT04357886 |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
1000 |
Aysenur Erekdag, Student, Ipek Yeldan, PhD, Saliha Gurdal Karakelle, MSc |
2020-04-27 |
| CoVS: COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being |
Coronavirus disease 19 infection |
staying home alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Illinois Institute of Technology |
|
US |
2020-04-17 |
2021-04-30 |
CoVS, IRB-2020-91, NCT04357041 |
Phase Not Applicable |
Recruiting |
0 |
12 Months |
500 |
Britt Burton-Freeman, Ph.D, Di Xiao, MAS, Indika Edirisinghe, Ph.D |
2020-04-23 |
| PSYCHIC: Psychiatric Disorders and Covid-19 |
Coronavirus disease 19 infection, Post traumatic stress disorder, Psychiatric disorder |
Brief Psychiatric Rating Scale alone, Connor-Davidson Resilience Scale 10 items (CD-RISC 10) alone, Impact of Event Scale-Revised alone, depression, Anxiety and Stress Scale alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
CHU De Nantes |
|
France |
2020-04-25 |
2023-01-01 |
NCT04358042, PSYCHIC, RC20-0165 |
Phase Not Applicable |
Not yet recruiting |
1 |
32 Months |
250 |
Gaelle CHALLET, Marie GRALL-BRONNEC |
2020-04-27 |
| A prospective, multicenter, randomized, placebo-controlled, double-blind, phase II clinical study to assess the efficacy, safety and tolerability of IMU-838 in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection |
standard-of-care antiviral therapy alone, vidofludimus alone |
Dihydroorotate dehydrogenase inhibitor, IL-17 antagonist |
|
Immunic Inc |
|
Europe, US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
|
|
2020-04-23 |
| A multinational, randomized, controlled, investigator-initiated clinical trial in patients with confirmed COVID-19 infections |
Coronavirus disease 19 infection |
conestat alfa alone |
Complement C1s subcomponent inhibitor, Kallikrein modulator, Mannan-binding lectin serine protease inhibitor |
|
Pharming Group NV |
|
Switzerland |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
150 |
Michael Osthoff |
2020-04-23 |
| A Human Clinical Study to Collect Calibration and Performance Data for the RBA-2 Device |
Coronavirus disease 19 infection |
RBA-2, Kaligia Biosciences alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kaligia Biosciences LLC |
University of South Florida |
US |
2020-04-30 |
2020-12-31 |
KBS005, NCT04357977 |
Phase Not Applicable |
Not yet recruiting |
0 |
8 Months |
300 |
Asa Oxner, MD, Elsie Medina, MS, Fazal Fazlin, Janice Shirley, MPH MBA PA-C, Jose Tirado, Rachel Karlnoski, PhD |
2020-04-24 |
| Etoposide in Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
etoposide phosphate alone |
Topoisomerase II inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Boston Medical Center Corp |
|
US |
2020-04-30 |
2021-12-31 |
H-40102, NCT04356690 |
Phase 2 Clinical |
Not yet recruiting |
0 |
20 Months |
134 |
John Mark Sloan, MD, Sally A Fennessey, BS |
2020-04-24 |
| COVID-19 Surveillance of Patients and Healthcare Workers in a Hospital Department |
Coronavirus disease 19 infection, Upper respiratory tract infection |
COVID-19 test alone, polymerase chain reaction alone |
|
Healthy volunteers accepted |
Rigshospitalet, Denmark |
|
Denmark |
2020-03-23 |
2020-12-31 |
DT P-2020-353, NCT04356560 |
Phase Not Applicable |
Recruiting |
1 |
9 Months |
300 |
Inge J Knudsen, MD, Nikolai S Kirkeby, MSc, Ramon G Jensen, MD |
2020-04-25 |
| Cell therapy in patients with coronavirus19 |
Coronavirus disease 19 infection |
mesenchymal stem cells alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Barakat Pharmaceutical Group, Tehran University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.TUMS.VCR.REC.1399.203, IRCT20190717044241N2 |
Phase 1 Clinical |
Recruiting |
1 |
|
10 |
Dr Javad Verdi- Dr Neda Alijani, Dr Mohammad Ali Sahraian, Dr Neda Alijani, Dr. Akbar Borandegi, Mahshid Saleh |
2020-04-24 |
| KONS-COVID-19: Kerecis Oral and Nasal Spray for Treating the Symptoms of COVID-19 |
Coronavirus disease 19 infection, Upper respiratory tract infection |
Kerecis Oral and Nasal Spray device (Kerecis Ehf) alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kerecis Ehf |
|
Iceland |
2020-04-30 |
2020-07-31 |
KONS-COVID-19, KS-0470, NCT04357990 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
81 |
|
2020-04-27 |
| TRAPSAH: Long-term Use of Drugs That Could Prevent the Risk of Serious COVID-19 Infections or Make it Worse |
Coronavirus disease 19 infection, Diabetes mellitus, Respiratory failure |
angiotensin receptor blocker (ARB) therapy alone, angiotensin-converting enzyme (ACE) therapy alone, chloroquine alone, hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
GIS EPI-PHARE |
France |
2020-04-30 |
2020-06-30 |
APHP200412, NCT04356417, TRAPSAH |
Phase Not Applicable |
Not yet recruiting |
1 |
2 Months |
6000000 |
Emilie SBIDIAN, Pr, Emilie Sbidian, Pr |
2020-04-26 |
| STARS: Study of Alteplase for Respiratory Failure in SARS-Cov2 (COVID-19) |
Coronavirus disease 19 infection, Respiratory failure |
alteplase plus unfractionated heparin |
Tissue plasminogen activator stimulator |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Denver Health and Hospital Authority |
Beth Israel Deaconess Medical Center, Genentech Inc, Long Island Jewish Med Center, National Jewish Health, University of Colorado, Denver, US |
US |
2020-04-30 |
2020-10-31 |
20-0880, NCT04357730, STARS |
Phase 2a Clinical |
Not yet recruiting |
0 |
6 Months |
60 |
Arsen Ghasabyan, MPH, Ernest "Gene" Moore, MD, Ernest E Moore, MD |
2020-04-26 |
| A new clinical trial to significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives using D'OXYVA (deoxyhemoglobin vasodilator) |
Coronavirus disease 19 infection |
D'OXYVA (deoxyhemoglobin vasodilator) alone |
|
|
Circularity Healthcare LLC |
|
US |
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-23 |
| Cardiac Arrhythmias In Patients With Coronavirus Disease (COVID-19) |
Coronavirus disease 19 infection, Heart arrhythmia |
|
|
|
Mount Sinai School of Medicine |
|
US |
2020-04-09 |
2021-12-31 |
GCO 20-0931, NCT04358029 |
Phase Not Applicable |
Recruiting |
0 |
20 Months |
10000 |
Betsy Ellsworth, MSN, Martin Goldman, MD, Stephanie Harcum, MS, Vivek Reddy, MD |
2020-04-27 |
| PsyCOVID: COVID-19 Pandemic Burden in Severe Mental Disease Patients |
Acute stress disorder, Anxiety disorder, Bipolar disorder, Coronavirus disease 19 infection, Major depressive disorder, Psychotic disorder, Schizophrenia |
GAD-7 (7-item Generalized Anxiety Disorder) alone, PHQ-9 (9-item Patient Health Questionnaire) alone, PSS (Perceived Stress Scale) alone, SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales alone, Zaritt Burden Interview alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universita degli Studi di Napoli Federico II |
|
Italy |
2020-04-10 |
2020-04-25 |
152/20, NCT04357769, PsyCOVID |
Phase Not Applicable |
Recruiting |
1 |
|
400 |
Felice Iasevoli, Felice Iasevoli, M.D., Ph.D. |
2020-04-26 |
| COVeR: COVID-19 Epidemic Response Study |
Coronavirus disease 19 infection |
|
|
Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centogene Gmbh |
|
Germany |
2020-04-20 |
2020-10-30 |
COVER-2020, COVeR, NCT04357496 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
400 |
Arndt Rolfs, Prof., Volha Skrahina, PhD |
2020-04-26 |
| The Mental Health Status of the General Population During the COVID-19 Pandemic and Its Association With Adherence to Government-initiated Non-pharmacological Epidemiological Interventions (NPI's) |
Anxiety disorder, Coronavirus disease 19 infection, Depression |
Non-pharmacological interventions alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Oslo |
Modum Bad |
Norway |
2020-03-31 |
2020-04-07 |
NCT04356365, REK125510 |
Phase Not Applicable |
Completed |
1 |
|
10084 |
Asle Hoffart, PhD, Omid V. E Ebrahimi, Double PhD Candidate, Sverre Urnes Johnson, PhD |
2020-04-27 |
| Non-Invasive Monitoring of Respiratory Function in Spontaneously Breathing Patients With COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory failure |
AirGo respiratory monitor alone, non-invasive monitoring alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Massachusetts General Hospital |
|
US |
2020-04-15 |
2020-12-31 |
2020P000881, NCT04356443 |
Phase Not Applicable |
Recruiting |
0 |
8 Months |
500 |
Jeanine Wiener-Kronish, MD, M. Brandon Westover, MD, PhD, Omar Hyder, Omar Hyder, MD, MS |
2020-04-27 |
| Prognosis of Coronavirus Disease 2019 (COVID-19) Patients Receiving Receiving Antihypertensives |
Cardiac failure, Coronary artery disease, Coronavirus disease 19 infection, Diabetes mellitus, Hypertension, Respiratory distress syndrome |
angiotensin II receptor blocker therapy alone, angiotensin-converting enzyme inhibitor therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
King Faisal Specialized Hospital & Research Center |
|
Saudi Arabia |
2020-04-12 |
2020-09-30 |
2210061, NCT04357535 |
Phase Not Applicable |
Recruiting |
1 |
5 Months |
226 |
Abir H Omer, Hakeam A Hakeam, MS Pharm, Hakeam A Hakeam, MSPharm BCPS, Muhannad A Alsemari, MBBS |
2020-04-27 |
| SCHIZOVID-19: COVID-19 and Psychotic Symptoms in France |
Coronavirus disease 19 infection, Hallucination, Paranoia, Psychotic disorder |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University Hospital, Montpellier |
Centre référent de réhabilitation psychosociale de Grenoble, Epsylon Laboratory, Universite Grenoble Alpes |
France |
2020-04-01 |
2020-08-01 |
NCT04356885, RECHMPL20_0225, SCHIZOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
4 Months |
600 |
Stephane Raffard, PhD, Stéphane RAFFARD, PhD |
2020-04-24 |
| COPLA: Treatment of Severe Forms of Coronavirus Infection With Convalescent Plasma |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centro de Hematologia y Medicina Interna |
Laboratorios Clinicos de Puebla, Laboratorios Ruiz |
Mexico |
2020-04-13 |
2020-08-31 |
CHMI-030420-01, COPLA, NCT04357106 |
Phase 2 Clinical |
Recruiting |
1 |
4 Months |
10 |
Guillermo J Ruiz-Arguelles, MD, FRCP, MACP, DSc, Guillermo J. RUIZ-ARGÜELLES, José Manuel Priesca-Marin, MD, Juan Carlos Olivares-Gazca, MD, MPH, Juan Carlos Olivares-Gazca, MD,MPH |
2020-04-27 |
| Investigating the efficacy of Zofa (a herbal medicine) in symptom management of patients with COVID-19 |
Coronavirus disease 19 infection |
Zofa alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Baqiyatallah University of Medical Sciences, Niak Pharmaceutical Company |
|
Iran |
2020-03-30 |
|
IR.BMSU.REC.1399.027, IRCT20080901001165N48 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
Ali Ghazvini, Parisa Kianpour, Yunes Panahi |
2020-04-28 |
| Efficacy of convalescent plasma transfusion of COVID-19 survivors on the treatment of respiratory failure of these patients |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure, Viral pneumonia |
antivirals alone, convalescent plasma alone, mechanical ventilation alone, oxygen therapy alone, supportive care therapies alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tabriz University of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.TBZMED.REC.1399.018, IRCT20200406046968N2 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
30 |
Haleh Mikaeili |
2020-04-28 |
| A prospective, cohort study to follow the health status of medical staff engage in COVID-19 |
Coronavirus disease 19 infection |
medical staff followup alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Yokohama City University |
|
Japan |
2020-04-23 |
|
UMIN000040219 |
Phase Not Applicable |
Recruiting |
1 |
|
30 |
Takuma HIGURASHI |
2020-04-27 |
| IMAGE-19: Imatinib In COVID-19 Disease In Aged Patients |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Versailles University Hospital |
|
France |
2020-05-01 |
2020-12-01 |
IMAGE-19, NCT04357613, P20/05_IMAGE19 |
Phase 2 Clinical |
Not yet recruiting |
2 |
7 Months |
99 |
Laure Morisset, Malvy, Philippe Rousselot |
2020-04-27 |
| Tranilast in COVID19 |
Coronavirus disease 19 infection, Viral pneumonia |
Tranilast ( TAIYO ) alone, routine treatment alone |
|
Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ahvaz University of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.AJUMS.REC.1399.050, IRCT20200419047128N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
60 |
Ali khodadadi, َAli Khodadadi |
2020-04-28 |
| LILIADE-COVID: Low Dose of IL-2 In Acute Respiratory Distress Syndrome Related to COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
aldesleukin (subcutaneous, autoimmune/inflammatory disorders/allergy/spontaneous abortion), ILTOO Pharma alone |
Interleukin-2 ligand |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
ILTOO Pharma |
France |
2020-04-30 |
2020-07-31 |
2020-001571-32, APHP200406, LILIADE-COVID, NCT04357444 |
Phase 2 Clinical |
Not yet recruiting |
1 |
3 Months |
30 |
Jean-Michel CONSTANTIN, Jean-Michel CONSTANTIN, MD, PhD |
2020-04-24 |
| A Phase II Study of DN-TNF to treat patients with pulmonary complications from COVID-19 infection |
Coronavirus disease 19 infection, Hypoxia, Lung disease, Respiratory distress syndrome |
anti-TNF therapy, (pulmonary complications/COVID-19), INmune Bio alone |
ICAM-1 stimulator, TNF antagonist, Vascular cell adhesion protein 1 agonist |
|
INmune Bio Inc |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-27 |
| AIRVM-COVID: Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to COVID-19-related Pneumonia |
Coronavirus disease 19 infection, Hypoxia, Respiratory failure, Viral pneumonia |
almitrine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Assistance Publique Hopitaux de Paris |
Centre Hospitalier of Chartres |
France |
2020-04-30 |
2020-07-31 |
2020-001909-22, AIRVM-COVID, APHP200461, NCT04357457 |
Phase 3 Clinical |
Not yet recruiting |
1 |
3 Months |
212 |
Pierre KALFON, PU-PH, Yonathan FREUND, PU-PH, Yonathan Freund, PU-PH |
2020-04-27 |
| Clinical trial of RLS-0071 for inflammatory disorders, such as acute lung injury, caused by an inflammatory response, such as due to COVID-19 infection |
Coronavirus disease 19 infection, Inflammatory disease, Lung injury |
PIC1-01 alone |
Complement C1s subcomponent inhibitor |
|
ReAlta Life Sciences Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-27 |
| TOC-COVID: A prospective, randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
conventional treatment alone, tocilizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-27 |
|
2020-001408-41, 203/20 (FF-MC), DRKS00021238, TOC-COVID |
Phase 2 Clinical |
Recruiting |
2 |
|
200 |
Mr PD Dr Tobias Wengenmayer |
2020-04-29 |
| Biomarker COVID-19: Local and systemic markers of inflammation and circadian rhythmicity in COVID-19 disease and their role in the prediction of clinical outcome |
Coronavirus disease 19 infection, Respiratory failure |
intensive care therapy alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum der Albert-Ludwigs Universitaet Freiburg |
|
Germany |
2020-04-21 |
|
225/20, Biomarker COVID-19, DRKS00021522 |
Phase Not Applicable |
Recruiting |
1 |
|
50 |
Nils Schallner |
2020-04-24 |
| COVID-19 BaWu: Prevalence of COVID-19 in children aged 1 to 10 years in Baden-Wurttemberg |
Coronavirus disease 19 infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs) |
Zentrum für Infektionskrankheiten |
|
Germany |
2020-04-22 |
|
COVID-19 BaWu, DRKS00021521, S-294/2020 |
Phase 0 Clinical |
Recruiting |
5 |
|
2000 |
Georg Friedrich Hoffmann, Hanna Renk, Hans-Georg Kräusslich, Klaus-Michael Debatin, Philipp Henneke |
2020-04-24 |
| COVID-19 Data-bank Project |
Coronavirus disease 19 infection |
|
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mahajan Imaging Center |
|
India |
2020-04-17 |
|
CTRI/2020/04/024697 |
Phase Not Applicable |
Not yet recruiting |
3 |
|
100000 |
Dr Anurag Agarwal, Dr Sushila Kataria, VIdur Mahajan |
2020-04-27 |
| A phase II clinical trial to evaluate the safety and efficacy of ArtemiC on patients diagnosed with COVID-19 |
Coronavirus disease 19 infection |
ArtemiC alone |
|
|
MGC Pharma |
Swiss PharmaCan AG |
Israel |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
50 |
|
2020-04-23 |
| A clinical study on side effects of hydroxychloroquine in health care workers |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
|
|
2020-04-24 |
| A clinical trial to evaluate the efficacy of hydroxychloroquine as a preventive medicine for COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase 3 Clinical |
Recruiting |
0 |
|
480 |
|
2020-04-24 |
| A large, multi-arm study to assess the effect of SARS-CoV-2 vaccine in the prevention of patients with Covid-19 |
Coronavirus disease 19 infection |
SARS-CoV-2 vaccine (Dynavax adjuvant CpG1018, COVID-19), CEPI/ University of Queensland alone |
|
|
University of Queensland |
|
Netherlands |
2020-09-30 |
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-27 |
| Use of UC-MSCs for COVID-19 Patients |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome |
standard of care alone, umbilical cord-derived mesenchymal stem cells alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Miami |
|
US |
2020-04-25 |
2021-05-01 |
20200370, NCT04355728 |
Phase 1/Phase 2 Clinical |
Recruiting |
0 |
12 Months |
24 |
Camillo Ricordi, MD, David A Baidal, M.D., Khemraj Hirani, MPharm PhD RPH, Rodolfo Alejandro, M.D. |
2020-04-29 |
| Gut Microbiota, 'Spark and Flame' of COVID-19 Disease |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidade Nova De Lisboa |
CINTESIS - Centre for Health Technology and Services Research, CUF Academic and Research Medical Center, Centro Hospitalar Lisboa Ocidental, Centro Hospitalar Sao Joao, Centro de Medicina Laboratorial Germano de Sousa, S.A., Hospital CUF Infante Santo, S.A., Nova Medical School |
Portugal |
2020-04-30 |
2020-12-31 |
COVID19_MICROBIOTA, NCT04355741 |
Phase Not Applicable |
Not yet recruiting |
3 |
8 Months |
60 |
André Rosário, PhD, Conceição Calhau, PhD, Cristina Granja, PhD, Gonçalo Marcelino, José Leal, PhD, Maria JR Sousa, PhD, Pedro Póvoa, PhD |
2020-04-24 |
| Convalescent Plasma versus Placebo in Emergency Room Patients With COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Stanford University |
|
US |
2020-05-31 |
2022-12-31 |
56249, NCT04355767 |
Phase 2 Clinical |
Not yet recruiting |
0 |
31 Months |
206 |
Kevin Schulman, MD, Study Team |
2020-04-23 |
| TARUS: The Ariel University Survey on Dietary Changes and Anxiety During the Coronavirus Pandemic |
Anxiety disorder, Coronavirus disease 19 infection |
survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ariel University |
|
Israel |
2020-03-31 |
2020-05-31 |
AU-HEA-VKS-20200329, NCT04353934, TARUS |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
3000 |
Mona Boaz, RD, PhD, Vered Kaufman-Shriqui, RD, PhD |
2020-04-23 |
| URGDENTCOVID: Evaluation of Dental Emergency Treatments During COVID19 Crisis |
Coronavirus disease 19 infection, Tooth disease |
survey alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
|
2020-04-13 |
2020-06-20 |
APHP200464, NCT04354272, URGDENTCOVID |
Phase Not Applicable |
Not yet recruiting |
0 |
2 Months |
840 |
Isabelle Rodriguez, Yves Boucher, MD, PhD |
2020-04-23 |
| ENVIROREA: Study of the Dissemination of SARS-COV-2 in the Environment of Infected Patients Admitted to Intensive Care Unit |
Coronavirus disease 19 infection, Lower respiratory tract infection |
Coriolis system alone, RT-PCR alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00897-32, APHP200411, ENVIROREA, NCT04355481 |
Phase Not Applicable |
Recruiting |
3 |
8 Months |
150 |
Guillaume Voiriot, Dr, Lila Bouadma, Dr, Nacira DARGHAL, Yacine TANDJAOUI-LAMBIOTTE, Dr |
2020-04-28 |
| An investigator-initiated clinical trial of valsartan in patients with COVID-19 infection |
Coronavirus disease 19 infection |
valsartan alone |
Angiotensin I receptor antagonist, Angiotensin II receptor antagonist |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| AVISA: Assessment of Incidence of SARS-CoV-2 Infection and COVID-19 in Brazil |
Coronavirus disease 19 infection |
IgG/IgM SARS-CoV-2 rapid test alone, blood sampling alone |
|
Healthy volunteers accepted |
Instituto Butantan |
|
Brazil |
2020-05-15 |
2022-05-15 |
AVISA, COV-01-IB, NCT04355338 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
4100 |
Ricardo Palacios, MD, PhD |
2020-04-29 |
| An investigator-initiated clinical study of secukinumab for the treatment in patients with COVID-19 infection |
Coronavirus disease 19 infection |
secukinumab alone |
IL-17 antagonist |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| An investigator-initiated clinical study of imatinib mesylate for the treatment in patients hospitalized with COVID-19 |
Coronavirus disease 19 infection |
imatinib alone |
Abl tyrosine kinase inhibitor, Bcr protein inhibitor, Kit tyrosine kinase inhibitor, PDGF receptor antagonist, Signal transduction inhibitor |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| A clinical study of canakinumab for the treatment in patients hospitalized with COVID-19 infection |
Coronavirus disease 19 infection |
canakinumab alone |
Immunoglobulin G1 agonist, Interleukin-1 beta ligand inhibitor |
|
Novartis AG |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection |
Coronavirus disease 19 infection, Respiratory distress syndrome |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Incyte Corp |
|
US |
|
|
INCB 18424-MA-COVID-19-301, NCT04355793 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Incyte Corporation Call Center (US) |
2020-04-25 |
| CORIA: Coronavirus (COVID-19) Outcomes Registries in Immunocompromised Individuals Australia |
Cancer, Coronavirus disease 19 infection, HIV infection, Immune deficiency |
blood sampling alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
National Centre in HIV Epidemiology and Clinical Research |
Blacktown Hospital, Cancer Council New South Wales, Cancer Institute New South Wales, Garvan Institute of Medical Research, Gilead Sciences Inc, Holdsworth House Medical Practice, Melanoma Institute Australia, Positive Life NSW, Prince of Wales Hospital foundation, Royal North Shore Hospital, St Vincents Hospital Sydney Ltd, Westmead Hospital |
Australia |
2020-04-27 |
2022-04-27 |
2020-04-CORIA, CORIA, NCT04354818 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
1000 |
Griselda Buckland, Mark Polizzotto, MD |
2020-04-23 |
| COSTA: Open-label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to 'no Treatment' in SARS CoV 2 Virus |
Coronavirus disease 19 infection, Viral pneumonia |
camostat mesylate plus hydroxychloroquine |
Serine protease inhibitor, Trypsin inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Sheba Medical Center |
|
Israel |
2020-04-11 |
2020-12-11 |
7092-20-SMC, COSTA, NCT04355052 |
Phase 3 Clinical |
Recruiting |
1 |
8 Months |
250 |
Irit Avisar, RN, Itsik Levy Dr, Itzchak Levy, MD |
2020-04-22 |
| A randomized, double-blind, placebo-controlled Phase IIa study to evaluate the safety and efficacy of opaganib in adult patients hospitalized with positive SARS-CoV-2 and pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
opaganib alone |
Dihydroceramide delta 4 desaturase inhibitor, Sphingosine kinase 2 inhibitor |
|
RedHill Biopharma Ltd |
|
US |
|
|
|
Phase 2a Clinical |
Planned |
0 |
|
60 |
|
2020-04-29 |
| A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection |
Coronavirus disease 19 infection, SARS coronavirus infection |
anti-SARS-CoV-2 convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Medical College of Wisconsin |
Froedtert Hospital |
US |
2020-05-01 |
2023-05-01 |
NCT04354831, PRO00037712 |
Phase 2 Clinical |
Not yet recruiting |
0 |
36 Months |
131 |
Mary Beth Graham, Mary Beth Graham, MD, Sonija Parker |
2020-04-29 |
| Soliris (Eculizumab) Treatment of Participants With COVID-19 |
Acute lung injury, Coronavirus disease 19 infection, Respiratory distress syndrome, Viral pneumonia |
eculizumab alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Alexion Pharmaceuticals Inc |
|
France |
|
|
ECU-COV-401, NCT04355494 |
Phase Not Applicable |
Recruiting |
5 |
|
|
Alexion Pharmaceuticals Inc. |
2020-04-26 |
| Effect evaluation of herbal supplementation from the combination of sugarcane, black myrobalan and mastic along with the treatment protocol of the Ministry of Health on the course of coronavirus disease |
Coronavirus disease 19 infection |
Herbal supplement alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Jahrom University of Medical |
|
Iran |
2020-05-04 |
|
IR.JUMS.REC.1399.003, IRCT20200415047082N1 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
1 |
|
10 |
Alireza hashemi shiri, Esmail Rayat dost, Rahim raufi |
2020-04-23 |
| HyPreC: Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women |
Coronavirus disease 19 infection |
hydroxychloroquine (Plaquenil) alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sir Mortimer B Davis Jewish General Hospital |
|
|
2020-05-31 |
2020-11-30 |
1, MARCH 30, 2020, HyPreC, NCT04354441 |
Phase 2 Clinical |
Not yet recruiting |
0 |
6 Months |
600 |
Haim Abenhaim |
2020-04-23 |
| Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm |
Coronavirus disease 19 infection |
methylprednisolone alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Auxilio Mutuo Cancer Center |
|
Puerto Rico |
2020-04-14 |
2021-04-30 |
CCAM 20-01, NCT04355247 |
Phase 2 Clinical |
Recruiting |
2 |
12 Months |
20 |
Carmelo Santana-López, MD, Fernando Cabanillas, MD, Idalia Liboy, MD, James Bryan, MD, José Abreu-Arbelo, MD, Juan Arraut, MD, Luis Cotto, MD, Margarita Bruno, MD, Mirelis Acosta-Rivera, MD |
2020-04-24 |
| CovidAmiens20: French Single-center Experience of Critically Ill Patients With COVID-19 |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire D Amiens |
|
France |
2020-04-30 |
2021-04-30 |
CovidAmiens20, NCT04354558, PI2020_843_0026 |
Phase Not Applicable |
Not yet recruiting |
1 |
12 Months |
200 |
Osama Abou Arab, MD |
2020-04-22 |
| COVIPREG: Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns |
Coronavirus disease 19 infection |
PCR test alone, serology test alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-24 |
2021-08-31 |
APHP 200448, COVIPREG, NCT04355234 |
Phase Not Applicable |
Not yet recruiting |
1 |
16 Months |
2200 |
Christelle Vauloup Fellous, Vassilis Tsatsaris |
2020-04-28 |
| Evaluation of Activity and Safety of Two Regimens of Low Dose Oral Selinexor in Participants With Moderate or Severe COVID-19 |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Headache, Lower respiratory tract infection, Myalgia, Respiratory distress syndrome |
selinexor alone |
Exportin 1 inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Karyopharm Therapeutics Inc |
|
|
2020-04-30 |
2020-08-30 |
NCT04355676, XPORT-COV-1002 |
Phase 2 Clinical |
Not yet recruiting |
0 |
4 Months |
80 |
Dayana Michel, Jatin Shah Chief Medical Officer, Sharon Shacham President and CSO |
2020-04-23 |
| ILIAD: Interferon Lambda for Immediate Antiviral Therapy at Diagnosis |
Coronavirus disease 19 infection |
peginterferon lambda-1a alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University Health Network |
|
Canada |
2020-04-21 |
2020-11-30 |
ILIAD, JF-4-2020, NCT04354259 |
Phase 2 Clinical |
Not yet recruiting |
1 |
7 Months |
140 |
Jordan Feld, MD, Josh Booth |
2020-04-23 |
| Study to Evaluate Preventive Effect of Ayurveda and Homeopathy Treatment in COVID-19 |
Coronavirus disease 19 infection |
Variable regimens including Aesenic Album , Khadiradi Vat , Murrchhita Tila Taila , Samshamani Vati , Sudarshan Ghana Vati |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Parul Institute of Ayurved |
|
India |
2020-04-24 |
|
CTRI/2020/04/024731 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
50 |
Dr Harish Daga, Dr Hemant Toshikhane, Dr Shailesh Deshpande |
2020-04-24 |
| Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia |
Coronavirus disease 19 infection, Lung infection, Viral pneumonia |
bromhexine plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
General Hospital Celje |
|
Slovenia |
2020-04-10 |
2020-07-31 |
NCT04355026, SBCEBROMHEXINCOVID-19 |
Phase 4 Clinical |
Recruiting |
1 |
3 Months |
90 |
Matej Podbregar, Miha Mežnar, matej Podbregar |
2020-04-24 |
| COVID19@Spain: Characteristics and Outcomes of Hospitalized Patients With COVID-19 in Spain |
Coronavirus disease 19 infection |
chest x-ray alone, oxygen therapy alone, real-time polymerase chain reaction (RT-PCR) alone, systemic corticosteroids therapy alone, tocilizumab alone |
|
|
Fundacion SEIMC-GESIDA |
|
Spain |
2020-03-18 |
2020-04-17 |
COVID-19/SEIMC-FSG, COVID19@Spain, NCT04355871 |
Phase Not Applicable |
No longer recruiting |
6 |
1 Month |
3000 |
Jerónimo Pachón, MD, Jesús Rodriguez Baños, MD, Jordi Carratala, MD, Jose Ramón Arribas, MD, Juan Berenguer, MD, Pablo Ryan, MD |
2020-04-23 |
| DEFEAT COVID-19: A Multicenter, Retrospective Study to Evaluate the Efficacy of Systemic Gluco-corticoid Against COVID-19 |
Coronavirus disease 19 infection |
systemic Gluco-corticoid therapy alone |
|
|
Kanagawa Cardiovascular and Respiratory Center |
|
Japan |
2020-05-01 |
|
DEFEAT COVID-19, UMIN000040211 |
Phase Not Applicable |
Recruiting |
12 |
|
500 |
Satoshi Ikeda, Takashi Ogura |
2020-04-24 |
| Asymptomatic COVID-19 Infection Among Healthcare Workers |
Coronavirus disease 19 infection |
blood sampling alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Kasr El Aini Hospital |
|
Egypt |
2020-04-25 |
2020-07-10 |
N-18-2020, NCT04354792 |
Phase Not Applicable |
Not yet recruiting |
2 |
2 Months |
1000 |
Ahmed M Mukhtar, M.D, Ahmed Mukhtar, Mohamed Elayashy Mohamed Ahmed Hassan, M.D, FCAI |
2020-04-23 |
| A clinical study to assess convalescent plasma in the treatment of patients with COVID-19 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Froedtert & Medical College of Wisconsin |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
Mary Beth Graham, MD |
2020-04-22 |
| CoVID-19 Plasma in Treatment of COVID-19 Patients |
Coronavirus disease 19 infection |
convalescent COVID 19 plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Christ Hospital |
|
US |
2020-04-30 |
2020-08-31 |
20-23, NCT04355897 |
Phase 0 Clinical |
Recruiting |
0 |
4 Months |
100 |
Belinda Frakes, RN, Dean J Kereiakes, MD |
2020-04-28 |
| A randomized, placebo-controlled study to evaluate the use hydroxychloroquine for the prevention of COVID-19 amongst exposed healthcare workers and household contacts, as well as evaluates the use of hydroxychloroquine for the early treatment of mild cases |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
|
St Josephs Healthcare Hamilton |
Mint Pharmaceuticals Inc |
Canada |
|
|
|
Phase Not Applicable |
Status not specified |
1 |
|
|
Dr. Zain Chagla |
2020-04-23 |
| Ruxolitinib to Combat COVID-19 |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Washington University School of Medicine, US |
Incyte Corp |
US |
2020-06-30 |
2021-12-31 |
04-13-20-DUBBERKE, 04-13-20-DiPersio, NCT04354714 |
Phase 2 Clinical |
Not yet recruiting |
0 |
18 Months |
25 |
Erik Dubberke, M.D., MSPH, John DiPersio, M.D., Ph.D., Mark Fiala, MSW, Scott Goldsmith, M.D. |
2020-04-28 |
| COVID-19 PrEP HCW HCQ Study |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
NYU Langone Health |
|
US |
2020-04-03 |
2020-09-01 |
NCT04354870, S20-00390 |
Phase 2 Clinical |
Recruiting |
0 |
4 Months |
350 |
Emily Beato, Lisa Zhao, Michael Belmont, MD |
2020-04-23 |
| PED-COVID: Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19 |
Coronavirus disease 19 infection, Immune disorder |
Classic test (Institut Pasteur) alone, Immunoprotection (neutralizing Ab, Institut Pasteur) alone, Rapid test (NGBiotech / CEA) alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Assistance Publique Hopitaux de Paris |
Commissariat a l`Energie Atomique, INSERM, Institut Pasteur, NG Biotech |
France |
2020-04-30 |
2021-07-31 |
2020-A00999-30, APHP200467, NCT04355533, PED-COVID |
Phase Not Applicable |
Not yet recruiting |
3 |
15 Months |
1920 |
Isabelle SERMET-GAUDELUS, MD, PhD, Isabelle SERMET-GAUDELUS, MD,PhD, Nelly BRIAND, PhD |
2020-04-28 |
| COVID-Scan: Combination of Chest Scanography and Nasal Viral Detection Test to Detect COVID-19 Positive Patients Before Surgical Intervention in a University Hospital During Coronavirus Pandemia |
Coronavirus disease 19 infection |
RT-PCR Test alone, chest CT scan alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
|
France |
2019-04-01 |
2020-10-20 |
COVID-Scan, NCT04355715, RECHMPL20_0223 |
Phase Not Applicable |
No longer recruiting |
1 |
18 Months |
200 |
Philippe Gaudard, MD |
2020-04-28 |
| A clinical study to evaluate the efficacy of tPA in the treatment of patients with COVID-19 infection |
Coronavirus disease 19 infection, Respiratory failure |
tPA alone |
|
|
Mount Sinai Medical Center |
|
US |
|
|
|
Phase 2 Clinical |
Status not specified |
0 |
|
5 |
|
2020-04-23 |
| CAPTOCOVID: Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia |
Coronavirus disease 19 infection, Respiratory failure, Viral pneumonia |
captopril alone |
ACE inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
|
France |
2020-05-05 |
2020-08-31 |
APHP200410, CAPTOCOVID, NCT04355429 |
Phase 2 Clinical |
Not yet recruiting |
8 |
3 Months |
230 |
Alexandre BLEIBTREU, MD, Anne-Lise LECAPITAINE, MD, Gilles PIALOUX, Pr, Laurent PLANTIER, Pr, Louis BERNARD, MD, Mohammed RAHAOUI, PM, Nunes HILARIO, MD, Olivier BOUCHAUD, Pr, Pascale LONGUET, MD, Sylvain DIAMANTIS, MD, Yacine TANDJAOUI-LAMBIOTTE, MD |
2020-04-29 |
| Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
Standard of care alone, budesonide alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Fundacion Clinic per a la Recerca Biomédica |
AstraZeneca plc |
Spain |
2020-04-18 |
2020-10-18 |
2020-001616-18, NCT04355637, TACTIC-COVID |
Phase 4 Clinical |
Not yet recruiting |
8 |
6 Months |
300 |
ALVAR AGUSTI, ALVAR AGUSTI, MD, PhD, Alicia Marin, Alvar Agusti, Daniel Ross Monserrate, Jaume Ferrer Sancho, Joaquim Gea Giralt, Jordi Dorca Sargatal, ROSA FANER, Rosa Faner, Salud Santos, Sara Varea, Sergi Pascual, Vicente Plaza, Xavier Muñoz |
2020-04-23 |
| DAS-181 for STOP COVID-19 |
Coronavirus disease 19 infection |
DAS-181 alone, standard local care alone |
Exo-alpha sialidase modulator, Muscarinic receptor antagonist |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ansun BioPharma Inc |
|
Italy |
2020-04-25 |
2020-07-31 |
2020-001874-30, DAS181-3-02-EU, NCT04354389 |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
3 Months |
82 |
Andrea Gori, Cristina Mussini, Jennifer Ho, MD, PhD, Liz Dewaghe, Sylvie Lu |
2020-04-23 |
| COVKID: Kidney Involvement in COVID-19 Disease |
Coronavirus disease 19 infection, Renal injury |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-04-15 |
2020-07-30 |
20REAMEDCOVID.05, COVKID, NCT04355624 |
Phase Not Applicable |
Recruiting |
4 |
3 Months |
80 |
Hajar Ouahmi, Philippe DESWARDT, Pierre-Marie BERTRAND, Sonia BOYER-SUAVET, Sonia Boyer-Suavet, Sonia Boyer-Suavet, |
2020-04-23 |
| CCC19: COVID-19 and Cancer Consortium Registry |
Coronavirus disease 19 infection |
web-based REDCap survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Vanderbilt-Ingram Cancer Center |
|
US |
2020-03-17 |
2022-12-31 |
CCC19, NCT04354701, VICC MD 2032 |
Phase Not Applicable |
Recruiting |
0 |
33 Months |
1000 |
Jeremy Warner, MD, Teresa Melton, Vanderbilt-Ingram Service for Timely Access |
2020-04-23 |
| COLHEART-19: Colchicine to Reduce Myocardial Injury in COVID-19 |
Coronavirus disease 19 infection, Heart injury |
Current care alone, colchicine (oral, gout/familial Mediterranean fever), Takeda alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of California Los Angeles |
|
US |
2020-04-25 |
2021-04-25 |
20-000685, COLHEART-19, NCT04355143 |
Phase 2 Clinical |
Not yet recruiting |
0 |
12 Months |
150 |
Amir B Rabbani, MD, Reza Ardehali, MD, PhD |
2020-04-23 |
| A clinical trial of efficacy of BCG vaccine in preventing Covid-19 |
Coronavirus disease 19 infection |
BCG vaccine, ICMR alone |
|
|
Indian Council of Medical Research |
|
|
2020-04-30 |
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| Plasma therapy in patient with COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
convalescent plasma alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Shahid Beheshti University |
|
Iran |
2020-04-05 |
|
IR.SBMU.RETECH.REC.1399.047, IRCT20200416047099N1 |
Phase 2 Clinical |
Recruiting |
1 |
|
10 |
Abbas hajifathali, Elham Roshandel, Haniyeh Ghaffari-nazari, َAbbas Hajifathali |
2020-04-23 |
| A phase III, randomized, open-label study to assess the safety and efficacy of Ultomiris in adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS) |
Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome, Viral pneumonia |
ravulizumab alone |
Complement C5 factor inhibitor, IgG receptor FcRn large subunit p51 modulator |
|
Alexion Pharmaceuticals Inc |
|
|
2020-05-31 |
|
|
Phase 3 Clinical |
Not yet recruiting |
0 |
|
270 |
|
2020-04-22 |
| Covid-19 in Lupus Patients |
Coronavirus disease 19 infection, Systemic lupus erythematosus |
hydroxychloroquine alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital, Montpellier |
|
France |
2020-03-01 |
2020-05-30 |
NCT04355702, RECHMPL20_0219 |
Phase Not Applicable |
Recruiting |
1 |
2 Months |
130 |
Christian JORGENSEN, Christian JORGENSEN, PUPH, Christian JORGENSEN, Resident, Jan HOLUBAR |
2020-04-28 |
| Anosmie-COVID: Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection |
Coronavirus disease 19 infection, Dysomia |
gustatory test alone, olfactory test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire de Nimes |
|
France |
2020-03-27 |
2020-11-30 |
Anosmie-COVID, IRB: 20.04.09, NCT04354857 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
454 |
Albert Sotto, Anissa Megzari, Benjamin Lallemant, Caroline Alovisetti, Didier Laureillard, Gaelle Regnier, Jean-Philippe Lavigne, Marie-José Carles, Paul Loubet, Robin Stephan |
2020-04-23 |
| Opportunistic Screening for Asymptomatic Left Ventricular Dysfunction in Coronavirus Disease 2019 (COVID-19) Survivors |
Coronavirus disease 19 infection |
cardiac assessment alone, echocardiography alone, standard 12-lead ECG alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The University of Hong Kong |
|
Hong Kong |
2020-04-20 |
2020-05-01 |
COVID_LVD_SCREEN, NCT04355884 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
100 |
Chung Wah SIU, MD, Venus HO, BSc |
2020-04-27 |
| MOPHYDA: Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID-19 Patients |
Coronavirus disease 19 infection |
azithromycin plus hydroxychloroquine |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
King Hussein Cancer Center |
|
Jordan |
2020-04-15 |
2020-10-15 |
20 KHCC 67, MOPHYDA, NCT04354597 |
Phase 2 Clinical |
Not yet recruiting |
1 |
6 Months |
200 |
Amal Al Omari, PhD, Dalia Al Rimawi, MDS, Hikmat Abdel-Razeq, MD, Iyad Al-Ammouri, MD, Iyad Sultan, Iyad Sultan, MD, Lama Nazer, PharmD, Nedal Al-Rawashdeh, MPH, Osama Abu Ata, MD, Rana Damsees, MPH |
2020-04-23 |
| ANTI-COV-2: COVID-19: Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2 |
Coronavirus disease 19 infection, Viral pneumonia |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
Eurobio scientific |
France |
2020-04-27 |
2020-07-31 |
2020-A01038-31, 69HCL20_0340, ANTI-COV-2, NCT04354766 |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
10 |
Frédéric COUTANT, MD, Tristan FERRY, MD |
2020-04-23 |
| COVAC-TP: COVID-19 Anticoagulation in Children - Thromboprophlaxis Trial |
Coronavirus disease 19 infection, Thromboembolism |
enoxaparin sodium alone |
Low molecular weight heparin |
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs) |
Johns Hopkins All Children's Hospital |
|
US |
2020-05-15 |
2022-10-15 |
COVAC-TP, COVAC-TP, NCT04354155 |
Phase 2 Clinical |
Not yet recruiting |
0 |
29 Months |
38 |
Anthony Sochet, MD, Frances L Hamblin, MSHS, Laurel McDevitt, MS, Neil Goldenberg |
2020-04-23 |
| SevCov: Sevoflurane in COVID-19 ARDS |
Coronavirus disease 19 infection, Lung injury, Respiratory distress syndrome |
sevoflurane alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Zurich |
|
Switzerland |
2020-04-23 |
2021-03-31 |
2020-00719, NCT04355962, SevCov |
Phase 3 Clinical |
Recruiting |
1 |
11 Months |
64 |
Beatrice Beck Schimmer, Prof, Martin H Schläpfer, PD MD, Martin Schläpfer, PD |
2020-04-28 |
| STOIC: Computed Tomography for COVID-19 Diagnosis |
Coronavirus disease 19 infection, Viral pneumonia |
chest computed tomography alone, reverse-transcription polymerase chain reaction alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Assistance Publique Hopitaux de Paris |
GE Healthcare, INSERM, TheraPanacea |
France |
2020-04-30 |
2020-07-31 |
APHP200434, NCT04355507, STOIC |
Phase Not Applicable |
Not yet recruiting |
1 |
3 Months |
10000 |
Adèle BELLINO, Marie-Pierre REVEL, MD, PhD, Marie-Pierre REVEL, MD,PhD |
2020-04-23 |
| A phase III large clinical trial of hydroxychloroquine for the treatment in hospitalized patients with COVID-19 disease |
Coronavirus disease 19 infection |
hydroxychloroquine alone, standard of care alone, azithromycin plus hydroxychloroquine |
|
|
Novartis AG |
|
US |
|
|
|
Phase 3 Clinical |
Not yet recruiting |
0 |
|
440 |
|
2020-04-22 |
| Traumax: Evolution of Facial Trauma During COVID Containment Measures |
Bone injury, Coronavirus disease 19 infection |
facial fractures reduction alone, osteosynthesis alone |
|
|
University Hospital, Montpellier |
Amiens (Dr Dapke), Clermont Ferrand (Dr Sesque), Lyon (Dr Bourlet – Croix Rousse), Marseille (Dr Foletti – La conception), Nantes (Pr Corre), Nice (Dr Savoldelli), Perpignan (Dr Llobet), Toulouse (Pr Lauwers - Purpan), Unités de CMF des CHU de Paris |
France |
2020-04-01 |
2020-05-30 |
NCT04355442, RECHMPL20_0228, Traumax |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
300 |
Marie de BOUTRAY, PH |
2020-04-23 |
| Administration of Chloropromazine as a Treatment for COVID-19 |
Coronavirus disease 19 infection, Viral pneumonia |
chlorpromazine (Neurazine) alone, convential treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Cairo University |
|
Egypt |
2020-05-31 |
2020-09-30 |
MEDICAL, NCT04354805 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
1 |
4 Months |
60 |
Ahmed Nasreldin Rezk, Ahmed Rezk, Noha Rezk |
2020-04-23 |
| Treatment for SARS-CoV-2 in High-Risk Adult Outpatients |
Asthma, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Emphysema, Lower respiratory tract infection, Lung disease, Pulmonary hypertension |
Variable regimens including azithromycin , folic acid , hydroxychloroquine sulfate |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Washington |
Bill & Melinda Gates Foundation |
US |
2020-04-16 |
2020-10-31 |
NCT04354428, STUDY00009878 |
Phase 2/Phase 3 Clinical |
Recruiting |
0 |
6 Months |
630 |
Christine Johnston, MD, MPH, Hannah Leingang, Kirsten Hauge |
2020-04-23 |
| COV2ICU-DK: Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19 |
Coronavirus disease 19 infection, Respiratory distress syndrome |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
HS Hvidovre Hospital |
|
Denmark |
2020-04-06 |
2021-04-06 |
COV2ICU-DK, COV2ICU-DK, H-20023159, NCT04354584, R349-2020-540 |
Phase Not Applicable |
Recruiting |
1 |
12 Months |
20 |
Ronni R Plovsing, MD, PhD |
2020-04-23 |
| A human trial to assess linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx for COVID-19 |
Coronavirus disease 19 infection |
linear DNA vaccine (COVID-19), Takis Biotech/ LineaRx alone |
|
|
Applied DNA Sciences Inc |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| COVISEP: Epidemiological Characteristics of COVID-19 in Patients With MS or NMO |
Coronavirus disease 19 infection |
|
|
|
Assistance Publique Hopitaux de Paris |
|
France |
2020-04-20 |
2022-04-20 |
APHP200482, COVISEP, NCT04355611 |
Phase Not Applicable |
Not yet recruiting |
1 |
24 Months |
2000 |
Céline LOUAPRE, MD,PhD |
2020-04-23 |
| A randomized, double-blind, placebo-controlled, phase II trial to assess the efficacy and safety of MRx-4DP0004 in patients hospitalized with symptoms indicative of COVID-19 |
Coronavirus disease 19 infection |
MRx-0004 alone |
|
|
4D pharma plc |
|
UK |
|
|
|
Phase 2 Clinical |
Not yet recruiting |
1 |
|
90 |
Dr. Dinesh Saralaya |
2020-04-22 |
| Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020 |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
HILTON PHARMA (PVT) LTD |
|
Pakistan |
2020-04-30 |
2021-04-30 |
NCT04352751, PIPK- 0000 /NIBD-0000/2020 |
Phase 4 Clinical |
Not yet recruiting |
1 |
12 Months |
2000 |
Dr. Arshi Naz, PhD,Diplab, Dr. Neeta Maheshwary, Dr. Neeta Maheshwary, MBBS M.Phil, Dr. Tahir Shamsi, FRCP MRCPath, Professor Bikha Ram, Professor Ikram Din Ujjan, Professor Javed Akram, Professor Nadeem Samad Sheikh, Professor Nisar Ahmed, Professor Shahtaj Masood, Saba Fatima |
2020-04-23 |
| UKMSRCV19: The United Kingdom Multiple Sclerosis Register Covid-19 Substudy |
Coronavirus disease 19 infection, Multiple sclerosis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Swansea University, Wales |
|
UK |
2020-03-14 |
2022-07-14 |
16SW0194, NCT04354519, UKMSRCV19 |
Phase Not Applicable |
Recruiting |
1 |
28 Months |
3000 |
Katie A Tuite-Dalton, BSc, Nikos Evangelou, Richard S Nicholas, Rod M Middleton, MBA |
2020-04-23 |
| Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel |
Coronavirus disease 19 infection |
antibody test alone, enzyme-linked immunosorbent assay alone, reverse transcription polymerase chain reaction alone |
|
Healthy volunteers accepted, Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
AUVA-Allgemeine Unfallversicherungsanstalt |
Paracelsus Medical University |
Austria |
2020-04-30 |
2020-10-31 |
AUVA SARS-COV-2 STUDIE, NCT04354779 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
4000 |
Wolfgang Schaden, MD, Wolfgang Schadenc |
2020-04-24 |
| Effect of ppd on recovery of covid disease 19 |
Coronavirus disease 19 infection |
CT scan alone, Corona testing alone, purified protein derivative skin test alone, chloroquine plus lopinavir + ritonavir |
HIV protease inhibitor |
|
Fasa University of Medical Sciences |
|
Iran |
2020-05-04 |
|
IR.FUMS.REC.1399.004, IRCT20200414047070N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
50 |
Abdolah Azizi, Dr.Jalal Karimi, Dr.Mojtaba Farjam, Dr.jalal karimi |
2020-04-24 |
| AiM COVID for Covid 19 Tracking and Prediction |
Coronavirus disease 19 infection |
AiM COVID alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Aarogyam UK |
Clickmedix, The National Technical University of Ukraine "Igor Sikorsky Kyiv Polytechnic Institute" (NTUU "KPI"), Warwick University |
UK |
2020-03-28 |
2020-04-17 |
AU12, NCT04354753 |
Phase Not Applicable |
Completed |
1 |
|
80 |
Vishwesh Kulkarni |
2020-04-23 |
| Telmisartan for Treatment of COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
Bertel, Laboratorio Elea Phoenix alone, Standard care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Laboratorio Elea |
|
Argentina |
2020-04-01 |
2020-10-01 |
2020-001, NCT04355936 |
Phase 2 Clinical |
Recruiting |
1 |
6 Months |
400 |
Mariano Duarte, MD, Rodolfo P Rothlin, MD |
2020-04-23 |
| A final phase trial to evaluate ChAdOx1 nCoV-19 for the treatment of patients with covid-19 infection |
Coronavirus disease 19 infection |
ChAdOx1 nCoV-19 alone |
|
|
University of Oxford |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
5000 |
|
2020-04-22 |
| An Expanded Access Program (EAP) to evaluate the efficacy and safety of ruxolitinib in COVID-19 for patients with severe COVID-19 associated cytokine storm |
Coronavirus disease 19 infection |
ruxolitinib (oral, myeloproliferative disorders), Incyte/Novartis alone |
Jak1 tyrosine kinase inhibitor, Jak2 tyrosine kinase inhibitor |
|
Incyte Corp |
|
US |
|
|
|
Phase Not Applicable |
Recruiting |
0 |
|
|
|
2020-04-28 |
| Topical Chloroquine Nasal Drops in Early Stage Covid 19- Impact on Viral load and cure rates |
Coronavirus disease 19 infection |
Chloroquine alone, Standard Treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
All India Institute of Medical Sciences |
|
India |
2020-04-21 |
|
CTRI/2020/04/024729 |
Phase 2 Clinical |
Not yet recruiting |
1 |
|
60 |
Alok Thakar |
2020-04-24 |
| A phase I/IIa, randomized, placebo-controlled study of COV-ENT-1 for the treatment in hospitalized patients with COVID-19 infection |
Coronavirus disease 19 infection, Viral pneumonia |
COV-ENT-1 alone |
|
|
Enterin Inc |
|
US |
2020-07-31 |
|
|
Phase 1/Phase 2 Clinical |
Planned |
0 |
|
80 |
|
2020-04-24 |
| CONFINE: Birth Experience During COVID-19 Confinement |
Coronavirus disease 19 infection, Postnatal depression |
Self-administered questionnaires alone |
|
Female, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Central Hospital, Nancy, France |
|
France |
2020-04-16 |
2021-11-01 |
2020-A00881-38, CONFINE, NCT04348929 |
Phase Not Applicable |
Recruiting |
1 |
18 Months |
600 |
Charline BERTHOLDT |
2020-04-23 |
| VT4COVID: Ultraprotective Ventilation Without Extracorporeal Circulation During COVID-19 Pneumonia |
Coronavirus disease 19 infection, Respiratory distress syndrome, Respiratory failure, Viral pneumonia |
ultraprotective ventilation alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Hospices Civils De Lyon |
|
France |
2020-04-14 |
2022-04-14 |
69HCL20_0322, NCT04349618, VT4COVID |
Phase Not Applicable |
Not yet recruiting |
11 |
24 Months |
200 |
Arnaud FRIGGERI, Dr, Bertrand DELANNOY, Dr, Christian POMMIER, Dr, Claire DUPUIS, Dr, Frédéric AUBRUN, Pr, Guillaume THIERY, Pr, Hodane YONIS, Dr, Jean-Christophe RICHARD, Pr, Laurent ARGAUD, Pr, Loredana BABOI, Michel MULLER, Dr, Nicolas TERZI, Pr, Thomas RIMMELE, Pr |
2020-04-23 |
| COVI-PRONE: Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial |
Coronavirus disease 19 infection, Respiratory failure |
Awake Proning alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
St Josephs Healthcare Hamilton |
|
Canada |
2020-04-20 |
2020-10-31 |
2154, COVI-PRONE, NCT04350723 |
Phase Not Applicable |
Not yet recruiting |
1 |
6 Months |
350 |
Sarah Culgin, Waleed Alhazzani, Zainab Al Duhalib |
2020-04-23 |
| RASCOVID-19: Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19 |
Coronavirus disease 19 infection |
ACEi alone, ARB alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Gentofte |
Novo Nordisk Foundation |
Denmark |
2020-04-30 |
2020-12-31 |
2020-001544-26, H-20026205, NCT04351581, RASCOVID-19 |
Phase Not Applicable |
Recruiting |
1 |
8 Months |
215 |
Filip K Knop, MD, PhD |
2020-04-27 |
| Meals MATTER: A Trial of Medically Tailored Meals 2 Weeks vs. 4 Weeks Post Hospital Discharge |
Anxiety disorder, Cancer, Cardiac failure, Chronic obstructive pulmonary disease, Coronavirus disease 19 infection, Depression, Diabetes mellitus, End stage renal disease, Liver cirrhosis, Liver disease |
Medically Tailored Meals alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kaiser Permanente |
|
US |
2020-04-15 |
2021-07-31 |
IRB-1556587, Meals MATTER, NCT04351880 |
Phase Not Applicable |
Not yet recruiting |
0 |
15 Months |
640 |
John Steiner, MD, MPH, Melanie L Drace, MPH, Rebecca S Boxer, MD, MS |
2020-04-26 |
| Effect of herbal medicine containing Saatar, Hofarigon and Fennel on COVID-19 patients |
Coronavirus disease 19 infection, Lung disease |
Variable regimens including herbal medicine , hydroxychloroquine , lopinavir + ritonavir |
HIV protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.MAZUMS.REC.1398.1457, IRCT20200404046935N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Farhang Babamahmoodi |
2020-04-23 |
| HEROES: The COVID-19 Health Care Workers Study |
Coronavirus disease 19 infection, Psychiatric disorder |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University of Chile |
|
Italy, US, Chile, Spain |
2020-04-15 |
2021-04-14 |
HEROES, HEROES COVID-19, NCT04352634 |
Phase Not Applicable |
Not yet recruiting |
3 |
12 Months |
2000 |
Eduardo Fernández-Jiménez, PhD, Eric Tapia, MPH, Francesca Moro, MD, Gonzalo Martínez-Alés, MD, Maria-Fe Bravo-Ortiz, MD, PhD, Mauro Carta, MD, Roberto Mediavilla, PhD, Ruben Alvarado, PhD, Rubén Alvarado, PhD, Sara Schilling, MPH |
2020-04-23 |
| Echocardiographic Manifestation in Patient With Coronavirus Disease 2019 (COVID-19) |
Coronavirus disease 19 infection |
GE Logiq E portable color ultrasound diagnostic machine (GE Healthcare) alone, doppler echocardiography alone, two-dimensional echocardiography alone |
|
|
Renji Hospital |
|
China |
2020-02-19 |
2020-04-06 |
COVID19-ECHOCARDIOGRAPHY, NCT04352842 |
Phase Not Applicable |
Completed |
1 |
1 Month |
55 |
Jun Pu, M.D |
2020-04-24 |
| Assessment of Objective clinical scoring system to rule out COVID-19 with high sensitivity |
Coronavirus disease 19 infection |
Outbreak of Respiratory Tract Infection Score (ORTIS) sytstem alone |
|
Newborn Infants (up to 5 months), Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs) |
Dr Atul's Child Hospital |
|
India |
2020-05-01 |
|
CTRI/2020/04/024636 |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1000 |
Varnit Shanker |
2020-04-23 |
| PROLIFIC: Chemoprophylaxis Trial (COVID-19) |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Cambridge University Hospitals NHS Foundation Trust |
|
UK |
2020-04-30 |
2021-04-30 |
NCT04352933, PROLIFIC, PROLIFIC2020 (A095583) |
Phase 3 Clinical |
Not yet recruiting |
1 |
12 Months |
1000 |
Ella James, PhD, Heike Templin, Joseph Cheriyan, MBCHB, FRCP |
2020-04-21 |
| COVID-19-hematological Malignancies: the Italian Hematology Alliance |
Acute leukemia, Coronavirus disease 19 infection, Lymphoma, Multiple myeloma, Myelodysplastic syndrome, Myeloproliferative disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ospedale di Circolo - Fondazione Macchi |
|
Italy |
2020-04-07 |
2021-04-30 |
HM-COVID19-ITALY, NCT04352556 |
Phase Not Applicable |
Recruiting |
69 |
12 Months |
250 |
Adriano Venditti, MD, Alberto Bosi, MD, Alessandro Busca, MD, Alessandro Corso, MD, Alessandro Inzoli, MD, Alfredo Molteni, MD, Anna Conconi, MD, Antonio Cuneo, MD, Antonio Pinto, MD, Antonio Spadano, MD, Attilio Guarini, MD, Attilio Olivieri, MD, Atto Billio, MD, Augusto Federici, MD, Benedetto Bruno, MD, Brunangelo Falini, MD, Bruno Martino, MD, Carlo Gambacorti Passerini, MD, Carlo Visco, MD, Carmen Fava, MD, Carmine Selleri, MD, Caterina Musolino, MD, Celestino Ferrandina, MD, Chiara Cattaneo, MD, Corrado Tarella, MD, Daniela Cilloni, MD, Daniele Vallisa, MD, Domenico Russo, MD, Emanuele Angelucci, MD, Fabio Ciceri, MD, Fabrizio Ciambelli, MD, Fabrizio Pane, MD, Felicetto Ferrara, MD, Filippo Gherlinzoni, MD, Francesco Di Raimondo, MD, Francesco Lanza, MD, Francesco Merli, MD, Francesco Passamonti, MD, Francesco Zaja, MD, Giampietro Semenzato, MD, Gianluca Gaidano, MD, Giorgio La Nasa, MD, Giuseppe Avvisati, MD, Giuseppe Visani, MD, Livio Pagano, MD, Luca Arcaini, MD, Luigi Rigacci, MD, Marco Ladetto, MD, Marco Ruggeri, MD, Marco Salvini, MD, Mario Luppi, MD, Massimo Gentile, MD, Massimo Massaia, MD, Matteo Della Porta, MD, Maurizio Martelli, MD, Mauro Krampera, MD, Mauro Turrini, MD, Michele Cavo, MD, Michele Spina, MD, Monica Bocchia, MD, Nicola Di Renzo, MD, Nicola Fracchiolla, MD, Nicola Giuliani, MD, Paolo Corradini, MD, Patrizia Tosi, MD, Patrizio Mazza, MD, Pellegrino Musto, MD, Piero Galieni, MD, Renato Bassan, MD, Renato Fanin, MD, Roberto Cairoli, MD, Roberto Lemoli, MD, Sara Galimberti, MD, Sergio Siragusa, MD, Valerio De Stefano, MD |
2020-04-21 |
| HERO: Health Care Worker Prophylaxis Against COVID-19 |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
GeoSentinel Foundation |
|
US |
2020-04-24 |
2020-08-24 |
GFICOVID-19-1, HERO, NCT04352946 |
Phase 3 Clinical |
Not yet recruiting |
0 |
4 Months |
374 |
Bradley A Connor, MD, Kevin Kain, MD, Marina Rogova, RN, Megan Landes, MD, Robert S Brown, Jr, MD, William MacLeod, ScD |
2020-04-23 |
| The effect of PHR spray on patients with coronavirus-19 |
Coronavirus disease 19 infection, Lung disease |
PHR160 Inhaler Spray alone, routine treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-03-10 |
2020-03-24 |
IR.BMSU.REC.1398.387, IRCT20160131026298N2 |
Phase 2/Phase 3 Clinical |
Completed |
1 |
|
64 |
Ahmad Reza Sharifi Olounabadi, REZAMOHTASHAMI, AHMAD REZA SHARIFI OLOUNABADI, Reza Mohtashami |
2020-04-22 |
| The effect of herbal drugs (Echinacea and Ginger) on Improvement of clinical symptoms and hospitalizations in suspected COVID-19 outpatient cases |
Coronavirus disease 19 infection |
standard treatment alone, Rucoldup, Ghaem Daru plus Vomigone, Dineh Pharmaceutical Company |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Saveh University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.SAVEHUMS.REC.1399.004, IRCT20200415047089N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
100 |
hamidreza koohestani, mehdi mesri |
2020-04-22 |
| The design of an updated iron lung ventilator which can be easily built and used by people with minimal training in situations such as COVID-19 where skilled doctors or normal ventilators are unavailable |
Coronavirus disease 19 infection |
Hudson face mask alone, sedation therapy alone, simplified negative pressure cuirass style ventilator alone, supplemental oxygen therapy alone |
|
Healthy volunteers accepted, Male, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Perth Anaesthetic Group |
St John of God Murdoch Hospital, Australia |
Australia |
2020-04-20 |
2020-04-20 |
ACTRN12620000477921p |
Phase Not Applicable |
Not yet recruiting |
1 |
|
1 |
Dr Michael Soares |
2020-04-22 |
| Phase II, open-label, randomized clinical trial with the primary objective to assess the safety and efficacy of the convalescent plasma to limit complications in Covid-19 patients |
Coronavirus disease 19 infection |
convalescent plasma alone |
|
|
Indian Council of Medical Research |
|
|
|
|
|
Phase 2 Clinical |
Not yet recruiting |
0 |
|
|
|
2020-04-22 |
| Phase II, randomized trial of Brukinsa to treat in later-stage COVID-19 patients |
Coronavirus disease 19 infection |
mechanical ventilation alone, zanubrutinib alone |
Btk tyrosine kinase inhibitor |
|
BeiGene Co Ltd |
|
US |
|
|
|
Phase 2 Clinical |
Planned |
0 |
|
42 |
Treon |
2020-04-22 |
| Thalidomide in COVID19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including Talidex. Alan pharmaceuticals , acetaminophen + codeine , azithromycin , ceftriaxone , diphenhydramine , enoxaparin sodium , hydroxychloroquine , methylprednisolone , vancomycin |
Low molecular weight heparin, Peptidoglycan recognition protein inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Isfahan University of medical Sciences |
Deputy minister of technology research |
Iran |
2020-04-15 |
|
IRCT20170207032444N3, http://ethics.research.ac.ir/IR.MUI.MED.REC.1399.027 |
Phase 3 Clinical |
Recruiting |
1 |
|
60 |
Farzane Ashrafi, Mehrzad Salmasi, Ramin Sami, Shaghayegh Haghjooy Javanmard, farzane ashrafi |
2020-04-22 |
| Cord Blood Therapy to prevent progression of COVID-19 related pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
cord blood therapy alone, standard supportive management alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Monash Health |
|
Australia |
2020-06-01 |
2020-12-31 |
ACTRN12620000478910, CBC-19 |
Phase 2 Clinical |
Not yet recruiting |
1 |
7 Months |
24 |
Dr Atul Malhotra |
2020-04-22 |
| FEELIV COVID: An Online Survey to Understand Feelings Related to COVID-19 Among ILBS Patients With Liver Disease |
Coronavirus disease 19 infection, Liver disease |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Institute of Liver and Biliary Sciences, India |
|
India |
2020-04-22 |
2020-04-30 |
FEELIV COVID, ILBS-COVID-03, NCT04352491 |
Phase Not Applicable |
Recruiting |
1 |
|
1500 |
Dr Mohit Varshney, DM, Dr Mohit Varshney, MD, Dr Shiv Kumar Sarin, DM |
2020-04-23 |
| A clinical trial to investigate the role of Pegylated Interferon alpha-2b for COVID 19 |
Coronavirus disease 19 infection |
peginterferon alfa-2b follow-on-biologic, Zydus-Cadila alone |
Interferon alpha 2 ligand |
|
Zydus-Cadila Group |
|
|
|
|
|
Phase Not Applicable |
Planned |
0 |
|
|
|
2020-04-22 |
| The IMSOMNIA study: Mental health and wellbeing on general population during the COVID-19 outbreak |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Insomnia |
|
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
The George Institute for Global Health |
|
China, Germany, Spain, US, Italy, Australia |
2020-05-01 |
|
ACTRN12620000479909p, The IMSOMNIA study |
Phase Not Applicable |
Not yet recruiting |
5 |
|
3000 |
Dr Amanda Y Wang, Dr Qi Mei |
2020-04-22 |
| BBCovid: COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses |
Coronavirus disease 19 infection |
Citrox plus beta-cyclodextrin |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universite Claude Bernard |
Hospices Civils De Lyon, University Hospital, Montpellier, University Hospital, Tours |
France |
2020-04-27 |
2020-06-20 |
BBCOVID, BBCovid, NCT04352959 |
Phase 2 Clinical |
Not yet recruiting |
1 |
1 Month |
178 |
Carrouel Florence |
2020-04-27 |
| SpectrOVID19: Prospective gas chromatographic and spectrometric analysis of the exhalation of healthy test persons and of SARS-CoV2 infected patients as well as of patients suffering from COVID-19 at the Klinikum Dortmund |
Coronavirus disease 19 infection |
gas chromatography alone, ionic motility spectrometry alone |
|
Healthy volunteers accepted, Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Klinikum Dortmund GgmbH |
|
Germany |
2020-04-12 |
|
176/2020, DRKS00021399, SpectrOVID19 |
Phase Not Applicable |
Recruiting |
1 |
|
450 |
Oliver Müller |
2020-04-23 |
| Efficacy and Safety of MTX-loaded Nanoparticles to Treat Severe COVID-19 Patients |
Coronavirus disease 19 infection, Respiratory distress syndrome |
methotrexate loaded nanoparticle alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Azidus Brasil |
Hospital Santa Marcelina, InCor Heart Institute |
|
2020-05-01 |
2020-11-30 |
LDE-MTX_COVID19, NCT04352465 |
Phase 1/Phase 2 Clinical |
Not yet recruiting |
0 |
7 Months |
42 |
Luciana Ferrara, Rodrido Esper, MD, PhD |
2020-04-23 |
| Stress-reduction Using Probiotics to Promote Ongoing Resilience Throughout COVID-19 for Healthcare Workers (SUPPORT COVID-19 Healthcare Workers) |
Acute stress disorder, Coronavirus disease 19 infection |
Lactobacillus rhamnosus HN001 alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
University of Auckland |
|
New Zealand |
2020-06-01 |
2020-07-16 |
ACTRN12620000480987p |
Phase Not Applicable |
Not yet recruiting |
1 |
1 Month |
507 |
Dr Rebecca Slykerman |
2020-04-23 |
| The RAPID COVID TRIAGE Algorithm |
Coronavirus disease 19 infection |
Spartan Cube point-of-care Covid-19 test alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Ottawa Heart Institute Research Corp |
|
|
2020-04-15 |
2021-02-28 |
20200228-01H, NCT04353154 |
Phase Not Applicable |
Not yet recruiting |
0 |
10 Months |
20 |
Dr. Derek So, Poppy MacPhee |
2020-04-23 |
| RACONA: Efficacy of Nafamostat in Covid-19 Patients |
Coronavirus disease 19 infection |
nafamostat mesylate alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
University Hospital Padova |
University of Zurich, Yokohama City University |
Italy |
2020-04-30 |
2021-12-31 |
NCT04352400, RACONA, RACONA NAFAMOSTAT |
Phase 2/Phase 3 Clinical |
Not yet recruiting |
2 |
20 Months |
256 |
Gian Paolo Rossi, Gian Paolo Rossi, Prof. |
2020-04-22 |
| VACAT: COVID-19 and Vaccination Attitudes |
Coronavirus disease 19 infection |
|
|
Healthy volunteers accepted |
Hopitaux Universitaires De Geneve |
University of Lausanne, University of Zurich |
UK |
2020-04-14 |
2020-04-30 |
NCT04352582, VACAT, VACAT |
Phase Not Applicable |
Recruiting |
1 |
|
1000 |
Dominic Rohner, PhD, Geraldine Blanchard-Rohner, Geraldine Blanchard-Rohner, MD-PhD |
2020-04-22 |
| Impact of high intensity interval training and aerobic training on stress, depression symptoms, anxiety and resilience in self-isolated people during the COVID-19 health emergency in Spain |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
high intensity interval training alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Universidad de Extremadura |
|
Spain |
2020-03-17 |
2020-04-26 |
ACTRN12620000482965 |
Phase Not Applicable |
No longer recruiting |
1 |
1 Month |
77 |
Dr Juan Pedro Fuente-García, Mr Santos Villafaina |
2020-04-22 |
| Effects of digital home exercise programs on physical and mental well-being during the COVID-19 pandemic: a multicenter trial |
Coronavirus disease 19 infection |
digital home exercise programs alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Johann Wolfgang Goethe-Universitat Frankfurt am Main |
Foro Italico University of Rome, Spaulding Rehabilitation Network, The University Children’s Hospital Basel, Universidade Cidade de Sao Paulo, Universite Jean Monnet, University of Cadiz |
Germany, Switzerland, Spain, US, Austria, Chile, France, Brazil |
2020-04-22 |
|
2020-25, DRKS00021273 |
Phase Not Applicable |
Not yet recruiting |
7 |
|
544 |
Mr Dr Jan Wilke, Mr Prof Luiz Hespanhol, Mr. Dr Christoph Heidt, Mr. Prof David Jiménez-Pavón, Mr. Prof Pascal Edouard, Ms. Dr Chiara Fossati |
2020-04-22 |
| Effect of Ozone Therapy in Treatment of COVID-19 |
Coronavirus disease 19 infection |
conventional treatment alone, oxygen/ozone alone, ozone major autohemotherapy alone |
|
|
Bagheiat-allah University of Medical Sciences |
|
Iran |
2020-04-23 |
|
IR.BMSU.REC.1399.060, IRCT20191125045492N2 |
Phase 2 Clinical |
Recruiting |
1 |
|
80 |
Ali Sarrafzadeh, Dr. Gholamhosein Alishiri, Morteza Izadi |
2020-04-23 |
| Outcomes of Urological Surgery During Periods of Social COVID-19 Containemnt: is it Reasonable to Limit Access to Surgical Care for All? |
Coronavirus disease 19 infection, Urinary tract tumor |
surgery alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Universitaire De Nice |
|
France |
2020-03-15 |
2020-05-01 |
20UROCOVID.03, NCT04352699 |
Phase Not Applicable |
Recruiting |
1 |
1 Month |
120 |
Aysha SHAIKH, Matthieu DURAND, Matthieu DURAND, MD, PhD |
2020-04-22 |
| AUS-COVID: Australian cardiovascular COVID-19 registry |
Coronavirus disease 19 infection, Heart injury, Myocardial disease, Myocarditis |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Paul Ramsay Foundation |
|
Australia |
2020-04-20 |
2020-08-19 |
ACTRN12620000486921, AUS-COVID |
Phase Not Applicable |
Not yet recruiting |
20 |
4 Months |
865 |
Prof Ravinay Bhindi |
2020-04-22 |
| PATCH 2 and 3: Prevention and Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine |
Coronavirus disease 19 infection |
hydroxychloroquine alone |
|
Healthy volunteers accepted, Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
UnitedHealth Group Inc |
Perelman School of Medicine, Prohealth Care Associates |
US |
2020-04-07 |
2021-06-15 |
2020-0003, NCT04353037, PATCH 2 and 3 |
Phase 2 Clinical |
Recruiting |
0 |
14 Months |
850 |
Daniel Griffin, MD PhD, Daniel Griffin, MD, PhD, Deneen Vojta, MD, Ravi Amaravadi, MD |
2020-04-27 |
| COVID-19 associated brainstem encephalitis - is SARS-CoV-2 a neurotropic agent? |
Ageusia, Coronavirus disease 19 infection, Dysomia, Encephalitis, Taste disorder |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Neurosurgical University Clinic Freiburg |
|
Germany |
2020-04-20 |
|
211/20, DRKS00021439 |
Phase Not Applicable |
Recruiting |
1 |
|
70 |
Jonas Hosp |
2020-04-22 |
| Evaluating the Use of Polymyxin B Cartridge Hemoperfusion for Patients With Septic Shock and COVID 19 |
Coronavirus disease 19 infection, Septic shock |
Toraymyxin PMX-20R cartridge alone, hemoperfusion alone, standard medical care alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Spectral Diagnostics (US) Inc |
|
|
|
|
NCT04352985, SDI-PMX-013 |
Phase Not Applicable |
Recruiting |
0 |
|
|
Debra Foster |
2020-04-22 |
| DolPsyCOVID: Psychological Impact of Quarantine in Chronic Pain Patient During COVID-19 Outbreak |
Anxiety disorder, Coronavirus disease 19 infection, Depression, Pain |
questionnaire assesment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Centre Hospitalier Regional Universitaire de Lille |
|
France |
2020-04-30 |
2020-12-31 |
2020-A00912-37, DolPsyCOVID, EQ_2020_02, NCT04353011 |
Phase Not Applicable |
Not yet recruiting |
1 |
8 Months |
50 |
Anne BERA, MD |
2020-04-22 |
| Antibody-based Tests for SARS-CoV-2 COVID-19: Evaluation of Patients and Healthcare Providers in the Confines of Healthcare Settings |
Coronavirus disease 19 infection |
CoronaCide COVID-19 IgM/IgG rapid test alone, Premier Biotech COVID-19 IgM/IgG rapid test alone |
|
Healthy volunteers accepted |
Texas Cardiac Arrhythmia |
|
US |
2020-03-27 |
2021-01-31 |
NCT04352764, TCAI_COVID-19 |
Phase Not Applicable |
Recruiting |
0 |
10 Months |
5000 |
Andrea Natale, MD, Andrea Natale, MD FACC FHRS, Deb Cardinal, RN |
2020-04-28 |
| Safety and Immunogenicity Study of 2019-nCoV Vaccine (Inactivated) for Prophylaxis SARS CoV-2 Infection (COVID-19) |
Coronavirus disease 19 infection |
Inactivated vaccine (COVID-19), Sinovac Biotech alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Sinovac Research & Development Co Ltd |
Sinovac Biotech Ltd |
China |
2020-04-16 |
2020-12-13 |
NCT04352608, PRO-NCOV-1001 |
Phase 1/Phase 2 Clinical |
Recruiting |
2 |
7 Months |
744 |
Congbing Jiang, Bachelor, Fengcai Zhu, Doctor, Hongxing Pan, Doctor |
2020-04-29 |
| Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease |
Adult respiratory distress syndrome, Coronavirus disease 19 infection, Viral pneumonia |
autologous adipose derived mesenchymal cells alone, conventional treatment alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Regeneris Medical |
|
|
2020-04-30 |
2026-04-30 |
COVID-MSCIV, NCT04352803 |
Phase 1 Clinical |
Not yet recruiting |
0 |
72 Months |
20 |
Ryan Welter, MD PhD |
2020-04-23 |
| Influence Physical Activity Psychological Responses COVID-19 Pandemic |
Acute stress disorder, Anxiety disorder, Coronavirus disease 19 infection, Depression |
Google Forms online survey alone |
|
Healthy volunteers accepted, Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universidad de Extremadura |
|
Brazil, Uruguay, Chile |
2020-03-16 |
2020-09-30 |
3.954.038, NCT04352517 |
Phase Not Applicable |
Recruiting |
3 |
6 Months |
3500 |
Alba Dr Camacho-Cardenosa, Doctor, Atila Alexandre Trapé, Dr, Eugenio Narciso Merellano Navarro, Javier Dr Brazo-Sayavera, Doctor, Marta Dr Camacho-Cardenosa, Doctor |
2020-04-23 |
| Pirfenidine in SARS-COV2 |
Coronavirus disease 19 infection, Pulmonary fibrosis, Respiratory distress syndrome |
Variable regimens including chloroquine , lopinavir + ritonavir , oseltamivir , pirfenidone , ribavirin |
Exo-alpha sialidase inhibitor, HIV protease inhibitor, PDGF receptor antagonist, TGF beta receptor antagonist, p38 MAP kinase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kermanshah University of Medical Sciences |
|
Iran |
2020-04-26 |
|
IR.KUMS.REC.1399.017, IRCT20200314046764N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
40 |
Bahareh Baghchi, Farid Najafi, Mohammad Nazarian Pirdoosti |
2020-04-28 |
| Atorvastatin effect on COVID-19 |
Coronavirus disease 19 infection |
atorvastatin alone |
HMG CoA reductase inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-05 |
|
IR.MAZUMS.REC.1399.042, IRCT20190727044343N2 |
Phase 2/Phase 3 Clinical |
No longer recruiting |
1 |
|
100 |
Lotfollah Davoodi |
2020-04-22 |
| ILUSA: International Lung UltraSound Analysis (ILUSA) Study |
Coronavirus disease 19 infection, Cough, Dyspnea, Fever, Respiratory disease, Respiratory tract infection |
Lung ultrasound examination alone |
|
Female |
Katholieke Universiteit Leuven |
|
Belgium, Italy, UK |
2020-04-20 |
2020-12-31 |
COVID-19: ILUSA (S63988), ILUSA, NCT04353141 |
Phase Not Applicable |
Not yet recruiting |
8 |
8 Months |
1850 |
Antonia Testa, PhD, Antonio Lanzone, PhD, Dirk Timmerman, PhD, Federico Prefumo, Francesca Moro, Francesca Moro, MD, Francesco D'Antonio, Giovanni Scambia, PhD, Hannes Van der Merwe, MD, Hannes Van der Merwe, PhD, Irene Cetin, Jan Deprest, PhD, Tiziana Frusca, Tom Bourne, PhD, Wouter Froyman, MD |
2020-04-22 |
| A clinical study to assess antiviral efficacy of DWRX-2003 for the potential treatment of COVID-19 |
Coronavirus disease 19 infection |
repositioned niclosamide (refractory lung disease/COVID-19), Daewoong Pharmaceutical/Institut Pasteur Korea alone |
|
|
Daewoong Pharmaceutical Co Ltd, Institut Pasteur Korea |
|
South Korea |
|
|
|
Phase Not Applicable |
Planned |
1 |
|
|
|
2020-04-23 |
| Evaluation of SinaCurcumin capsule efficacy as an supplement therapy for mild to moderate COVID-19 in Mashhad |
Coronavirus disease 19 infection, Viral pneumonia |
SinaCurcumin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Mashhad University of Medical Sciences |
|
Iran |
2020-05-19 |
|
IR.MUMS.REC.1399.054, IRCT20200408046990N1 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
60 |
Mohsen Tafaghodi, Sepideh Elyasi |
2020-04-23 |
| The effect of azithromycin in treatment of COVID19 |
Coronavirus disease 19 infection, Viral pneumonia |
Variable regimens including atazanavir , azithromycin , hydroxychloroquine , lopinavir + ritonavir , oseltamivir |
Exo-alpha sialidase inhibitor, HIV GAG POL polyprotein inhibitor, HIV GAG protein inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Tehran University of Medical Sciences |
|
Iran |
2020-04-24 |
|
IR.TUMS.VCR.REC.1399.165, IRCT20200415047092N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
110 |
Ehsan Sekhavati Moghadam, Fereshte Ghiasvand, Mohammad Ali Sahraian |
2020-04-28 |
| Treatment of COVID-19-induced cytokine storm by hemoperfusion |
Coronavirus disease 19 infection |
hemodialysis alone, hemoperfusion HA330 filter (JAFRON BIOMEDICAL.CO.LTD, China) alone, heparin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs) |
Tabriz University of Medical Sciences |
|
Iran |
2020-04-20 |
|
IR.TBZMED.REC.1399.024, IRCT20200317046797N5 |
Phase 2 Clinical |
Recruiting |
1 |
|
10 |
Ali Taghizadieh, Dr Bahram Niknafs, Dr Mohammad Samiei, Mohammadreza Ardalan, Sepideh Zununi Vahed |
2020-04-23 |
| The effect of melatonin on the quality of sleep in COVID-19 patients |
Coronavirus disease 19 infection |
Variable regimens including azithromycin , hydroxychloroquine , melatonin |
|
|
Mazandaran University of Medical Sciences |
|
Iran |
2020-04-14 |
|
IR.MAZUMS.REC.1399.056, IRCT20200411047030N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
82 |
Prof. Majid Saeedi, Reza Alizadeh-Navaei, Seyyed Abbas Mousavi |
2020-04-22 |
| COCON: Control of COVID-19 in hospitals |
Coronavirus disease 19 infection |
|
|
|
Universitair Medisch Centrum Utrecht |
The Netherlands Organisation for Health Research and Development |
Netherlands |
2020-04-22 |
2020-08-31 |
COCON, NL8528 |
Phase Not Applicable |
Not yet recruiting |
1 |
4 Months |
2000 |
Marjolein Kluytmans |
2020-04-22 |
| A clinical study of CRISPR-based DETECTR assay for the diagnosis of patients with COVID-19 infection and patients with other viral respiratory infections |
Coronavirus disease 19 infection, Viral respiratory tract infection |
CRISPR-based DETECTR assay alone |
|
|
Mammoth Biosciences |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
78 |
Dr Charles Chiu, Dr James Broughton, Dr Janice Chen |
2020-04-24 |
| General practice cooperative COVID-19 centre Urmond |
Coronavirus disease 19 infection |
|
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
MCC Omnes |
|
Netherlands |
2020-05-01 |
2022-01-03 |
METCZ20200068, NL8529 |
Phase Not Applicable |
Not yet recruiting |
1 |
20 Months |
2000 |
Luc Gidding |
2020-04-22 |
| An expanded access compassionate use program to assess remestemcel-L in patients with COVID-19 acute respiratory distress syndrome (ARDS) |
Coronavirus disease 19 infection, Respiratory distress syndrome |
remestemcel-L alone |
|
|
Mesoblast Ltd |
|
US |
|
|
|
Phase Not Applicable |
Status not specified |
0 |
|
12 |
|
2020-04-28 |
| CPAP-Covid: Continuous positive airway pressure in severe Covid-19 pneumonia |
Coronavirus disease 19 infection, Viral pneumonia |
continuous positive airway pressure (CPAP) alone, face mask alone, non-rebreathing mask alone, oxygen alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Academic Medical Center, University of Amsterdam |
Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose |
Netherlands |
2020-04-18 |
2020-07-18 |
CPAP-Covid, NL8521 |
Phase 1 Clinical |
Not yet recruiting |
1 |
3 Months |
13 |
Joost van den Aardweg |
2020-04-22 |
| Effect of Arbidol in treatment of COVID-19 |
Coronavirus disease 19 infection |
arbidol plus hydroxychloroquine |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Iran University of Medical Sciences |
|
Iran |
2020-04-29 |
|
IR.IUMS.REC.1399.090, IRCT20180725040596N2 |
Phase 3 Clinical |
Not yet recruiting |
1 |
|
100 |
Dr Abbas Motevalian, Dr. Marzieh Nojomi, Dr. Mitra ranjbar, ِDr. Mitra Ranjbar |
2020-04-22 |
| SOS COVID: SARS-CoV-2 Observational Study |
Coronavirus disease 19 infection, Respiratory tract infection |
|
|
Infants (6-23 months), Preschool Children (2-5 yrs), Children (6-12 yrs), Adolescents (13-17 yrs), Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Universitair Medisch Centrum Utrecht |
European Commission |
Europe, Netherlands |
2020-04-14 |
2022-02-01 |
NL73596.041.20, NL8520, SOS COVID |
Phase Not Applicable |
Not yet recruiting |
1 |
21 Months |
600 |
Alike van der Velden |
2020-04-23 |
| Comparison between the efficacy of intravenous immunoglobulin and convalescent plasma in COVID-19 |
Coronavirus disease 19 infection |
common national protocol alone, convalescent plasma alone, immunoglobulin alone |
|
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs) |
Birjand University of Medical Sciences |
|
Iran |
2020-04-18 |
|
IR.BUMS.REC.1399.008, IRCT20200413047056N1 |
Phase 3 Clinical |
Recruiting |
1 |
|
15 |
Malihe Zangoue, Mohammad Fereidouni, Tooba Kazemi |
2020-04-22 |
| Assessment the Activity Value of 13- Cis-Retinoic Acid(Isotretinoin) in the Treatment of COVID-19 (Isotretinoin) |
Coronavirus disease 19 infection |
standard therapy alone, Variable regimens including ascorbic acid , azithromycin , cis-retinoic acid , clarithromycin , cyanocobalamin , hydroxychloroquine , lopinavir , oseltamivir , paracetamol , ritonavir |
Cytochrome P450 3A4 inhibitor, Exo-alpha sialidase inhibitor, HIV protease inhibitor, HIV-1 protease inhibitor |
Young Adults (18-44 yrs), Middle-aged Adults (45-64 yrs), Aged Adults (65-79 yrs), Elderly Adults (80 and over) |
Kafrelsheikh University |
|
Egypt |
2020-04-30 |
2020-06-30 |
, PROPOSED BY MAHMOUD ELKAZZAZ, NCT04353180 |
Phase 3 Clinical |
Recruiting |
1 |
2 Months |
45 |
Dr.Tamer Hydara, Doctor of internal medicine, M.Sc. Mahmoud Elkazzaz, M.Sc.Biochemistry, M.Sc.Mahmoud Elkazzaz, M.Sc.Biochemistry, Mahmoud Elkazzaz, M.Sc.of Biochemistry, Mahmoud Ramadan mohamed Elkazzaz |
2020-04-27 |